uuid stringlengths 4 8 | template_uuid stringclasses 40
values | question stringlengths 13 193 | answer stringlengths 29 2.2k | benchmark_query stringlengths 133 622 | execution_results stringlengths 2 1.14M | query_type stringclasses 2
values | sql_category stringclasses 26
values | bio_category stringclasses 14
values |
|---|---|---|---|---|---|---|---|---|
Q22.91 | Q22 | What is Tracleer? | Tracleer, also known generically as Bosentan, was approved by the FDA in 2001 to treat hypertension, pulmonary arterial hypertension, pulmonary hypertension, and idiopathic and/or familial pulmonary arterial hypertension. It is a small molecule therapy that acts as a(n) antagonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%tracleer%" OR LOWER(tradeNames_string) LIKE "%tracleer%" OR LOWER(drugSynonyms_string) LIKE "%tracleer%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_379', 'tradeNames_string': 'Tracleer', 'drugName': 'Bosentan', 'drugMolecularType': 'Small molecule', 'drugActionType': 'antagonist', 'drugMechanismOfAction': 'Endothelin receptor, ET-A/ET-B antagonist', 'linkedDiseasesDrug_string': 'Diabetes Mellitus (EFO_0000400), Eisenmenger Syndrome (EFO_0009200), Pulmonary Hypertension (MONDO_0005149), Pulmonary Arterial Hypertension (EFO_0001361), Glaucoma (MONDO_0005041), Idiopathic Pulmonary Fibrosis (EFO_0000768), Anterior Ischemic Optic Neuropathy (EFO_1000809), Congestive Heart Failure (EFO_0000373), Hypertension (EFO_0000537), Persistent Fetal Circulation Syndrome (EFO_1001103), Hypoplastic Left Heart Syndrome (MONDO_0004933), Ulcer Disease (MONDO_0043839), Pancreatic Carcinoma (EFO_0002618), Asthma (MONDO_0004979), Fever (HP_0001945), Chronic Obstructive Pulmonary Disease (EFO_0000341), Hepatopulmonary Syndrome (EFO_1001346), Systemic Scleroderma (EFO_0000717), Congenital Heart Disease (EFO_0005207), Sleep Apnea (EFO_0003877), Neoplasm (EFO_0000616), Idiopathic And/Or Familial Pulmonary Arterial Hypertension (MONDO_0008347), Melanoma (EFO_0000756), Type 2 Diabetes Mellitus (MONDO_0005148), Mitral Valve Stenosis (EFO_0007372), Cirrhosis Of Liver (EFO_0001422)', 'newLinkedTargets_string': 'EDNRB (ENSG00000136160), EDNRA (ENSG00000151617)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2001, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.597 | Q22 | What is Tosymra? | Tosymra, also known generically as Sumatriptan, was approved by the FDA in 1992 to treat migraine disorder. It is a small molecule therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%tosymra%" OR LOWER(tradeNames_string) LIKE "%tosymra%" OR LOWER(drugSynonyms_string) LIKE "%tosymra%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_6077', 'tradeNames_string': 'Imitrex, Sumatriptan, Tosymra', 'drugName': 'Sumatriptan', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Serotonin 1d (5-HT1d) receptor agonist', 'linkedDiseasesDrug_string': 'Migraine Without Aura (MONDO_0100431), Migraine Disorder (MONDO_0005277), Obesity (EFO_0001073), Migraine With Aura (MONDO_0005475)', 'newLinkedTargets_string': 'HTR1D (ENSG00000179546), HTR1B (ENSG00000135312)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1992, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_6078', 'tradeNames_string': 'Imitrex, Sumatriptan, Tosymra', 'drugName': 'Sumatriptan', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Serotonin 1b (5-HT1b) receptor agonist', 'linkedDiseasesDrug_string': 'Migraine Without Aura (MONDO_0100431), Migraine Disorder (MONDO_0005277), Obesity (EFO_0001073), Migraine With Aura (MONDO_0005475)', 'newLinkedTargets_string': 'HTR1D (ENSG00000179546), HTR1B (ENSG00000135312)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1992, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.120 | Q22 | What is Kengreal? | Kengreal, also known generically as Cangrelor Tetrasodium, was approved by the FDA in 2015 to treat Recurrent thrombophlebitis and myocardial infarction. It is a small molecule therapy that acts as a(n) antagonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%kengreal%" OR LOWER(tradeNames_string) LIKE "%kengreal%" OR LOWER(drugSynonyms_string) LIKE "%kengreal%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1075', 'tradeNames_string': 'Kengreal', 'drugName': 'Cangrelor Tetrasodium', 'drugMolecularType': 'Small molecule', 'drugActionType': 'antagonist', 'drugMechanismOfAction': 'Purinergic receptor P2Y12 antagonist', 'linkedDiseasesDrug_string': 'Recurrent Thrombophlebitis (HP_0004419), Myocardial Infarction (EFO_0000612)', 'newLinkedTargets_string': 'P2RY12 (ENSG00000169313)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2015, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.128 | Q22 | What is Coreg Cr? | Coreg Cr, also known generically as Carvedilol, was approved by the FDA in 1995 to treat cardiovascular disease, congestive heart failure, hypertension, myocardial infarction, and heart failure. It is a small molecule therapy that acts as a(n) antagonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%coreg cr%" OR LOWER(tradeNames_string) LIKE "%coreg cr%" OR LOWER(drugSynonyms_string) LIKE "%coreg cr%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3793', 'tradeNames_string': 'Carvedilol, Coreg, Coreg CR, Eucardic 12.5, Eucardic 25, Eucardic 3.125, Eucardic 6.25', 'drugName': 'Carvedilol', 'drugMolecularType': 'Small molecule', 'drugActionType': 'antagonist', 'drugMechanismOfAction': 'Adrenergic receptor beta antagonist', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Multiple Myeloma (EFO_0001378), Coronary Artery Disease (EFO_0001645), Pulmonary Hypertension (MONDO_0005149), Pulmonary Arterial Hypertension (EFO_0001361), Essential Hypertension (MONDO_0001134), Hypoglycemia (HP_0001943), Atrial Fibrillation (EFO_0000275), Post-Traumatic Stress Disorder (EFO_0001358), Congestive Heart Failure (EFO_0000373), Prostate Cancer (MONDO_0008315), Breast Cancer (MONDO_0007254), Angina Pectoris (EFO_0003913), Left Ventricular Hypertrophy (EFO_0003896), Hypertension (EFO_0000537), Cardiovascular Disease (EFO_0000319), Lymphoma (EFO_0000574), Acute Myeloid Leukemia (EFO_0000222), Cocaine Dependence (EFO_0002610), Epilepsy (EFO_0000474), Myocardial Infarction (EFO_0000612), Hypercholesterolemia (HP_0003124), Portal Hypertension (EFO_0000666), Esophageal Varices (EFO_0009545), Lymphoid Leukemia (EFO_0004289), Heart Failure (EFO_0003144), Kidney Disease (EFO_0003086), Vascular Disease (EFO_0004264), Glioblastoma Multiforme (EFO_0000519), Type 2 Diabetes Mellitus (MONDO_0005148), Atherosclerosis (EFO_0003914)', 'newLinkedTargets_string': 'ADRB1 (ENSG00000043591), ADRB2 (ENSG00000169252), ADRB3 (ENSG00000188778), ADRA1A (ENSG00000120907), ADRA1D (ENSG00000171873), ADRA1B (ENSG00000170214)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1995, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_3794', 'tradeNames_string': 'Carvedilol, Coreg, Coreg CR, Eucardic 12.5, Eucardic 25, Eucardic 3.125, Eucardic 6.25', 'drugName': 'Carvedilol', 'drugMolecularType': 'Small molecule', 'drugActionType': 'antagonist', 'drugMechanismOfAction': 'Adrenergic receptor alpha-1 antagonist', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Multiple Myeloma (EFO_0001378), Coronary Artery Disease (EFO_0001645), Pulmonary Hypertension (MONDO_0005149), Pulmonary Arterial Hypertension (EFO_0001361), Essential Hypertension (MONDO_0001134), Hypoglycemia (HP_0001943), Atrial Fibrillation (EFO_0000275), Post-Traumatic Stress Disorder (EFO_0001358), Congestive Heart Failure (EFO_0000373), Prostate Cancer (MONDO_0008315), Breast Cancer (MONDO_0007254), Angina Pectoris (EFO_0003913), Left Ventricular Hypertrophy (EFO_0003896), Hypertension (EFO_0000537), Cardiovascular Disease (EFO_0000319), Lymphoma (EFO_0000574), Acute Myeloid Leukemia (EFO_0000222), Cocaine Dependence (EFO_0002610), Epilepsy (EFO_0000474), Myocardial Infarction (EFO_0000612), Hypercholesterolemia (HP_0003124), Portal Hypertension (EFO_0000666), Esophageal Varices (EFO_0009545), Lymphoid Leukemia (EFO_0004289), Heart Failure (EFO_0003144), Kidney Disease (EFO_0003086), Vascular Disease (EFO_0004264), Glioblastoma Multiforme (EFO_0000519), Type 2 Diabetes Mellitus (MONDO_0005148), Atherosclerosis (EFO_0003914)', 'newLinkedTargets_string': 'ADRB1 (ENSG00000043591), ADRB2 (ENSG00000169252), ADRB3 (ENSG00000188778), ADRA1A (ENSG00000120907), ADRA1D (ENSG00000171873), ADRA1B (ENSG00000170214)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1995, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_906', 'tradeNames_string': 'Coreg cr', 'drugName': 'Carvedilol Phosphate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'antagonist', 'drugMechanismOfAction': 'Adrenergic receptor beta antagonist', 'linkedDiseasesDrug_string': 'Congestive Heart Failure (EFO_0000373), Hypertension (EFO_0000537), Myocardial Infarction (EFO_0000612)', 'newLinkedTargets_string': 'ADRB1 (ENSG00000043591), ADRB2 (ENSG00000169252), ADRB3 (ENSG00000188778), ADRA1A (ENSG00000120907), ADRA1D (ENSG00000171873), ADRA1B (ENSG00000170214)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2006, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_907', 'tradeNames_string': 'Coreg cr', 'drugName': 'Carvedilol Phosphate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'antagonist', 'drugMechanismOfAction': 'Adrenergic receptor alpha-1 antagonist', 'linkedDiseasesDrug_string': 'Congestive Heart Failure (EFO_0000373), Hypertension (EFO_0000537), Myocardial Infarction (EFO_0000612)', 'newLinkedTargets_string': 'ADRB1 (ENSG00000043591), ADRB2 (ENSG00000169252), ADRB3 (ENSG00000188778), ADRA1A (ENSG00000120907), ADRA1D (ENSG00000171873), ADRA1B (ENSG00000170214)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2006, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.578 | Q22 | What is Rybelsus? | Rybelsus, also known generically as Semaglutide, was approved by the FDA in 2017 to treat diabetes mellitus and type 2 diabetes mellitus. It is a protein therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%rybelsus%" OR LOWER(tradeNames_string) LIKE "%rybelsus%" OR LOWER(drugSynonyms_string) LIKE "%rybelsus%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_6086', 'tradeNames_string': 'Ozempic, Rybelsus, Wegovy', 'drugName': 'Semaglutide', 'drugMolecularType': 'Protein', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Glucagon-like peptide 1 receptor agonist', 'linkedDiseasesDrug_string': 'Diabetes Mellitus (EFO_0000400), Osteopenia (HP_0000938), Alzheimer Disease (MONDO_0004975), Asthma (MONDO_0004979), Coronary Artery Disease (EFO_0001645), Obesity (EFO_0001073), Non-Alcoholic Steatohepatitis (EFO_1001249), Parkinson Disease (MONDO_0005180), Non-Alcoholic Fatty Liver Disease (EFO_0003095), Major Depressive Disorder (MONDO_0002009), Type 1 Diabetes Mellitus (MONDO_0005147), Type 2 Diabetes Mellitus (MONDO_0005148)', 'newLinkedTargets_string': 'GLP1R (ENSG00000112164)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2017, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.242 | Q22 | What is Exondys 51? | Exondys 51, also known generically as Eteplirsen, was approved by the FDA in 2016 to treat Duchenne muscular dystrophy and muscular dystrophy. It is a oligonucleotide therapy that acts as a(n) positive modulator. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%exondys 51%" OR LOWER(tradeNames_string) LIKE "%exondys 51%" OR LOWER(drugSynonyms_string) LIKE "%exondys 51%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3184', 'tradeNames_string': 'Exondys 51', 'drugName': 'Eteplirsen', 'drugMolecularType': 'Oligonucleotide', 'drugActionType': 'positive modulator', 'drugMechanismOfAction': 'Dystrophin pre-mRNA positive modulator', 'linkedDiseasesDrug_string': 'Muscular Dystrophy (MONDO_0020121), Duchenne Muscular Dystrophy (MONDO_0010679)', 'newLinkedTargets_string': 'DMD (ENSG00000198947)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2016, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.1 | Q22 | What is Tymlos? | Tymlos, also known generically as Abaloparatide, was approved by the FDA in 2017 to treat osteoporosis. It is a protein therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%tymlos%" OR LOWER(tradeNames_string) LIKE "%tymlos%" OR LOWER(drugSynonyms_string) LIKE "%tymlos%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1895', 'tradeNames_string': 'Tymlos', 'drugName': 'Abaloparatide', 'drugMolecularType': 'Protein', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Parathyroid hormone receptor agonist', 'linkedDiseasesDrug_string': 'Osteoporosis (EFO_0003882), Bone Fracture (EFO_0003931), Postmenopausal Osteoporosis (EFO_0003854)', 'newLinkedTargets_string': 'PTH1R (ENSG00000160801)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2017, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.698 | Q22 | What is Oxbryta? | Oxbryta, also known generically as Voxelotor, was approved by the FDA in 2019 to treat sickle cell anemia. It is a small molecule therapy that acts as a(n) positive modulator. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%oxbryta%" OR LOWER(tradeNames_string) LIKE "%oxbryta%" OR LOWER(drugSynonyms_string) LIKE "%oxbryta%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2318', 'tradeNames_string': 'Oxbryta', 'drugName': 'Voxelotor', 'drugMolecularType': 'Small molecule', 'drugActionType': 'positive modulator', 'drugMechanismOfAction': 'Hemoglobin HbA positive modulator', 'linkedDiseasesDrug_string': 'Acute Lung Injury (EFO_0004610), Liver Disease (EFO_0001421), Sickle Cell Anemia (MONDO_0011382), Kidney Disease (EFO_0003086), Idiopathic Pulmonary Fibrosis (EFO_0000768)', 'newLinkedTargets_string': 'HBA1 (ENSG00000206172), HBA2 (ENSG00000188536), HBB (ENSG00000244734)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2019, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.537 | Q22 | What is Milprosa? | Milprosa, also known generically as Progesterone, was approved by the FDA in 1976 to treat hemorrhage, amenorrhea, and endometrial hyperplasia. It is a small molecule therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%milprosa%" OR LOWER(tradeNames_string) LIKE "%milprosa%" OR LOWER(drugSynonyms_string) LIKE "%milprosa%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4799', 'tradeNames_string': 'Crinone, Cyclogest, Endometrin, Gesterol, Lutigest, Milprosa, Prochieve, Progesta-care, Progestasert, Progesterone, Progestin, Prometrium, Regumate, Serenity for women, Syngestrone, Utrogestan', 'drugName': 'Progesterone', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Progesterone receptor agonist', 'linkedDiseasesDrug_string': 'Diabetes Mellitus (EFO_0000400), Alzheimer Disease (MONDO_0004975), Coronary Artery Disease (EFO_0001645), Hemorrhage (MP_0001914), Covid-19 (MONDO_0100096), Uterine Fibroid (EFO_0000731), Cannabis Dependence (EFO_0007191), Ovarian Hyperstimulation Syndrome (MONDO_0011972), Placenta Praevia (EFO_0007442), Endometrial Cancer (MONDO_0011962), Pregnancy (EFO_0002950), Anorexia Nervosa (MONDO_0005351), Myocardial Ischemia (EFO_1001375), Breast Neoplasm (EFO_0003869), Osteopenia (HP_0000938), Polycystic Ovary Syndrome (EFO_0000660), Gliosarcoma (EFO_1001465), Postpartum Depression (EFO_0007453), Preeclampsia (EFO_0000668), Breast Cancer (MONDO_0007254), Vulvar Lichen Sclerosus (EFO_1000623), Nicotine Dependence (EFO_0003768), Osteoporosis (EFO_0003882), Hypertension (EFO_0000537), Thrombotic Disease (MONDO_0000831), Intermediate Coronary Syndrome (EFO_1000985), Amenorrhea (EFO_0010269), Epilepsy (EFO_0000474), Cocaine Dependence (EFO_0002610), Methamphetamine Dependence (EFO_0004701), Memory Impairment (EFO_0001072), Cervical Intraepithelial Neoplasia (MONDO_0022394), Premature Birth (EFO_0003917), Menopause (EFO_0003922), Orthostatic Intolerance (EFO_1000645), Infertility (EFO_0000545), Hypercholesterolemia (HP_0003124), Hiv-1 Infection (EFO_0000180), Brain Injury (MONDO_0043510), Ovarian Neoplasm (EFO_0003893), Female Infertility (EFO_0008560), Bulimia Nervosa (EFO_0005204), Type 1 Diabetes Mellitus (MONDO_0005147)', 'newLinkedTargets_string': 'PGR (ENSG00000082175)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1976, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.637 | Q22 | What is Tlando? | Tlando, also known generically as Testosterone Undecanoate, was approved by the FDA in 2014 to treat neoplasm, Klinefelter's syndrome, orchitis, hypogonadism, and hypogonadotropic hypogonadism. It is a small molecule therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%tlando%" OR LOWER(tradeNames_string) LIKE "%tlando%" OR LOWER(drugSynonyms_string) LIKE "%tlando%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_939', 'tradeNames_string': 'Andriol, Aveed, Jatenzo, Kyzatrex, Nebido, Restandol, Restandol testocap, Tlando, Undestor', 'drugName': 'Testosterone Undecanoate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Androgen Receptor agonist', 'linkedDiseasesDrug_string': "Hypogonadism (MONDO_0002146), Coronary Artery Disease (EFO_0001645), Prostate Cancer (MONDO_0008315), Neoplasm (EFO_0000616), Respiratory Failure (EFO_0009686), Renal Cell Carcinoma (EFO_0000681), Klinefelter'S Syndrome (EFO_1001006), Hypogonadotropic Hypogonadism (MONDO_0018555), Aging (GO_0007568), Malnutrition (EFO_0008572), Sexual Dysfunction (EFO_0004714), Spinal Cord Injury (EFO_1001919), Orchitis (EFO_1001078)", 'newLinkedTargets_string': 'AR (ENSG00000169083)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2014, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.615 | Q22 | What is Hetlioz Lq? | Hetlioz Lq, also known generically as Tasimelteon, was approved by the FDA in 2014 to treat sleep-wake disorder, Smith-Magenis syndrome, and Chromosomal anomaly. It is a small molecule therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%hetlioz lq%" OR LOWER(tradeNames_string) LIKE "%hetlioz lq%" OR LOWER(drugSynonyms_string) LIKE "%hetlioz lq%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_6185', 'tradeNames_string': 'Hetlioz, Hetlioz lq', 'drugName': 'Tasimelteon', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Melatonin receptor agonist', 'linkedDiseasesDrug_string': 'Circadian Rhythm Sleep Disorder (MONDO_0024361), Chromosomal Anomaly (Orphanet_68335), Liver Disease (EFO_0001421), Sleep-Wake Disorder (MONDO_0003406), Kidney Disease (EFO_0003086), Smith-Magenis Syndrome (MONDO_0008434), Major Depressive Disorder (MONDO_0002009), Insomnia (EFO_0004698)', 'newLinkedTargets_string': 'MTNR1A (ENSG00000168412), MTNR1B (ENSG00000134640)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2014, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.282 | Q22 | What is Ztalmy? | Ztalmy, also known generically as Ganaxolone, was approved by the FDA in 2022 to treat Seizure, epilepsy, and West syndrome. It is a small molecule therapy that acts as a(n) positive allosteric modulator. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%ztalmy%" OR LOWER(tradeNames_string) LIKE "%ztalmy%" OR LOWER(drugSynonyms_string) LIKE "%ztalmy%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1369', 'tradeNames_string': 'Ztalmy', 'drugName': 'Ganaxolone', 'drugMolecularType': 'Small molecule', 'drugActionType': 'positive allosteric modulator', 'drugMechanismOfAction': 'GABA-A receptor; anion channel positive allosteric modulator', 'linkedDiseasesDrug_string': 'Post-Traumatic Stress Disorder (EFO_0001358), Smoking Cessation (EFO_0004319), West Syndrome (MONDO_0018097), Fragile X Syndrome (MONDO_0010383), Partial Epilepsy (EFO_0004263), Tuberous Sclerosis (MONDO_0001734), Epilepsy (EFO_0000474), Seizure (HP_0001250), Status Epilepticus (EFO_0008526), Complex Partial Epilepsy (EFO_1000877)', 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2022, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.119 | Q22 | What is Invokana? | Invokana, also known generically as Canagliflozin, was approved by the FDA in 2011 to treat diabetes mellitus and type 2 diabetes mellitus. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%invokana%" OR LOWER(tradeNames_string) LIKE "%invokana%" OR LOWER(drugSynonyms_string) LIKE "%invokana%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4559', 'tradeNames_string': 'Invokana', 'drugName': 'Canagliflozin', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Sodium/glucose cotransporter 2 inhibitor', 'linkedDiseasesDrug_string': 'Diabetes Mellitus (EFO_0000400), Polycystic Ovary Syndrome (EFO_0000660), Breast Cancer (MONDO_0007254), Diabetic Nephropathy (EFO_0000401), Heart Failure (EFO_0003144), Obesity (EFO_0001073), Renal Insufficiency (HP_0000083), Type 1 Diabetes Mellitus (MONDO_0005147), Type 2 Diabetes Mellitus (MONDO_0005148)', 'newLinkedTargets_string': 'SLC5A2 (ENSG00000140675)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2011, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.232 | Q22 | What is Lexapro? | Lexapro, also known generically as Escitalopram Oxalate, was approved by the FDA in 2002 to treat unipolar depression, anxiety disorder, generalized anxiety disorder, and major depressive disorder. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%lexapro%" OR LOWER(tradeNames_string) LIKE "%lexapro%" OR LOWER(drugSynonyms_string) LIKE "%lexapro%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4125', 'tradeNames_string': 'Escitalopram oxalate, Lexapro', 'drugName': 'Escitalopram Oxalate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Serotonin transporter inhibitor', 'linkedDiseasesDrug_string': 'Unipolar Depression (EFO_0003761), Anxiety Disorder (EFO_0006788), Generalized Anxiety Disorder (EFO_1001892), Panic Disorder (EFO_0004262), Major Depressive Disorder (MONDO_0002009), Depressive Disorder (MONDO_0002050), Spinal Cord Injury (EFO_1001919)', 'newLinkedTargets_string': 'SLC6A4 (ENSG00000108576)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2002, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.704 | Q22 | What is Intermezzo? | Intermezzo, also known generically as Zolpidem Tartrate, was approved by the FDA in 1992 to treat insomnia. It is a small molecule therapy that acts as a(n) positive allosteric modulator. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%intermezzo%" OR LOWER(tradeNames_string) LIKE "%intermezzo%" OR LOWER(drugSynonyms_string) LIKE "%intermezzo%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5904', 'tradeNames_string': 'Ambien, Ambien cr, Edluar, Intermezzo, Stilnoct, Tovalt odt, Zolpidem tartrate, Zolpimist', 'drugName': 'Zolpidem Tartrate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'positive allosteric modulator', 'drugMechanismOfAction': 'GABA A receptor alpha-1/beta-1/gamma-2 positive allosteric modulator', 'linkedDiseasesDrug_string': 'Sleep Disorder (EFO_0008568), Obesity (EFO_0001073), Insomnia (EFO_0004698)', 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRG2 (ENSG00000113327), GABRB1 (ENSG00000163288)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1992, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.324 | Q22 | What is Onivyde? | Onivyde, also known generically as Irinotecan Hydrochloride, was approved by the FDA in 1996 to treat adenocarcinoma and carcinoma. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%onivyde%" OR LOWER(tradeNames_string) LIKE "%onivyde%" OR LOWER(drugSynonyms_string) LIKE "%onivyde%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5193', 'tradeNames_string': 'Campto, Camptosar, Irinotecan hydrochloride, Onivyde', 'drugName': 'Irinotecan Hydrochloride', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'DNA topoisomerase I inhibitor', 'linkedDiseasesDrug_string': "Ovarian Carcinoma (EFO_0001075), Verrucous Carcinoma (EFO_0007535), Oligodendroglioma (EFO_0000632), Lung Carcinoma (EFO_0001071), Malignant Colon Neoplasm (MONDO_0021063), Pineoblastoma (EFO_1000475), Malignant Glioma (MONDO_0100342), Malignant Epithelial Tumor Of Ovary (MONDO_0018364), Carcinoma (EFO_0000313), Malt Lymphoma (EFO_0000191), Liver Cancer (MONDO_0002691), Cervical Cancer (MONDO_0002974), Osteosarcoma (EFO_0000637), Ewing Sarcoma (EFO_0000174), Lung Cancer (MONDO_0008903), Follicular Lymphoma (MONDO_0018906), Leukemia (EFO_0000565), Lymphoma, Aids-Related (EFO_1001365), Anus Cancer (MONDO_0001879), Colorectal Adenocarcinoma (EFO_0000365), Glioblastoma Multiforme (EFO_0000519), Adult T-Cell Leukemia/Lymphoma (MONDO_0019471), Sezary'S Disease (EFO_1000785), Cancer (MONDO_0004992), Chronic Lymphocytic Leukemia (EFO_0000095), Anaplastic Large Cell Lymphoma (EFO_0003032), Gastrointestinal Stromal Tumor (MONDO_0011719), Colorectal Carcinoma (EFO_1001951), Neuroendocrine Carcinoma (MONDO_0002120), Gliosarcoma (EFO_1001465), Fallopian Tube Carcinoma (EFO_1000251), Mantle Cell Lymphoma (EFO_1001469), Gastric Adenocarcinoma (EFO_0000503), Basal Cell Carcinoma (EFO_0004193), Olfactory Neuroblastoma (EFO_1000407), Diffuse Large B-Cell Lymphoma (EFO_0000403), Inverted Papilloma (MONDO_0002537), Gastric Carcinoma (EFO_0000178), Anaplastic Oligodendroglioma (EFO_0002501), Hypopharyngeal Carcinoma (EFO_0002938), Small Cell Lung Carcinoma (EFO_0000702), Lethal Midline Granuloma (EFO_1001013), Appendix Carcinoma (MONDO_0003196), Triple-Negative Breast Cancer (EFO_0005537), Salivary Gland Cancer (MONDO_0004669), Hodgkins Lymphoma (EFO_0000183), Rectum Cancer (EFO_1000657), Merkel Cell Skin Cancer (EFO_1001471), Non-Small Cell Lung Carcinoma (EFO_0003060), Peripheral Primitive Neuroectodermal Tumor (MONDO_0018271), Neuroblastoma (EFO_0000621), Hepatoblastoma (EFO_1000292), Laryngeal Squamous Cell Carcinoma (EFO_0006352), Gastric Cancer (MONDO_0001056), Ovarian Cancer (MONDO_0008170), Anaplastic Astrocytoma (EFO_0002499), Diarrhea (HP_0002014), Breast Cancer (MONDO_0007254), Embryonal Rhabdomyosarcoma (EFO_0000437), Lymphoma (EFO_0000574), Pancreatic Ductal Adenocarcinoma (EFO_0002517), Mycosis Fungoides (EFO_1001051), Biliary Tract Cancer (MONDO_0003060), Penile Cancer (MONDO_0001325), Pancreatic Carcinoma (EFO_0002618), Central Nervous System Neoplasm (EFO_1000158), Rhabdomyosarcoma (EFO_0002918), Gallbladder Cancer (MONDO_0005411), Ganglioneuroblastoma (EFO_0000502), Carcinoid Tumor (EFO_0004243), Peritoneum Cancer (MONDO_0002087), Oropharyngeal Carcinoma (MONDO_0044926), Cutaneous Melanoma (EFO_0000389), Neoplasm (EFO_0000616), Adenocarcinoma (EFO_0000228), Urinary Bladder Cancer (MONDO_0001187), Sarcoma (EFO_0000691), Grade Iii Meningioma (MONDO_0020634), Medulloblastoma (EFO_0002939), Metastatic Melanoma (EFO_0002617), Burkitts Lymphoma (EFO_0000309), Angioimmunoblastic T-Cell Lymphoma (EFO_0000255), Rectal Carcinoma (MONDO_0044937), Breast Carcinoma (EFO_0000305), Prostate Cancer (MONDO_0008315), Neutropenia (MONDO_0001475), Colorectal Neoplasm (EFO_0004142), Cerebral Astrocytoma (MONDO_0021633), Urethra Cancer (MONDO_0004192), Endometrial Carcinoma (EFO_1001512), Esophageal Cancer (MONDO_0007576), Lymphoblastic Lymphoma (MONDO_0000873), Alveolar Rhabdomyosarcoma (EFO_0000248), Renal Cell Carcinoma (EFO_0000681), Head And Neck Malignant Neoplasia (EFO_0006859), Fallopian Tube Cancer (MONDO_0002158), Squamous Cell Carcinoma (EFO_0000707), Mesenchymoma (EFO_1001042), Kidney Cancer (MONDO_0002367), Choroid Plexus Neoplasm (MONDO_0016717)", 'newLinkedTargets_string': 'TOP1 (ENSG00000198900)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1996, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.278 | Q22 | What is Tavalisse? | Tavalisse, also known generically as Fostamatinib Disodium, was approved by the FDA in 2018 to treat Thrombocytopenia and autoimmune thrombocytopenic purpura. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%tavalisse%" OR LOWER(tradeNames_string) LIKE "%tavalisse%" OR LOWER(drugSynonyms_string) LIKE "%tavalisse%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4030', 'tradeNames_string': 'Tavalisse', 'drugName': 'Fostamatinib Disodium', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Tyrosine-protein kinase SYK inhibitor', 'linkedDiseasesDrug_string': 'Thrombocytopenia (HP_0001873), Autoimmune Thrombocytopenic Purpura (EFO_0007160), Anemia, Hemolytic, Autoimmune (EFO_1001264), Lymphoma (EFO_0000574), Iga Glomerulonephritis (EFO_0004194), Systemic Lupus Erythematosus (MONDO_0007915), Rheumatoid Arthritis (EFO_0000685)', 'newLinkedTargets_string': 'SYK (ENSG00000165025)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2018, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.699 | Q22 | What is Amvuttra? | Amvuttra, also known generically as Vutrisiran, was approved by the FDA in 2022 to treat familial amyloid neuropathy and polyneuropathy. It is a oligonucleotide therapy that acts as a(n) rnai inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%amvuttra%" OR LOWER(tradeNames_string) LIKE "%amvuttra%" OR LOWER(drugSynonyms_string) LIKE "%amvuttra%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2234', 'tradeNames_string': 'Amvuttra', 'drugName': 'Vutrisiran', 'drugMolecularType': 'Oligonucleotide', 'drugActionType': 'rnai inhibitor', 'drugMechanismOfAction': 'Transthyretin mRNA rnai inhibitor', 'linkedDiseasesDrug_string': 'Familial Amyloid Neuropathy (EFO_0004129), Polyneuropathy (EFO_0009562)', 'newLinkedTargets_string': 'TTR (ENSG00000118271)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2022, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.147 | Q22 | What is Olux E? | Olux E, also known generically as Clobetasol Propionate, was approved by the FDA in 1985 to treat psoriasis, skin disease, and psoriasis vulgaris. It is a small molecule therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%olux e%" OR LOWER(tradeNames_string) LIKE "%olux e%" OR LOWER(drugSynonyms_string) LIKE "%olux e%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5376', 'tradeNames_string': 'Clarelux, Clobaderm, Clobetasol propionate, Clobetasol propionate (emollient), Clobex, Cormax, Dermovate, Dermovate nn, Embeline, Embeline e, Etrivex, Impeklo, Impoyz, Olux, Olux e, Temovate, Temovate e', 'drugName': 'Clobetasol Propionate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Glucocorticoid receptor agonist', 'linkedDiseasesDrug_string': 'Psoriasis (EFO_0000676), Oral Lichen Planus (EFO_0008517), Graft Versus Host Disease (MONDO_0013730), Scleroderma (EFO_1001993), Psoriasis Vulgaris (EFO_1001494), Herpes Labialis (EFO_1001347), Vulvar Lichen Sclerosus (EFO_1000623), Cataract (MONDO_0005129), Atopic Eczema (EFO_0000274), Bullous Pemphigoid (EFO_0007187), Lichen Planus (EFO_1000726), Alopecia Areata (EFO_0004192), Rheumatoid Arthritis (EFO_0000685), Toxic Epidermal Necrolysis (EFO_0004775), Rectum Cancer (EFO_1000657), Colon Adenocarcinoma (EFO_1001949), Lichen Disease (EFO_1000724), Skin Disease (EFO_0000701), Seborrheic Dermatitis (EFO_1000764), Phlebitis (EFO_1001395)', 'newLinkedTargets_string': 'NR3C1 (ENSG00000113580)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1985, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.388 | Q22 | What is Adasuve? | Adasuve, also known generically as Loxapine, was approved by the FDA in 1975 to treat Agitation, psychosis, bipolar I disorder, and schizophrenia. It is a small molecule therapy that acts as a(n) antagonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%adasuve%" OR LOWER(tradeNames_string) LIKE "%adasuve%" OR LOWER(drugSynonyms_string) LIKE "%adasuve%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4041', 'tradeNames_string': 'Adasuve, Loxitane intramuscular [as hydrochloride], Loxitane-c oral suspension [as hydrochloride]', 'drugName': 'Loxapine', 'drugMolecularType': 'Small molecule', 'drugActionType': 'antagonist', 'drugMechanismOfAction': 'Serotonin 2a (5-HT2a) receptor antagonist', 'linkedDiseasesDrug_string': 'Psychosis (EFO_0005407), Asthma (MONDO_0004979), Bipolar I Disorder (EFO_0009963), Nicotine Dependence (EFO_0003768), Agitation (HP_0000713), Delirium (EFO_0009267), Migraine Disorder (MONDO_0005277), Chronic Obstructive Pulmonary Disease (EFO_0000341), Neuropathic Pain (EFO_0005762), Anxiety (EFO_0005230), Schizophrenia (MONDO_0005090)', 'newLinkedTargets_string': 'HTR2A (ENSG00000102468), HTR2C (ENSG00000147246), DRD2 (ENSG00000149295), DRD3 (ENSG00000151577), DRD4 (ENSG00000069696)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1975, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_4042', 'tradeNames_string': 'Adasuve, Loxitane intramuscular [as hydrochloride], Loxitane-c oral suspension [as hydrochloride]', 'drugName': 'Loxapine', 'drugMolecularType': 'Small molecule', 'drugActionType': 'antagonist', 'drugMechanismOfAction': 'Serotonin 2c (5-HT2c) receptor antagonist', 'linkedDiseasesDrug_string': 'Psychosis (EFO_0005407), Asthma (MONDO_0004979), Bipolar I Disorder (EFO_0009963), Nicotine Dependence (EFO_0003768), Agitation (HP_0000713), Delirium (EFO_0009267), Migraine Disorder (MONDO_0005277), Chronic Obstructive Pulmonary Disease (EFO_0000341), Neuropathic Pain (EFO_0005762), Anxiety (EFO_0005230), Schizophrenia (MONDO_0005090)', 'newLinkedTargets_string': 'HTR2A (ENSG00000102468), HTR2C (ENSG00000147246), DRD2 (ENSG00000149295), DRD3 (ENSG00000151577), DRD4 (ENSG00000069696)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1975, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_4043', 'tradeNames_string': 'Adasuve, Loxitane intramuscular [as hydrochloride], Loxitane-c oral suspension [as hydrochloride]', 'drugName': 'Loxapine', 'drugMolecularType': 'Small molecule', 'drugActionType': 'antagonist', 'drugMechanismOfAction': 'D2-like dopamine receptor antagonist', 'linkedDiseasesDrug_string': 'Psychosis (EFO_0005407), Asthma (MONDO_0004979), Bipolar I Disorder (EFO_0009963), Nicotine Dependence (EFO_0003768), Agitation (HP_0000713), Delirium (EFO_0009267), Migraine Disorder (MONDO_0005277), Chronic Obstructive Pulmonary Disease (EFO_0000341), Neuropathic Pain (EFO_0005762), Anxiety (EFO_0005230), Schizophrenia (MONDO_0005090)', 'newLinkedTargets_string': 'HTR2A (ENSG00000102468), HTR2C (ENSG00000147246), DRD2 (ENSG00000149295), DRD3 (ENSG00000151577), DRD4 (ENSG00000069696)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1975, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.432 | Q22 | What is Provigil? | Provigil, also known generically as Modafinil, was approved by the FDA in 1998 to treat attention deficit hyperactivity disorder. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%provigil%" OR LOWER(tradeNames_string) LIKE "%provigil%" OR LOWER(drugSynonyms_string) LIKE "%provigil%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5145', 'tradeNames_string': 'Modafinil, Provigil', 'drugName': 'Modafinil', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Dopamine transporter inhibitor', 'linkedDiseasesDrug_string': 'Alzheimer Disease (MONDO_0004975), Orthostatic Hypotension (EFO_0005252), Substance Abuse (MONDO_0002491), Multiple Sclerosis (MONDO_0005301), Metastatic Melanoma (EFO_0002617), Ovarian Cancer (MONDO_0008170), Post-Traumatic Stress Disorder (EFO_0001358), Nicotine Dependence (EFO_0003768), Schizoaffective Disorder (EFO_0005411), Parkinson Disease (MONDO_0005180), Attention Deficit Hyperactivity Disorder (EFO_0003888), Cocaine Dependence (EFO_0002610), Sleep Disorder (EFO_0008568), Methamphetamine Dependence (EFO_0004701), Drug Dependence (EFO_0003890), Stroke (EFO_0000712), Narcolepsy (MONDO_0021107), Brain Neoplasm (EFO_0003833), Postpoliomyelitis Syndrome (EFO_0007454), Insomnia (EFO_0004698), Obstructive Sleep Apnea (EFO_0003918), Depressive Disorder (MONDO_0002050), Alcohol Dependence (MONDO_0007079), Opioid Dependence (EFO_0005611), Sleep Apnea (EFO_0003877), Ewing Sarcoma (EFO_0000174), Cognitive Impairment (HP_0100543), Melanoma (EFO_0000756), Dysphagia (HP_0002015), Tinnitus (HP_0000360), Major Depressive Disorder (MONDO_0002009), Fatigue (HP_0012378), Low Back Pain (HP_0003419), Schizophrenia (MONDO_0005090)', 'newLinkedTargets_string': 'SLC6A3 (ENSG00000142319)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1998, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.638 | Q22 | What is Thalomid? | Thalomid, also known generically as Thalidomide, was approved by the FDA in 1998 to treat immune system disease and multiple myeloma. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%thalomid%" OR LOWER(tradeNames_string) LIKE "%thalomid%" OR LOWER(drugSynonyms_string) LIKE "%thalomid%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_64', 'tradeNames_string': 'Talidex, Thalomid', 'drugName': 'Thalidomide', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'CRL4(CRBN) E3 ubiquitin ligase inhibitor', 'linkedDiseasesDrug_string': "Psoriasis (EFO_0000676), Multiple Myeloma (EFO_0001378), Ankylosing Spondylitis (EFO_0003898), Malignant Colon Neoplasm (MONDO_0021063), Neuroendocrine Neoplasm (EFO_1001901), Vascular Malformation (EFO_0006888), Malignant Epithelial Tumor Of Ovary (MONDO_0018364), Castleman Disease (MONDO_0015564), Malt Lymphoma (EFO_0000191), Liver Cancer (MONDO_0002691), Discoid Lupus Erythematosus (MONDO_0019558), Follicular Lymphoma (MONDO_0018906), Lung Cancer (MONDO_0008903), Leukemia (EFO_0000565), Colorectal Adenocarcinoma (EFO_0000365), Glioblastoma Multiforme (EFO_0000519), Cancer (MONDO_0004992), Pancreatic Neuroendocrine Tumor (EFO_1000045), Non-Hodgkins Lymphoma (EFO_0005952), Chronic Lymphocytic Leukemia (EFO_0000095), Al Amyloidosis (MONDO_0019438), Autoimmune Thrombocytopenic Purpura (EFO_0007160), Pain (EFO_0003843), Myelodysplastic Syndrome (EFO_0000198), Colorectal Carcinoma (EFO_1001951), Hepatocellular Carcinoma (EFO_0000182), Mantle Cell Lymphoma (EFO_1001469), Beta-Thalassemia (Orphanet_848), Myelofibrosis (MONDO_0044903), Endometriosis (EFO_0001065), Chronic Pancreatitis (EFO_0000342), Diffuse Large B-Cell Lymphoma (EFO_0000403), Appendix Carcinoma (MONDO_0003196), Hodgkins Lymphoma (EFO_0000183), Hiv Infection (EFO_0000764), Non-Small Cell Lung Carcinoma (EFO_0003060), Brain Stem Neoplasm (EFO_1001767), Sclerosing Cholangitis (EFO_0004268), Neuroblastoma (EFO_0000621), Alzheimer Disease (MONDO_0004975), Primary Myelofibrosis (EFO_0002430), Langerhans Cell Histiocytosis (EFO_1000318), Aids (EFO_0000765), Hypoalbuminemia (HP_0003073), Idiopathic Pulmonary Fibrosis (EFO_0000768), Gastric Cancer (MONDO_0001056), Ovarian Cancer (MONDO_0008170), Breast Cancer (MONDO_0007254), Thalassemia (EFO_1001996), Lymphoma (EFO_0000574), Epilepsy (EFO_0000474), Central Nervous System Neoplasm (EFO_1000158), Neoplasm Of Mature B-Cells (EFO_0000096), Peritoneum Cancer (MONDO_0002087), Glioma (EFO_0005543), Waldenstrom Macroglobulinemia (EFO_0009441), Cutaneous Melanoma (EFO_0000389), Sarcoidosis (MONDO_0019338), Neoplasm (EFO_0000616), Uterine Carcinosarcoma (EFO_1000613), Sarcoma (EFO_0000691), Primary Systemic Amyloidosis (MONDO_0017816), Amyloidosis (EFO_1001875), Medulloblastoma (EFO_0002939), Oral Cavity Cancer (EFO_0005570), Cough (HP_0012735), Covid-19 (MONDO_0100096), Ulcerative Colitis (EFO_0000729), Prostate Adenocarcinoma (EFO_0000673), Hepatitis C Virus Infection (EFO_0003047), Proctitis (EFO_0005628), Prostate Cancer (MONDO_0008315), Crohn'S Disease (EFO_0000384), Colorectal Neoplasm (EFO_0004142), Immune System Disease (EFO_0000540), Extranodal Nasal Nk/T Cell Lymphoma (MONDO_0019472), Soft Tissue Sarcoma (EFO_1001968), Renal Cell Carcinoma (EFO_0000681), Kidney Neoplasm (EFO_0003865), Systemic Scleroderma (EFO_0000717), Head And Neck Malignant Neoplasia (EFO_0006859), Fallopian Tube Cancer (MONDO_0002158), Amyotrophic Lateral Sclerosis (MONDO_0004976), Kidney Cancer (MONDO_0002367), Melanoma (EFO_0000756), Hiv Wasting Syndrome (EFO_0007312), Esophageal Cancer (MONDO_0007576)", 'newLinkedTargets_string': 'CRBN (ENSG00000113851), DDB1 (ENSG00000167986), CUL4A (ENSG00000139842), RBX1 (ENSG00000100387)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1998, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.507 | Q22 | What is Onpattro? | Onpattro, also known generically as Patisiran Sodium, was approved by the FDA in 2018 to treat familial amyloid neuropathy, polyneuropathy, and amyloidosis. It is a oligonucleotide therapy that acts as a(n) rnai inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%onpattro%" OR LOWER(tradeNames_string) LIKE "%onpattro%" OR LOWER(drugSynonyms_string) LIKE "%onpattro%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2512', 'tradeNames_string': 'Onpattro', 'drugName': 'Patisiran Sodium', 'drugMolecularType': 'Oligonucleotide', 'drugActionType': 'rnai inhibitor', 'drugMechanismOfAction': 'Transthyretin mRNA RNAi inhibitor', 'linkedDiseasesDrug_string': 'Amyloidosis (EFO_1001875), Familial Amyloid Neuropathy (EFO_0004129), Polyneuropathy (EFO_0009562)', 'newLinkedTargets_string': 'TTR (ENSG00000118271)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2018, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.272 | Q22 | What is Tolak? | Tolak, also known generically as Fluorouracil, was approved by the FDA in 1962 to treat adenocarcinoma, cancer, neoplasm, actinic keratosis, basal cell carcinoma, and keratosis. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%tolak%" OR LOWER(tradeNames_string) LIKE "%tolak%" OR LOWER(drugSynonyms_string) LIKE "%tolak%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1558', 'tradeNames_string': '5.f.u., Accusite, Actikerall, Adrucil, Carac, Efudex, Efudix, Fluoro-uracil roche, Fluoroplex, Fluorouracil, Tolak', 'drugName': 'Fluorouracil', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Thymidylate synthase inhibitor', 'linkedDiseasesDrug_string': 'Ovarian Carcinoma (EFO_0001075), Multiple Myeloma (EFO_0001378), Keratosis (EFO_1000720), Malignant Colon Neoplasm (MONDO_0021063), Signet Ring Cell Carcinoma (EFO_0000698), Inflammatory Breast Carcinoma (EFO_1000984), Neuroendocrine Neoplasm (EFO_1001901), Urinary Bladder Carcinoma (MONDO_0004986), Pharynx Cancer (EFO_0005577), Carcinoma (EFO_0000313), Liver Cancer (MONDO_0002691), Cervical Cancer (MONDO_0002974), Lymphoma, Aids-Related (EFO_1001365), Anus Cancer (MONDO_0001879), Colorectal Adenocarcinoma (EFO_0000365), Cancer (MONDO_0004992), Non-Hodgkins Lymphoma (EFO_0005952), Gastrointestinal Stromal Tumor (MONDO_0011719), Central Nervous System Cancer (EFO_0000326), Myelodysplastic Syndrome (EFO_0000198), Colorectal Carcinoma (EFO_1001951), Neuroendocrine Carcinoma (MONDO_0002120), Digestive System Cancer (MONDO_0002516), Hepatocellular Carcinoma (EFO_0000182), Fallopian Tube Carcinoma (EFO_1000251), Mucinous Carcinoma (EFO_0000197), Uterine Neoplasm (EFO_0003859), Gastric Adenocarcinoma (EFO_0000503), Basal Cell Carcinoma (EFO_0004193), Gastric Carcinoma (EFO_0000178), Metastasis (EFO_0009708), Hypopharyngeal Carcinoma (EFO_0002938), Proliferative Vitreoretinopathy (EFO_1001129), Head And Neck Neoplasia (EFO_0005950), Actinic Keratosis (EFO_0002496), Oropharynx Squamous Cell Carcinoma (MONDO_0044704), Dysplasia Of Cervix (EFO_1000910), Laryngeal Neoplasm (EFO_0003817), Rectum Cancer (EFO_1000657), Merkel Cell Skin Cancer (EFO_1001471), Esophageal Squamous Cell Carcinoma (EFO_0005922), Non-Small Cell Lung Carcinoma (EFO_0003060), Colonic Neoplasm (EFO_0004288), Head And Neck Carcinoma (MONDO_0002038), Peripheral Neuropathy (EFO_0003100), Upper Aerodigestive Tract Neoplasm (EFO_0004284), Urothelial Carcinoma (EFO_0008528), Intrahepatic Cholangiocarcinoma (EFO_1001961), Glaucoma (MONDO_0005041), Hepatoblastoma (EFO_1000292), Esophageal Carcinoma (EFO_0002916), Gastric Cancer (MONDO_0001056), Gastrointestinal Disease (EFO_0010282), Ovarian Cancer (MONDO_0008170), Breast Neoplasm (EFO_0003869), Breast Cancer (MONDO_0007254), Lymphoma (EFO_0000574), Pancreatic Ductal Adenocarcinoma (EFO_0002517), Head And Neck Squamous Cell Carcinoma (EFO_0000181), Biliary Tract Cancer (MONDO_0003060), Cholangiocarcinoma (EFO_0005221), Paranasal Sinus Neoplasm (EFO_0003866), Pancreatic Carcinoma (EFO_0002618), Lynch Syndrome (MONDO_0005835), Meibomian Cyst (EFO_0007363), Colorectal Cancer (MONDO_0005575), Skin Carcinoma (EFO_0009259), Peritoneum Cancer (MONDO_0002087), Cutaneous Melanoma (EFO_0000389), Biliary Tract Neoplasm (EFO_0003891), Chronic Myeloproliferative Disorder (EFO_0002428), Neoplasm (EFO_0000616), Adenocarcinoma (EFO_0000228), Urinary Bladder Cancer (MONDO_0001187), Colon Adenocarcinoma (EFO_1001949), Laryngeal Carcinoma (MONDO_0002358), Stomach Neoplasm (EFO_0003897), Oral Cavity Cancer (EFO_0005570), Neoplasm Of Esophagus (MONDO_0021355), Peritoneal Neoplasm (EFO_1001100), Metastatic Melanoma (EFO_0002617), Anal Neoplasm (EFO_0003835), Rectal Carcinoma (MONDO_0044937), Breast Carcinoma (EFO_0000305), Bile Duct Cancer (MONDO_0003059), Colorectal Neoplasm (EFO_0004142), Thrombotic Disease (MONDO_0000831), Oral Squamous Cell Carcinoma (EFO_0000199), Pancreatic Endocrine Carcinoma (EFO_0007416), Urethra Cancer (MONDO_0004192), Renal Cell Carcinoma (EFO_0000681), Ependymoma (EFO_1000028), Digestive System Neoplasm (EFO_0008549), Anal Carcinoma (MONDO_0003199), Head And Neck Malignant Neoplasia (EFO_0006859), Squamous Cell Carcinoma (EFO_0000707), Nasopharyngeal Neoplasm (EFO_0004252), Kidney Cancer (MONDO_0002367), Melanoma (EFO_0000756), Squamous Cell Intraepithelial Neoplasia (MONDO_0024475), Pancreatic Neoplasm (EFO_0003860), Esophageal Cancer (MONDO_0007576), Bladder Tumor (EFO_0000294)', 'newLinkedTargets_string': 'TYMS (ENSG00000176890)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1962, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.471 | Q22 | What is Lynparza? | Lynparza, also known generically as Olaparib, was approved by the FDA in 2014 to treat cancer, neoplasm, ovarian carcinoma, ovarian neoplasm, and ovarian cancer. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%lynparza%" OR LOWER(tradeNames_string) LIKE "%lynparza%" OR LOWER(drugSynonyms_string) LIKE "%lynparza%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_279', 'tradeNames_string': 'Lynparza', 'drugName': 'Olaparib', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'PARP 1, 2 and 3 inhibitor', 'linkedDiseasesDrug_string': 'Ovarian Carcinoma (EFO_0001075), Cancer (MONDO_0004992), Chronic Lymphocytic Leukemia (EFO_0000095), Uterine Cancer (MONDO_0002715), Pulmonary Arterial Hypertension (EFO_0001361), Peritoneal Neoplasm (EFO_1001100), Metastatic Melanoma (EFO_0002617), Colorectal Carcinoma (EFO_1001951), Endometrial Cancer (MONDO_0011962), Gastric Cancer (MONDO_0001056), Angiosarcoma (EFO_0003968), Acinar Cell Carcinoma (EFO_0000216), Breast Carcinoma (EFO_0000305), Breast Neoplasm (EFO_0003869), Prostate Carcinoma (EFO_0001663), Ovarian Cancer (MONDO_0008170), Fallopian Tube Carcinoma (EFO_1000251), Prostate Cancer (MONDO_0008315), Breast Cancer (MONDO_0007254), Bile Duct Cancer (MONDO_0003059), Prostate Adenocarcinoma (EFO_0000673), Gastric Adenocarcinoma (EFO_0000503), Lymphoma (EFO_0000574), Pancreatic Ductal Adenocarcinoma (EFO_0002517), Cervical Carcinoma (EFO_0001061), Head And Neck Squamous Cell Carcinoma (EFO_0000181), Biliary Tract Cancer (MONDO_0003060), Cholangiocarcinoma (EFO_0005221), Metastasis (EFO_0009708), Malignant Glioma (MONDO_0100342), Inflammatory Breast Carcinoma (EFO_1000984), Endometrial Carcinoma (EFO_1001512), Pancreatic Carcinoma (EFO_0002618), Neuroendocrine Neoplasm (EFO_1001901), Rhabdomyosarcoma (EFO_0002918), Central Nervous System Neoplasm (EFO_1000158), Carcinosarcoma (MONDO_0002928), Urinary Bladder Carcinoma (MONDO_0004986), Small Cell Lung Carcinoma (EFO_0000702), Mesothelioma (EFO_0000588), Triple-Negative Breast Cancer (EFO_0005537), Soft Tissue Sarcoma (EFO_1001968), Renal Cell Carcinoma (EFO_0000681), Peritoneum Cancer (MONDO_0002087), Malignant Epithelial Tumor Of Ovary (MONDO_0018364), Carcinoma (EFO_0000313), Cutaneous Melanoma (EFO_0000389), Endometrial Neoplasm (EFO_0004230), Ovarian Neoplasm (EFO_0003893), Cervical Cancer (MONDO_0002974), Germ Cell Tumor (EFO_0000514), Head And Neck Malignant Neoplasia (EFO_0006859), Osteosarcoma (EFO_0000637), Ewing Sarcoma (EFO_0000174), Squamous Cell Carcinoma (EFO_0000707), Lung Cancer (MONDO_0008903), Neoplasm (EFO_0000616), Urinary Bladder Cancer (MONDO_0001187), Fallopian Tube Cancer (MONDO_0002158), Non-Small Cell Lung Carcinoma (EFO_0003060), Metastatic Prostate Cancer (EFO_0000196), Sarcoma (EFO_0000691), Glioblastoma Multiforme (EFO_0000519), Serous Adenocarcinoma (EFO_0003825), Hereditary Breast And Ovarian Cancer Syndrome (Orphanet_145), Pancreatic Neoplasm (EFO_0003860), Bladder Tumor (EFO_0000294)', 'newLinkedTargets_string': 'PARP1 (ENSG00000143799), PARP3 (ENSG00000041880), PARP2 (ENSG00000129484)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2014, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.47 | Q22 | What is Emend? | Emend, also known generically as Aprepitant, was approved by the FDA in 2003 to treat Nausea and vomiting, Nausea, cancer, post operative nausea and vomiting, and Chemotherapy-induced nausea and vomiting. It is a small molecule therapy that acts as a(n) antagonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%emend%" OR LOWER(tradeNames_string) LIKE "%emend%" OR LOWER(drugSynonyms_string) LIKE "%emend%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1299', 'tradeNames_string': 'Aprepitant, Cinvanti, Emend', 'drugName': 'Aprepitant', 'drugMolecularType': 'Small molecule', 'drugActionType': 'antagonist', 'drugMechanismOfAction': 'Neurokinin 1 receptor antagonist', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Multiple Myeloma (EFO_0001378), Nausea (HP_0002018), Chemotherapy-Induced Nausea And Vomiting (EFO_0006911), Pain (EFO_0003843), Covid-19 (MONDO_0100096), Cannabis Dependence (EFO_0007191), Post Operative Nausea And Vomiting (EFO_0004888), Gastroparesis (EFO_1000948), Acute Myeloid Leukemia (EFO_0000222), Cocaine Dependence (EFO_0002610), Pruritus (HP_0000989), Heroin Dependence (EFO_0004240), Alcohol Dependence (MONDO_0007079), Opioid Dependence (EFO_0005611), Hiv Infection (EFO_0000764), Nausea And Vomiting (HP_0002017), Non-Small Cell Lung Carcinoma (EFO_0003060), Major Depressive Disorder (MONDO_0002009), Vomiting (HP_0002013), Glioblastoma Multiforme (EFO_0000519), Germ Cell Tumor (EFO_0000514)', 'newLinkedTargets_string': 'TACR1 (ENSG00000115353)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2003, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_5495', 'tradeNames_string': 'Emend, Fosaprepitant dimeglumine', 'drugName': 'Fosaprepitant Dimeglumine', 'drugMolecularType': 'Small molecule', 'drugActionType': 'antagonist', 'drugMechanismOfAction': 'Neurokinin 1 receptor antagonist', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Chemotherapy-Induced Nausea And Vomiting (EFO_0006911), Nausea And Vomiting (HP_0002017), Sarcoma (EFO_0000691), Post Operative Nausea And Vomiting (EFO_0004888)', 'newLinkedTargets_string': 'TACR1 (ENSG00000115353)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2008, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_542', 'tradeNames_string': 'Ivemend', 'drugName': 'Fosaprepitant', 'drugMolecularType': 'Small molecule', 'drugActionType': 'antagonist', 'drugMechanismOfAction': 'Neurokinin 1 receptor antagonist', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Multiple Myeloma (EFO_0001378), Chemotherapy-Induced Nausea And Vomiting (EFO_0006911), Neoplasm (EFO_0000616), Nausea And Vomiting (HP_0002017), Nasopharyngeal Neoplasm (EFO_0004252), Sarcoma (EFO_0000691), Female Reproductive System Neoplasm (MONDO_0021148), Post Operative Nausea And Vomiting (EFO_0004888), Brain Injury (MONDO_0043510)', 'newLinkedTargets_string': 'TACR1 (ENSG00000115353)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2008, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.265 | Q22 | What is Kerendia? | Kerendia, also known generically as Finerenone, was approved by the FDA in 2021 to treat cardiovascular disease and chronic kidney disease. It is a small molecule therapy that acts as a(n) antagonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%kerendia%" OR LOWER(tradeNames_string) LIKE "%kerendia%" OR LOWER(drugSynonyms_string) LIKE "%kerendia%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_365', 'tradeNames_string': 'Kerendia', 'drugName': 'Finerenone', 'drugMolecularType': 'Small molecule', 'drugActionType': 'antagonist', 'drugMechanismOfAction': 'Mineralocorticoid receptor antagonist', 'linkedDiseasesDrug_string': 'Chronic Kidney Disease (EFO_0003884), Heart Failure (EFO_0003144), Cardiovascular Disease (EFO_0000319), Diabetic Nephropathy (EFO_0000401)', 'newLinkedTargets_string': 'NR3C2 (ENSG00000151623)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2021, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.198 | Q22 | What is Vumerity? | Vumerity, also known generically as Diroximel Fumarate, was approved by the FDA in 2019 to treat immune system disease and multiple sclerosis. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%vumerity%" OR LOWER(tradeNames_string) LIKE "%vumerity%" OR LOWER(drugSynonyms_string) LIKE "%vumerity%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5578', 'tradeNames_string': 'Vumerity', 'drugName': 'Diroximel Fumarate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Kelch-like ECH-associated protein 1 inhibitor', 'linkedDiseasesDrug_string': 'Multiple Sclerosis (MONDO_0005301), Relapsing-Remitting Multiple Sclerosis (EFO_0003929), Immune System Disease (EFO_0000540)', 'newLinkedTargets_string': 'KEAP1 (ENSG00000079999)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2019, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.705 | Q22 | What is Zolpimist? | Zolpimist, also known generically as Zolpidem Tartrate, was approved by the FDA in 1992 to treat insomnia. It is a small molecule therapy that acts as a(n) positive allosteric modulator. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%zolpimist%" OR LOWER(tradeNames_string) LIKE "%zolpimist%" OR LOWER(drugSynonyms_string) LIKE "%zolpimist%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5904', 'tradeNames_string': 'Ambien, Ambien cr, Edluar, Intermezzo, Stilnoct, Tovalt odt, Zolpidem tartrate, Zolpimist', 'drugName': 'Zolpidem Tartrate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'positive allosteric modulator', 'drugMechanismOfAction': 'GABA A receptor alpha-1/beta-1/gamma-2 positive allosteric modulator', 'linkedDiseasesDrug_string': 'Sleep Disorder (EFO_0008568), Obesity (EFO_0001073), Insomnia (EFO_0004698)', 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRG2 (ENSG00000113327), GABRB1 (ENSG00000163288)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1992, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.590 | Q22 | What is Nexavar? | Nexavar, also known generically as Sorafenib, was approved by the FDA in 2005 to treat cancer, neoplasm, and renal cell carcinoma. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%nexavar%" OR LOWER(tradeNames_string) LIKE "%nexavar%" OR LOWER(drugSynonyms_string) LIKE "%nexavar%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1543', 'tradeNames_string': 'Nexavar', 'drugName': 'Sorafenib Tosylate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Serine/threonine-protein kinase B-raf inhibitor', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Multiple Myeloma (EFO_0001378), Papillary Thyroid Carcinoma (EFO_0000641), Chronic Lymphocytic Leukemia (EFO_0000095), Verrucous Carcinoma (EFO_0007535), Thyroid Carcinoma (EFO_0002892), Anaplastic Large Cell Lymphoma (EFO_0003032), Gastrointestinal Stromal Tumor (MONDO_0011719), Colorectal Carcinoma (EFO_1001951), Laryngeal Squamous Cell Carcinoma (EFO_0006352), Rectal Carcinoma (MONDO_0044937), Ovarian Cancer (MONDO_0008170), Malignant Colon Neoplasm (MONDO_0021063), Prostate Adenocarcinoma (EFO_0000673), Anaplastic Astrocytoma (EFO_0002499), Gliosarcoma (EFO_1001465), Hepatocellular Carcinoma (EFO_0000182), Myeloid Sarcoma (EFO_1001052), Acute Promyelocytic Leukemia (EFO_0000224), Mantle Cell Lymphoma (EFO_1001469), Breast Cancer (MONDO_0007254), Prostate Cancer (MONDO_0008315), Papillary Renal Cell Carcinoma (EFO_0000640), Acute Lymphoblastic Leukemia (EFO_0000220), Male Breast Carcinoma (EFO_0006861), Chromophobe Renal Cell Carcinoma (EFO_0000335), Acute Myeloid Leukemia (EFO_0000222), Diffuse Large B-Cell Lymphoma (EFO_0000403), Urethra Cancer (MONDO_0004192), Pancreatic Carcinoma (EFO_0002618), Central Nervous System Neoplasm (EFO_1000158), Anaplastic Oligodendroglioma (EFO_0002501), Tongue Neoplasm (EFO_0003871), Hypopharyngeal Carcinoma (EFO_0002938), Urinary Bladder Carcinoma (MONDO_0004986), Small Cell Lung Carcinoma (EFO_0000702), Mesothelioma (EFO_0000588), Clear Cell Renal Carcinoma (EFO_0000349), Soft Tissue Sarcoma (EFO_1001968), Thyroid Cancer (MONDO_0002108), Renal Cell Carcinoma (EFO_0000681), Brain Neoplasm (EFO_0003833), Peritoneum Cancer (MONDO_0002087), Cutaneous Melanoma (EFO_0000389), Oropharyngeal Carcinoma (MONDO_0044926), Liver Cancer (MONDO_0002691), Rectum Cancer (EFO_1000657), Osteosarcoma (EFO_0000637), Fallopian Tube Cancer (MONDO_0002158), Lung Cancer (MONDO_0008903), Neoplasm (EFO_0000616), Urinary Bladder Cancer (MONDO_0001187), Colorectal Adenocarcinoma (EFO_0000365), Uterine Carcinosarcoma (EFO_1000613), Non-Small Cell Lung Carcinoma (EFO_0003060), Kidney Cancer (MONDO_0002367), Sarcoma (EFO_0000691), Melanoma (EFO_0000756), Glioblastoma Multiforme (EFO_0000519), Follicular Thyroid Carcinoma (EFO_0000501), Desmoid-Type Fibromatosis (EFO_0009907)', 'newLinkedTargets_string': 'FLT3 (ENSG00000122025), RAF1 (ENSG00000132155), PDGFRB (ENSG00000113721), BRAF (ENSG00000157764), RET (ENSG00000165731), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), KIT (ENSG00000157404)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2005, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_1544', 'tradeNames_string': 'Nexavar', 'drugName': 'Sorafenib Tosylate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Tyrosine-protein kinase receptor FLT3 inhibitor', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Multiple Myeloma (EFO_0001378), Papillary Thyroid Carcinoma (EFO_0000641), Chronic Lymphocytic Leukemia (EFO_0000095), Verrucous Carcinoma (EFO_0007535), Thyroid Carcinoma (EFO_0002892), Anaplastic Large Cell Lymphoma (EFO_0003032), Gastrointestinal Stromal Tumor (MONDO_0011719), Colorectal Carcinoma (EFO_1001951), Laryngeal Squamous Cell Carcinoma (EFO_0006352), Rectal Carcinoma (MONDO_0044937), Ovarian Cancer (MONDO_0008170), Malignant Colon Neoplasm (MONDO_0021063), Prostate Adenocarcinoma (EFO_0000673), Anaplastic Astrocytoma (EFO_0002499), Gliosarcoma (EFO_1001465), Hepatocellular Carcinoma (EFO_0000182), Myeloid Sarcoma (EFO_1001052), Acute Promyelocytic Leukemia (EFO_0000224), Mantle Cell Lymphoma (EFO_1001469), Breast Cancer (MONDO_0007254), Prostate Cancer (MONDO_0008315), Papillary Renal Cell Carcinoma (EFO_0000640), Acute Lymphoblastic Leukemia (EFO_0000220), Male Breast Carcinoma (EFO_0006861), Chromophobe Renal Cell Carcinoma (EFO_0000335), Acute Myeloid Leukemia (EFO_0000222), Diffuse Large B-Cell Lymphoma (EFO_0000403), Urethra Cancer (MONDO_0004192), Pancreatic Carcinoma (EFO_0002618), Central Nervous System Neoplasm (EFO_1000158), Anaplastic Oligodendroglioma (EFO_0002501), Tongue Neoplasm (EFO_0003871), Hypopharyngeal Carcinoma (EFO_0002938), Urinary Bladder Carcinoma (MONDO_0004986), Small Cell Lung Carcinoma (EFO_0000702), Mesothelioma (EFO_0000588), Clear Cell Renal Carcinoma (EFO_0000349), Soft Tissue Sarcoma (EFO_1001968), Thyroid Cancer (MONDO_0002108), Renal Cell Carcinoma (EFO_0000681), Brain Neoplasm (EFO_0003833), Peritoneum Cancer (MONDO_0002087), Cutaneous Melanoma (EFO_0000389), Oropharyngeal Carcinoma (MONDO_0044926), Liver Cancer (MONDO_0002691), Rectum Cancer (EFO_1000657), Osteosarcoma (EFO_0000637), Fallopian Tube Cancer (MONDO_0002158), Lung Cancer (MONDO_0008903), Neoplasm (EFO_0000616), Urinary Bladder Cancer (MONDO_0001187), Colorectal Adenocarcinoma (EFO_0000365), Uterine Carcinosarcoma (EFO_1000613), Non-Small Cell Lung Carcinoma (EFO_0003060), Kidney Cancer (MONDO_0002367), Sarcoma (EFO_0000691), Melanoma (EFO_0000756), Glioblastoma Multiforme (EFO_0000519), Follicular Thyroid Carcinoma (EFO_0000501), Desmoid-Type Fibromatosis (EFO_0009907)', 'newLinkedTargets_string': 'FLT3 (ENSG00000122025), RAF1 (ENSG00000132155), PDGFRB (ENSG00000113721), BRAF (ENSG00000157764), RET (ENSG00000165731), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), KIT (ENSG00000157404)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2005, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_1545', 'tradeNames_string': 'Nexavar', 'drugName': 'Sorafenib Tosylate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Serine/threonine-protein kinase RAF inhibitor', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Multiple Myeloma (EFO_0001378), Papillary Thyroid Carcinoma (EFO_0000641), Chronic Lymphocytic Leukemia (EFO_0000095), Verrucous Carcinoma (EFO_0007535), Thyroid Carcinoma (EFO_0002892), Anaplastic Large Cell Lymphoma (EFO_0003032), Gastrointestinal Stromal Tumor (MONDO_0011719), Colorectal Carcinoma (EFO_1001951), Laryngeal Squamous Cell Carcinoma (EFO_0006352), Rectal Carcinoma (MONDO_0044937), Ovarian Cancer (MONDO_0008170), Malignant Colon Neoplasm (MONDO_0021063), Prostate Adenocarcinoma (EFO_0000673), Anaplastic Astrocytoma (EFO_0002499), Gliosarcoma (EFO_1001465), Hepatocellular Carcinoma (EFO_0000182), Myeloid Sarcoma (EFO_1001052), Acute Promyelocytic Leukemia (EFO_0000224), Mantle Cell Lymphoma (EFO_1001469), Breast Cancer (MONDO_0007254), Prostate Cancer (MONDO_0008315), Papillary Renal Cell Carcinoma (EFO_0000640), Acute Lymphoblastic Leukemia (EFO_0000220), Male Breast Carcinoma (EFO_0006861), Chromophobe Renal Cell Carcinoma (EFO_0000335), Acute Myeloid Leukemia (EFO_0000222), Diffuse Large B-Cell Lymphoma (EFO_0000403), Urethra Cancer (MONDO_0004192), Pancreatic Carcinoma (EFO_0002618), Central Nervous System Neoplasm (EFO_1000158), Anaplastic Oligodendroglioma (EFO_0002501), Tongue Neoplasm (EFO_0003871), Hypopharyngeal Carcinoma (EFO_0002938), Urinary Bladder Carcinoma (MONDO_0004986), Small Cell Lung Carcinoma (EFO_0000702), Mesothelioma (EFO_0000588), Clear Cell Renal Carcinoma (EFO_0000349), Soft Tissue Sarcoma (EFO_1001968), Thyroid Cancer (MONDO_0002108), Renal Cell Carcinoma (EFO_0000681), Brain Neoplasm (EFO_0003833), Peritoneum Cancer (MONDO_0002087), Cutaneous Melanoma (EFO_0000389), Oropharyngeal Carcinoma (MONDO_0044926), Liver Cancer (MONDO_0002691), Rectum Cancer (EFO_1000657), Osteosarcoma (EFO_0000637), Fallopian Tube Cancer (MONDO_0002158), Lung Cancer (MONDO_0008903), Neoplasm (EFO_0000616), Urinary Bladder Cancer (MONDO_0001187), Colorectal Adenocarcinoma (EFO_0000365), Uterine Carcinosarcoma (EFO_1000613), Non-Small Cell Lung Carcinoma (EFO_0003060), Kidney Cancer (MONDO_0002367), Sarcoma (EFO_0000691), Melanoma (EFO_0000756), Glioblastoma Multiforme (EFO_0000519), Follicular Thyroid Carcinoma (EFO_0000501), Desmoid-Type Fibromatosis (EFO_0009907)', 'newLinkedTargets_string': 'FLT3 (ENSG00000122025), RAF1 (ENSG00000132155), PDGFRB (ENSG00000113721), BRAF (ENSG00000157764), RET (ENSG00000165731), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), KIT (ENSG00000157404)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2005, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_1546', 'tradeNames_string': 'Nexavar', 'drugName': 'Sorafenib Tosylate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Platelet-derived growth factor receptor beta inhibitor', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Multiple Myeloma (EFO_0001378), Papillary Thyroid Carcinoma (EFO_0000641), Chronic Lymphocytic Leukemia (EFO_0000095), Verrucous Carcinoma (EFO_0007535), Thyroid Carcinoma (EFO_0002892), Anaplastic Large Cell Lymphoma (EFO_0003032), Gastrointestinal Stromal Tumor (MONDO_0011719), Colorectal Carcinoma (EFO_1001951), Laryngeal Squamous Cell Carcinoma (EFO_0006352), Rectal Carcinoma (MONDO_0044937), Ovarian Cancer (MONDO_0008170), Malignant Colon Neoplasm (MONDO_0021063), Prostate Adenocarcinoma (EFO_0000673), Anaplastic Astrocytoma (EFO_0002499), Gliosarcoma (EFO_1001465), Hepatocellular Carcinoma (EFO_0000182), Myeloid Sarcoma (EFO_1001052), Acute Promyelocytic Leukemia (EFO_0000224), Mantle Cell Lymphoma (EFO_1001469), Breast Cancer (MONDO_0007254), Prostate Cancer (MONDO_0008315), Papillary Renal Cell Carcinoma (EFO_0000640), Acute Lymphoblastic Leukemia (EFO_0000220), Male Breast Carcinoma (EFO_0006861), Chromophobe Renal Cell Carcinoma (EFO_0000335), Acute Myeloid Leukemia (EFO_0000222), Diffuse Large B-Cell Lymphoma (EFO_0000403), Urethra Cancer (MONDO_0004192), Pancreatic Carcinoma (EFO_0002618), Central Nervous System Neoplasm (EFO_1000158), Anaplastic Oligodendroglioma (EFO_0002501), Tongue Neoplasm (EFO_0003871), Hypopharyngeal Carcinoma (EFO_0002938), Urinary Bladder Carcinoma (MONDO_0004986), Small Cell Lung Carcinoma (EFO_0000702), Mesothelioma (EFO_0000588), Clear Cell Renal Carcinoma (EFO_0000349), Soft Tissue Sarcoma (EFO_1001968), Thyroid Cancer (MONDO_0002108), Renal Cell Carcinoma (EFO_0000681), Brain Neoplasm (EFO_0003833), Peritoneum Cancer (MONDO_0002087), Cutaneous Melanoma (EFO_0000389), Oropharyngeal Carcinoma (MONDO_0044926), Liver Cancer (MONDO_0002691), Rectum Cancer (EFO_1000657), Osteosarcoma (EFO_0000637), Fallopian Tube Cancer (MONDO_0002158), Lung Cancer (MONDO_0008903), Neoplasm (EFO_0000616), Urinary Bladder Cancer (MONDO_0001187), Colorectal Adenocarcinoma (EFO_0000365), Uterine Carcinosarcoma (EFO_1000613), Non-Small Cell Lung Carcinoma (EFO_0003060), Kidney Cancer (MONDO_0002367), Sarcoma (EFO_0000691), Melanoma (EFO_0000756), Glioblastoma Multiforme (EFO_0000519), Follicular Thyroid Carcinoma (EFO_0000501), Desmoid-Type Fibromatosis (EFO_0009907)', 'newLinkedTargets_string': 'FLT3 (ENSG00000122025), RAF1 (ENSG00000132155), PDGFRB (ENSG00000113721), BRAF (ENSG00000157764), RET (ENSG00000165731), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), KIT (ENSG00000157404)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2005, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_1547', 'tradeNames_string': 'Nexavar', 'drugName': 'Sorafenib Tosylate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Tyrosine-protein kinase receptor RET inhibitor', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Multiple Myeloma (EFO_0001378), Papillary Thyroid Carcinoma (EFO_0000641), Chronic Lymphocytic Leukemia (EFO_0000095), Verrucous Carcinoma (EFO_0007535), Thyroid Carcinoma (EFO_0002892), Anaplastic Large Cell Lymphoma (EFO_0003032), Gastrointestinal Stromal Tumor (MONDO_0011719), Colorectal Carcinoma (EFO_1001951), Laryngeal Squamous Cell Carcinoma (EFO_0006352), Rectal Carcinoma (MONDO_0044937), Ovarian Cancer (MONDO_0008170), Malignant Colon Neoplasm (MONDO_0021063), Prostate Adenocarcinoma (EFO_0000673), Anaplastic Astrocytoma (EFO_0002499), Gliosarcoma (EFO_1001465), Hepatocellular Carcinoma (EFO_0000182), Myeloid Sarcoma (EFO_1001052), Acute Promyelocytic Leukemia (EFO_0000224), Mantle Cell Lymphoma (EFO_1001469), Breast Cancer (MONDO_0007254), Prostate Cancer (MONDO_0008315), Papillary Renal Cell Carcinoma (EFO_0000640), Acute Lymphoblastic Leukemia (EFO_0000220), Male Breast Carcinoma (EFO_0006861), Chromophobe Renal Cell Carcinoma (EFO_0000335), Acute Myeloid Leukemia (EFO_0000222), Diffuse Large B-Cell Lymphoma (EFO_0000403), Urethra Cancer (MONDO_0004192), Pancreatic Carcinoma (EFO_0002618), Central Nervous System Neoplasm (EFO_1000158), Anaplastic Oligodendroglioma (EFO_0002501), Tongue Neoplasm (EFO_0003871), Hypopharyngeal Carcinoma (EFO_0002938), Urinary Bladder Carcinoma (MONDO_0004986), Small Cell Lung Carcinoma (EFO_0000702), Mesothelioma (EFO_0000588), Clear Cell Renal Carcinoma (EFO_0000349), Soft Tissue Sarcoma (EFO_1001968), Thyroid Cancer (MONDO_0002108), Renal Cell Carcinoma (EFO_0000681), Brain Neoplasm (EFO_0003833), Peritoneum Cancer (MONDO_0002087), Cutaneous Melanoma (EFO_0000389), Oropharyngeal Carcinoma (MONDO_0044926), Liver Cancer (MONDO_0002691), Rectum Cancer (EFO_1000657), Osteosarcoma (EFO_0000637), Fallopian Tube Cancer (MONDO_0002158), Lung Cancer (MONDO_0008903), Neoplasm (EFO_0000616), Urinary Bladder Cancer (MONDO_0001187), Colorectal Adenocarcinoma (EFO_0000365), Uterine Carcinosarcoma (EFO_1000613), Non-Small Cell Lung Carcinoma (EFO_0003060), Kidney Cancer (MONDO_0002367), Sarcoma (EFO_0000691), Melanoma (EFO_0000756), Glioblastoma Multiforme (EFO_0000519), Follicular Thyroid Carcinoma (EFO_0000501), Desmoid-Type Fibromatosis (EFO_0009907)', 'newLinkedTargets_string': 'FLT3 (ENSG00000122025), RAF1 (ENSG00000132155), PDGFRB (ENSG00000113721), BRAF (ENSG00000157764), RET (ENSG00000165731), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), KIT (ENSG00000157404)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2005, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_1548', 'tradeNames_string': 'Nexavar', 'drugName': 'Sorafenib Tosylate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Vascular endothelial growth factor receptor inhibitor', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Multiple Myeloma (EFO_0001378), Papillary Thyroid Carcinoma (EFO_0000641), Chronic Lymphocytic Leukemia (EFO_0000095), Verrucous Carcinoma (EFO_0007535), Thyroid Carcinoma (EFO_0002892), Anaplastic Large Cell Lymphoma (EFO_0003032), Gastrointestinal Stromal Tumor (MONDO_0011719), Colorectal Carcinoma (EFO_1001951), Laryngeal Squamous Cell Carcinoma (EFO_0006352), Rectal Carcinoma (MONDO_0044937), Ovarian Cancer (MONDO_0008170), Malignant Colon Neoplasm (MONDO_0021063), Prostate Adenocarcinoma (EFO_0000673), Anaplastic Astrocytoma (EFO_0002499), Gliosarcoma (EFO_1001465), Hepatocellular Carcinoma (EFO_0000182), Myeloid Sarcoma (EFO_1001052), Acute Promyelocytic Leukemia (EFO_0000224), Mantle Cell Lymphoma (EFO_1001469), Breast Cancer (MONDO_0007254), Prostate Cancer (MONDO_0008315), Papillary Renal Cell Carcinoma (EFO_0000640), Acute Lymphoblastic Leukemia (EFO_0000220), Male Breast Carcinoma (EFO_0006861), Chromophobe Renal Cell Carcinoma (EFO_0000335), Acute Myeloid Leukemia (EFO_0000222), Diffuse Large B-Cell Lymphoma (EFO_0000403), Urethra Cancer (MONDO_0004192), Pancreatic Carcinoma (EFO_0002618), Central Nervous System Neoplasm (EFO_1000158), Anaplastic Oligodendroglioma (EFO_0002501), Tongue Neoplasm (EFO_0003871), Hypopharyngeal Carcinoma (EFO_0002938), Urinary Bladder Carcinoma (MONDO_0004986), Small Cell Lung Carcinoma (EFO_0000702), Mesothelioma (EFO_0000588), Clear Cell Renal Carcinoma (EFO_0000349), Soft Tissue Sarcoma (EFO_1001968), Thyroid Cancer (MONDO_0002108), Renal Cell Carcinoma (EFO_0000681), Brain Neoplasm (EFO_0003833), Peritoneum Cancer (MONDO_0002087), Cutaneous Melanoma (EFO_0000389), Oropharyngeal Carcinoma (MONDO_0044926), Liver Cancer (MONDO_0002691), Rectum Cancer (EFO_1000657), Osteosarcoma (EFO_0000637), Fallopian Tube Cancer (MONDO_0002158), Lung Cancer (MONDO_0008903), Neoplasm (EFO_0000616), Urinary Bladder Cancer (MONDO_0001187), Colorectal Adenocarcinoma (EFO_0000365), Uterine Carcinosarcoma (EFO_1000613), Non-Small Cell Lung Carcinoma (EFO_0003060), Kidney Cancer (MONDO_0002367), Sarcoma (EFO_0000691), Melanoma (EFO_0000756), Glioblastoma Multiforme (EFO_0000519), Follicular Thyroid Carcinoma (EFO_0000501), Desmoid-Type Fibromatosis (EFO_0009907)', 'newLinkedTargets_string': 'FLT3 (ENSG00000122025), RAF1 (ENSG00000132155), PDGFRB (ENSG00000113721), BRAF (ENSG00000157764), RET (ENSG00000165731), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), KIT (ENSG00000157404)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2005, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_1549', 'tradeNames_string': 'Nexavar', 'drugName': 'Sorafenib Tosylate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Stem cell growth factor receptor inhibitor', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Multiple Myeloma (EFO_0001378), Papillary Thyroid Carcinoma (EFO_0000641), Chronic Lymphocytic Leukemia (EFO_0000095), Verrucous Carcinoma (EFO_0007535), Thyroid Carcinoma (EFO_0002892), Anaplastic Large Cell Lymphoma (EFO_0003032), Gastrointestinal Stromal Tumor (MONDO_0011719), Colorectal Carcinoma (EFO_1001951), Laryngeal Squamous Cell Carcinoma (EFO_0006352), Rectal Carcinoma (MONDO_0044937), Ovarian Cancer (MONDO_0008170), Malignant Colon Neoplasm (MONDO_0021063), Prostate Adenocarcinoma (EFO_0000673), Anaplastic Astrocytoma (EFO_0002499), Gliosarcoma (EFO_1001465), Hepatocellular Carcinoma (EFO_0000182), Myeloid Sarcoma (EFO_1001052), Acute Promyelocytic Leukemia (EFO_0000224), Mantle Cell Lymphoma (EFO_1001469), Breast Cancer (MONDO_0007254), Prostate Cancer (MONDO_0008315), Papillary Renal Cell Carcinoma (EFO_0000640), Acute Lymphoblastic Leukemia (EFO_0000220), Male Breast Carcinoma (EFO_0006861), Chromophobe Renal Cell Carcinoma (EFO_0000335), Acute Myeloid Leukemia (EFO_0000222), Diffuse Large B-Cell Lymphoma (EFO_0000403), Urethra Cancer (MONDO_0004192), Pancreatic Carcinoma (EFO_0002618), Central Nervous System Neoplasm (EFO_1000158), Anaplastic Oligodendroglioma (EFO_0002501), Tongue Neoplasm (EFO_0003871), Hypopharyngeal Carcinoma (EFO_0002938), Urinary Bladder Carcinoma (MONDO_0004986), Small Cell Lung Carcinoma (EFO_0000702), Mesothelioma (EFO_0000588), Clear Cell Renal Carcinoma (EFO_0000349), Soft Tissue Sarcoma (EFO_1001968), Thyroid Cancer (MONDO_0002108), Renal Cell Carcinoma (EFO_0000681), Brain Neoplasm (EFO_0003833), Peritoneum Cancer (MONDO_0002087), Cutaneous Melanoma (EFO_0000389), Oropharyngeal Carcinoma (MONDO_0044926), Liver Cancer (MONDO_0002691), Rectum Cancer (EFO_1000657), Osteosarcoma (EFO_0000637), Fallopian Tube Cancer (MONDO_0002158), Lung Cancer (MONDO_0008903), Neoplasm (EFO_0000616), Urinary Bladder Cancer (MONDO_0001187), Colorectal Adenocarcinoma (EFO_0000365), Uterine Carcinosarcoma (EFO_1000613), Non-Small Cell Lung Carcinoma (EFO_0003060), Kidney Cancer (MONDO_0002367), Sarcoma (EFO_0000691), Melanoma (EFO_0000756), Glioblastoma Multiforme (EFO_0000519), Follicular Thyroid Carcinoma (EFO_0000501), Desmoid-Type Fibromatosis (EFO_0009907)', 'newLinkedTargets_string': 'FLT3 (ENSG00000122025), RAF1 (ENSG00000132155), PDGFRB (ENSG00000113721), BRAF (ENSG00000157764), RET (ENSG00000165731), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), KIT (ENSG00000157404)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2005, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_75', 'tradeNames_string': 'Nexavar', 'drugName': 'Sorafenib', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Serine/threonine-protein kinase B-raf inhibitor', 'linkedDiseasesDrug_string': "Multiple Myeloma (EFO_0001378), Papillary Thyroid Carcinoma (EFO_0000641), Verrucous Carcinoma (EFO_0007535), Liver Disease (EFO_0001421), Small Cell Carcinoma (EFO_0008524), Malignant Colon Neoplasm (MONDO_0021063), Papillary Renal Cell Carcinoma (EFO_0000640), Chromophobe Renal Cell Carcinoma (EFO_0000335), Neuroendocrine Neoplasm (EFO_1001901), Urinary Bladder Carcinoma (MONDO_0004986), Clear Cell Renal Carcinoma (EFO_0000349), Brain Neoplasm (EFO_0003833), Carcinoma (EFO_0000313), Liver Cancer (MONDO_0002691), Osteosarcoma (EFO_0000637), Lung Cancer (MONDO_0008903), Leukemia (EFO_0000565), Colorectal Adenocarcinoma (EFO_0000365), Kidney Disease (EFO_0003086), Glioblastoma Multiforme (EFO_0000519), Cancer (MONDO_0004992), Chronic Lymphocytic Leukemia (EFO_0000095), Anaplastic Large Cell Lymphoma (EFO_0003032), Gastrointestinal Stromal Tumor (MONDO_0011719), Myelodysplastic Syndrome (EFO_0000198), Colorectal Carcinoma (EFO_1001951), Gliosarcoma (EFO_1001465), Hepatocellular Carcinoma (EFO_0000182), Mantle Cell Lymphoma (EFO_1001469), Medullary Thyroid Gland Carcinoma (MONDO_0015277), Acute Lymphoblastic Leukemia (EFO_0000220), Acute Myeloid Leukemia (EFO_0000222), Diffuse Large B-Cell Lymphoma (EFO_0000403), Tongue Neoplasm (EFO_0003871), Anaplastic Oligodendroglioma (EFO_0002501), Hypopharyngeal Carcinoma (EFO_0002938), Small Cell Lung Carcinoma (EFO_0000702), Thyroid Cancer (MONDO_0002108), Portal Hypertension (EFO_0000666), Rectum Cancer (EFO_1000657), Non-Small Cell Lung Carcinoma (EFO_0003060), Acute Monocytic Leukemia (EFO_0000221), Neuroblastoma (EFO_0000621), Pulmonary Arterial Hypertension (EFO_0001361), Upper Aerodigestive Tract Neoplasm (EFO_0004284), Hepatoblastoma (EFO_1000292), Laryngeal Squamous Cell Carcinoma (EFO_0006352), Gastric Cancer (MONDO_0001056), Ovarian Cancer (MONDO_0008170), Anaplastic Astrocytoma (EFO_0002499), Breast Cancer (MONDO_0007254), Lymphoma (EFO_0000574), Cholangiocarcinoma (EFO_0005221), Keloid (EFO_0004212), Pancreatic Carcinoma (EFO_0002618), Central Nervous System Neoplasm (EFO_1000158), Rhabdomyosarcoma (EFO_0002918), Mesothelioma (EFO_0000588), Peritoneum Cancer (MONDO_0002087), Biliary Tract Neoplasm (EFO_0003891), Hepatopulmonary Syndrome (EFO_1001346), Cutaneous Melanoma (EFO_0000389), Oropharyngeal Carcinoma (MONDO_0044926), Neoplasm (EFO_0000616), Testicular Carcinoma (EFO_0005088), Urinary Bladder Cancer (MONDO_0001187), Adenocarcinoma (EFO_0000228), Uterine Carcinosarcoma (EFO_1000613), Metastatic Prostate Cancer (EFO_0000196), Sarcoma (EFO_0000691), Thyroid Carcinoma (EFO_0002892), Rectal Carcinoma (MONDO_0044937), Chronic Myelogenous Leukemia (EFO_0000339), Myeloid Sarcoma (EFO_1001052), Prostate Adenocarcinoma (EFO_0000673), Acute Promyelocytic Leukemia (EFO_0000224), Prostate Cancer (MONDO_0008315), Colorectal Neoplasm (EFO_0004142), Male Breast Carcinoma (EFO_0006861), Thrombotic Disease (MONDO_0000831), Cervical Carcinoma (EFO_0001061), Urethra Cancer (MONDO_0004192), Thyroid Neoplasm (EFO_0003841), Soft Tissue Sarcoma (EFO_1001968), Renal Cell Carcinoma (EFO_0000681), Kidney Neoplasm (EFO_0003865), Carcinoma Of Liver And Intrahepatic Biliary Tract (MONDO_0018531), Ovarian Neoplasm (EFO_0003893), Fallopian Tube Cancer (MONDO_0002158), Squamous Cell Carcinoma (EFO_0000707), Nasopharyngeal Neoplasm (EFO_0004252), Adrenal Cortex Carcinoma (EFO_1000796), Kaposi'S Sarcoma (EFO_0000558), Kidney Cancer (MONDO_0002367), Melanoma (EFO_0000756), Follicular Thyroid Carcinoma (EFO_0000501), Pancreatic Neoplasm (EFO_0003860), Esophageal Cancer (MONDO_0007576), Desmoid-Type Fibromatosis (EFO_0009907)", 'newLinkedTargets_string': 'BRAF (ENSG00000157764), RET (ENSG00000165731), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), KIT (ENSG00000157404), FLT3 (ENSG00000122025), RAF1 (ENSG00000132155), PDGFRB (ENSG00000113721)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2005, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_76', 'tradeNames_string': 'Nexavar', 'drugName': 'Sorafenib', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Tyrosine-protein kinase receptor FLT3 inhibitor', 'linkedDiseasesDrug_string': "Multiple Myeloma (EFO_0001378), Papillary Thyroid Carcinoma (EFO_0000641), Verrucous Carcinoma (EFO_0007535), Liver Disease (EFO_0001421), Small Cell Carcinoma (EFO_0008524), Malignant Colon Neoplasm (MONDO_0021063), Papillary Renal Cell Carcinoma (EFO_0000640), Chromophobe Renal Cell Carcinoma (EFO_0000335), Neuroendocrine Neoplasm (EFO_1001901), Urinary Bladder Carcinoma (MONDO_0004986), Clear Cell Renal Carcinoma (EFO_0000349), Brain Neoplasm (EFO_0003833), Carcinoma (EFO_0000313), Liver Cancer (MONDO_0002691), Osteosarcoma (EFO_0000637), Lung Cancer (MONDO_0008903), Leukemia (EFO_0000565), Colorectal Adenocarcinoma (EFO_0000365), Kidney Disease (EFO_0003086), Glioblastoma Multiforme (EFO_0000519), Cancer (MONDO_0004992), Chronic Lymphocytic Leukemia (EFO_0000095), Anaplastic Large Cell Lymphoma (EFO_0003032), Gastrointestinal Stromal Tumor (MONDO_0011719), Myelodysplastic Syndrome (EFO_0000198), Colorectal Carcinoma (EFO_1001951), Gliosarcoma (EFO_1001465), Hepatocellular Carcinoma (EFO_0000182), Mantle Cell Lymphoma (EFO_1001469), Medullary Thyroid Gland Carcinoma (MONDO_0015277), Acute Lymphoblastic Leukemia (EFO_0000220), Acute Myeloid Leukemia (EFO_0000222), Diffuse Large B-Cell Lymphoma (EFO_0000403), Tongue Neoplasm (EFO_0003871), Anaplastic Oligodendroglioma (EFO_0002501), Hypopharyngeal Carcinoma (EFO_0002938), Small Cell Lung Carcinoma (EFO_0000702), Thyroid Cancer (MONDO_0002108), Portal Hypertension (EFO_0000666), Rectum Cancer (EFO_1000657), Non-Small Cell Lung Carcinoma (EFO_0003060), Acute Monocytic Leukemia (EFO_0000221), Neuroblastoma (EFO_0000621), Pulmonary Arterial Hypertension (EFO_0001361), Upper Aerodigestive Tract Neoplasm (EFO_0004284), Hepatoblastoma (EFO_1000292), Laryngeal Squamous Cell Carcinoma (EFO_0006352), Gastric Cancer (MONDO_0001056), Ovarian Cancer (MONDO_0008170), Anaplastic Astrocytoma (EFO_0002499), Breast Cancer (MONDO_0007254), Lymphoma (EFO_0000574), Cholangiocarcinoma (EFO_0005221), Keloid (EFO_0004212), Pancreatic Carcinoma (EFO_0002618), Central Nervous System Neoplasm (EFO_1000158), Rhabdomyosarcoma (EFO_0002918), Mesothelioma (EFO_0000588), Peritoneum Cancer (MONDO_0002087), Biliary Tract Neoplasm (EFO_0003891), Hepatopulmonary Syndrome (EFO_1001346), Cutaneous Melanoma (EFO_0000389), Oropharyngeal Carcinoma (MONDO_0044926), Neoplasm (EFO_0000616), Testicular Carcinoma (EFO_0005088), Urinary Bladder Cancer (MONDO_0001187), Adenocarcinoma (EFO_0000228), Uterine Carcinosarcoma (EFO_1000613), Metastatic Prostate Cancer (EFO_0000196), Sarcoma (EFO_0000691), Thyroid Carcinoma (EFO_0002892), Rectal Carcinoma (MONDO_0044937), Chronic Myelogenous Leukemia (EFO_0000339), Myeloid Sarcoma (EFO_1001052), Prostate Adenocarcinoma (EFO_0000673), Acute Promyelocytic Leukemia (EFO_0000224), Prostate Cancer (MONDO_0008315), Colorectal Neoplasm (EFO_0004142), Male Breast Carcinoma (EFO_0006861), Thrombotic Disease (MONDO_0000831), Cervical Carcinoma (EFO_0001061), Urethra Cancer (MONDO_0004192), Thyroid Neoplasm (EFO_0003841), Soft Tissue Sarcoma (EFO_1001968), Renal Cell Carcinoma (EFO_0000681), Kidney Neoplasm (EFO_0003865), Carcinoma Of Liver And Intrahepatic Biliary Tract (MONDO_0018531), Ovarian Neoplasm (EFO_0003893), Fallopian Tube Cancer (MONDO_0002158), Squamous Cell Carcinoma (EFO_0000707), Nasopharyngeal Neoplasm (EFO_0004252), Adrenal Cortex Carcinoma (EFO_1000796), Kaposi'S Sarcoma (EFO_0000558), Kidney Cancer (MONDO_0002367), Melanoma (EFO_0000756), Follicular Thyroid Carcinoma (EFO_0000501), Pancreatic Neoplasm (EFO_0003860), Esophageal Cancer (MONDO_0007576), Desmoid-Type Fibromatosis (EFO_0009907)", 'newLinkedTargets_string': 'BRAF (ENSG00000157764), RET (ENSG00000165731), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), KIT (ENSG00000157404), FLT3 (ENSG00000122025), RAF1 (ENSG00000132155), PDGFRB (ENSG00000113721)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2005, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_77', 'tradeNames_string': 'Nexavar', 'drugName': 'Sorafenib', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Serine/threonine-protein kinase RAF inhibitor', 'linkedDiseasesDrug_string': "Multiple Myeloma (EFO_0001378), Papillary Thyroid Carcinoma (EFO_0000641), Verrucous Carcinoma (EFO_0007535), Liver Disease (EFO_0001421), Small Cell Carcinoma (EFO_0008524), Malignant Colon Neoplasm (MONDO_0021063), Papillary Renal Cell Carcinoma (EFO_0000640), Chromophobe Renal Cell Carcinoma (EFO_0000335), Neuroendocrine Neoplasm (EFO_1001901), Urinary Bladder Carcinoma (MONDO_0004986), Clear Cell Renal Carcinoma (EFO_0000349), Brain Neoplasm (EFO_0003833), Carcinoma (EFO_0000313), Liver Cancer (MONDO_0002691), Osteosarcoma (EFO_0000637), Lung Cancer (MONDO_0008903), Leukemia (EFO_0000565), Colorectal Adenocarcinoma (EFO_0000365), Kidney Disease (EFO_0003086), Glioblastoma Multiforme (EFO_0000519), Cancer (MONDO_0004992), Chronic Lymphocytic Leukemia (EFO_0000095), Anaplastic Large Cell Lymphoma (EFO_0003032), Gastrointestinal Stromal Tumor (MONDO_0011719), Myelodysplastic Syndrome (EFO_0000198), Colorectal Carcinoma (EFO_1001951), Gliosarcoma (EFO_1001465), Hepatocellular Carcinoma (EFO_0000182), Mantle Cell Lymphoma (EFO_1001469), Medullary Thyroid Gland Carcinoma (MONDO_0015277), Acute Lymphoblastic Leukemia (EFO_0000220), Acute Myeloid Leukemia (EFO_0000222), Diffuse Large B-Cell Lymphoma (EFO_0000403), Tongue Neoplasm (EFO_0003871), Anaplastic Oligodendroglioma (EFO_0002501), Hypopharyngeal Carcinoma (EFO_0002938), Small Cell Lung Carcinoma (EFO_0000702), Thyroid Cancer (MONDO_0002108), Portal Hypertension (EFO_0000666), Rectum Cancer (EFO_1000657), Non-Small Cell Lung Carcinoma (EFO_0003060), Acute Monocytic Leukemia (EFO_0000221), Neuroblastoma (EFO_0000621), Pulmonary Arterial Hypertension (EFO_0001361), Upper Aerodigestive Tract Neoplasm (EFO_0004284), Hepatoblastoma (EFO_1000292), Laryngeal Squamous Cell Carcinoma (EFO_0006352), Gastric Cancer (MONDO_0001056), Ovarian Cancer (MONDO_0008170), Anaplastic Astrocytoma (EFO_0002499), Breast Cancer (MONDO_0007254), Lymphoma (EFO_0000574), Cholangiocarcinoma (EFO_0005221), Keloid (EFO_0004212), Pancreatic Carcinoma (EFO_0002618), Central Nervous System Neoplasm (EFO_1000158), Rhabdomyosarcoma (EFO_0002918), Mesothelioma (EFO_0000588), Peritoneum Cancer (MONDO_0002087), Biliary Tract Neoplasm (EFO_0003891), Hepatopulmonary Syndrome (EFO_1001346), Cutaneous Melanoma (EFO_0000389), Oropharyngeal Carcinoma (MONDO_0044926), Neoplasm (EFO_0000616), Testicular Carcinoma (EFO_0005088), Urinary Bladder Cancer (MONDO_0001187), Adenocarcinoma (EFO_0000228), Uterine Carcinosarcoma (EFO_1000613), Metastatic Prostate Cancer (EFO_0000196), Sarcoma (EFO_0000691), Thyroid Carcinoma (EFO_0002892), Rectal Carcinoma (MONDO_0044937), Chronic Myelogenous Leukemia (EFO_0000339), Myeloid Sarcoma (EFO_1001052), Prostate Adenocarcinoma (EFO_0000673), Acute Promyelocytic Leukemia (EFO_0000224), Prostate Cancer (MONDO_0008315), Colorectal Neoplasm (EFO_0004142), Male Breast Carcinoma (EFO_0006861), Thrombotic Disease (MONDO_0000831), Cervical Carcinoma (EFO_0001061), Urethra Cancer (MONDO_0004192), Thyroid Neoplasm (EFO_0003841), Soft Tissue Sarcoma (EFO_1001968), Renal Cell Carcinoma (EFO_0000681), Kidney Neoplasm (EFO_0003865), Carcinoma Of Liver And Intrahepatic Biliary Tract (MONDO_0018531), Ovarian Neoplasm (EFO_0003893), Fallopian Tube Cancer (MONDO_0002158), Squamous Cell Carcinoma (EFO_0000707), Nasopharyngeal Neoplasm (EFO_0004252), Adrenal Cortex Carcinoma (EFO_1000796), Kaposi'S Sarcoma (EFO_0000558), Kidney Cancer (MONDO_0002367), Melanoma (EFO_0000756), Follicular Thyroid Carcinoma (EFO_0000501), Pancreatic Neoplasm (EFO_0003860), Esophageal Cancer (MONDO_0007576), Desmoid-Type Fibromatosis (EFO_0009907)", 'newLinkedTargets_string': 'BRAF (ENSG00000157764), RET (ENSG00000165731), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), KIT (ENSG00000157404), FLT3 (ENSG00000122025), RAF1 (ENSG00000132155), PDGFRB (ENSG00000113721)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2005, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_78', 'tradeNames_string': 'Nexavar', 'drugName': 'Sorafenib', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Platelet-derived growth factor receptor beta inhibitor', 'linkedDiseasesDrug_string': "Multiple Myeloma (EFO_0001378), Papillary Thyroid Carcinoma (EFO_0000641), Verrucous Carcinoma (EFO_0007535), Liver Disease (EFO_0001421), Small Cell Carcinoma (EFO_0008524), Malignant Colon Neoplasm (MONDO_0021063), Papillary Renal Cell Carcinoma (EFO_0000640), Chromophobe Renal Cell Carcinoma (EFO_0000335), Neuroendocrine Neoplasm (EFO_1001901), Urinary Bladder Carcinoma (MONDO_0004986), Clear Cell Renal Carcinoma (EFO_0000349), Brain Neoplasm (EFO_0003833), Carcinoma (EFO_0000313), Liver Cancer (MONDO_0002691), Osteosarcoma (EFO_0000637), Lung Cancer (MONDO_0008903), Leukemia (EFO_0000565), Colorectal Adenocarcinoma (EFO_0000365), Kidney Disease (EFO_0003086), Glioblastoma Multiforme (EFO_0000519), Cancer (MONDO_0004992), Chronic Lymphocytic Leukemia (EFO_0000095), Anaplastic Large Cell Lymphoma (EFO_0003032), Gastrointestinal Stromal Tumor (MONDO_0011719), Myelodysplastic Syndrome (EFO_0000198), Colorectal Carcinoma (EFO_1001951), Gliosarcoma (EFO_1001465), Hepatocellular Carcinoma (EFO_0000182), Mantle Cell Lymphoma (EFO_1001469), Medullary Thyroid Gland Carcinoma (MONDO_0015277), Acute Lymphoblastic Leukemia (EFO_0000220), Acute Myeloid Leukemia (EFO_0000222), Diffuse Large B-Cell Lymphoma (EFO_0000403), Tongue Neoplasm (EFO_0003871), Anaplastic Oligodendroglioma (EFO_0002501), Hypopharyngeal Carcinoma (EFO_0002938), Small Cell Lung Carcinoma (EFO_0000702), Thyroid Cancer (MONDO_0002108), Portal Hypertension (EFO_0000666), Rectum Cancer (EFO_1000657), Non-Small Cell Lung Carcinoma (EFO_0003060), Acute Monocytic Leukemia (EFO_0000221), Neuroblastoma (EFO_0000621), Pulmonary Arterial Hypertension (EFO_0001361), Upper Aerodigestive Tract Neoplasm (EFO_0004284), Hepatoblastoma (EFO_1000292), Laryngeal Squamous Cell Carcinoma (EFO_0006352), Gastric Cancer (MONDO_0001056), Ovarian Cancer (MONDO_0008170), Anaplastic Astrocytoma (EFO_0002499), Breast Cancer (MONDO_0007254), Lymphoma (EFO_0000574), Cholangiocarcinoma (EFO_0005221), Keloid (EFO_0004212), Pancreatic Carcinoma (EFO_0002618), Central Nervous System Neoplasm (EFO_1000158), Rhabdomyosarcoma (EFO_0002918), Mesothelioma (EFO_0000588), Peritoneum Cancer (MONDO_0002087), Biliary Tract Neoplasm (EFO_0003891), Hepatopulmonary Syndrome (EFO_1001346), Cutaneous Melanoma (EFO_0000389), Oropharyngeal Carcinoma (MONDO_0044926), Neoplasm (EFO_0000616), Testicular Carcinoma (EFO_0005088), Urinary Bladder Cancer (MONDO_0001187), Adenocarcinoma (EFO_0000228), Uterine Carcinosarcoma (EFO_1000613), Metastatic Prostate Cancer (EFO_0000196), Sarcoma (EFO_0000691), Thyroid Carcinoma (EFO_0002892), Rectal Carcinoma (MONDO_0044937), Chronic Myelogenous Leukemia (EFO_0000339), Myeloid Sarcoma (EFO_1001052), Prostate Adenocarcinoma (EFO_0000673), Acute Promyelocytic Leukemia (EFO_0000224), Prostate Cancer (MONDO_0008315), Colorectal Neoplasm (EFO_0004142), Male Breast Carcinoma (EFO_0006861), Thrombotic Disease (MONDO_0000831), Cervical Carcinoma (EFO_0001061), Urethra Cancer (MONDO_0004192), Thyroid Neoplasm (EFO_0003841), Soft Tissue Sarcoma (EFO_1001968), Renal Cell Carcinoma (EFO_0000681), Kidney Neoplasm (EFO_0003865), Carcinoma Of Liver And Intrahepatic Biliary Tract (MONDO_0018531), Ovarian Neoplasm (EFO_0003893), Fallopian Tube Cancer (MONDO_0002158), Squamous Cell Carcinoma (EFO_0000707), Nasopharyngeal Neoplasm (EFO_0004252), Adrenal Cortex Carcinoma (EFO_1000796), Kaposi'S Sarcoma (EFO_0000558), Kidney Cancer (MONDO_0002367), Melanoma (EFO_0000756), Follicular Thyroid Carcinoma (EFO_0000501), Pancreatic Neoplasm (EFO_0003860), Esophageal Cancer (MONDO_0007576), Desmoid-Type Fibromatosis (EFO_0009907)", 'newLinkedTargets_string': 'BRAF (ENSG00000157764), RET (ENSG00000165731), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), KIT (ENSG00000157404), FLT3 (ENSG00000122025), RAF1 (ENSG00000132155), PDGFRB (ENSG00000113721)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2005, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_79', 'tradeNames_string': 'Nexavar', 'drugName': 'Sorafenib', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Tyrosine-protein kinase receptor RET inhibitor', 'linkedDiseasesDrug_string': "Multiple Myeloma (EFO_0001378), Papillary Thyroid Carcinoma (EFO_0000641), Verrucous Carcinoma (EFO_0007535), Liver Disease (EFO_0001421), Small Cell Carcinoma (EFO_0008524), Malignant Colon Neoplasm (MONDO_0021063), Papillary Renal Cell Carcinoma (EFO_0000640), Chromophobe Renal Cell Carcinoma (EFO_0000335), Neuroendocrine Neoplasm (EFO_1001901), Urinary Bladder Carcinoma (MONDO_0004986), Clear Cell Renal Carcinoma (EFO_0000349), Brain Neoplasm (EFO_0003833), Carcinoma (EFO_0000313), Liver Cancer (MONDO_0002691), Osteosarcoma (EFO_0000637), Lung Cancer (MONDO_0008903), Leukemia (EFO_0000565), Colorectal Adenocarcinoma (EFO_0000365), Kidney Disease (EFO_0003086), Glioblastoma Multiforme (EFO_0000519), Cancer (MONDO_0004992), Chronic Lymphocytic Leukemia (EFO_0000095), Anaplastic Large Cell Lymphoma (EFO_0003032), Gastrointestinal Stromal Tumor (MONDO_0011719), Myelodysplastic Syndrome (EFO_0000198), Colorectal Carcinoma (EFO_1001951), Gliosarcoma (EFO_1001465), Hepatocellular Carcinoma (EFO_0000182), Mantle Cell Lymphoma (EFO_1001469), Medullary Thyroid Gland Carcinoma (MONDO_0015277), Acute Lymphoblastic Leukemia (EFO_0000220), Acute Myeloid Leukemia (EFO_0000222), Diffuse Large B-Cell Lymphoma (EFO_0000403), Tongue Neoplasm (EFO_0003871), Anaplastic Oligodendroglioma (EFO_0002501), Hypopharyngeal Carcinoma (EFO_0002938), Small Cell Lung Carcinoma (EFO_0000702), Thyroid Cancer (MONDO_0002108), Portal Hypertension (EFO_0000666), Rectum Cancer (EFO_1000657), Non-Small Cell Lung Carcinoma (EFO_0003060), Acute Monocytic Leukemia (EFO_0000221), Neuroblastoma (EFO_0000621), Pulmonary Arterial Hypertension (EFO_0001361), Upper Aerodigestive Tract Neoplasm (EFO_0004284), Hepatoblastoma (EFO_1000292), Laryngeal Squamous Cell Carcinoma (EFO_0006352), Gastric Cancer (MONDO_0001056), Ovarian Cancer (MONDO_0008170), Anaplastic Astrocytoma (EFO_0002499), Breast Cancer (MONDO_0007254), Lymphoma (EFO_0000574), Cholangiocarcinoma (EFO_0005221), Keloid (EFO_0004212), Pancreatic Carcinoma (EFO_0002618), Central Nervous System Neoplasm (EFO_1000158), Rhabdomyosarcoma (EFO_0002918), Mesothelioma (EFO_0000588), Peritoneum Cancer (MONDO_0002087), Biliary Tract Neoplasm (EFO_0003891), Hepatopulmonary Syndrome (EFO_1001346), Cutaneous Melanoma (EFO_0000389), Oropharyngeal Carcinoma (MONDO_0044926), Neoplasm (EFO_0000616), Testicular Carcinoma (EFO_0005088), Urinary Bladder Cancer (MONDO_0001187), Adenocarcinoma (EFO_0000228), Uterine Carcinosarcoma (EFO_1000613), Metastatic Prostate Cancer (EFO_0000196), Sarcoma (EFO_0000691), Thyroid Carcinoma (EFO_0002892), Rectal Carcinoma (MONDO_0044937), Chronic Myelogenous Leukemia (EFO_0000339), Myeloid Sarcoma (EFO_1001052), Prostate Adenocarcinoma (EFO_0000673), Acute Promyelocytic Leukemia (EFO_0000224), Prostate Cancer (MONDO_0008315), Colorectal Neoplasm (EFO_0004142), Male Breast Carcinoma (EFO_0006861), Thrombotic Disease (MONDO_0000831), Cervical Carcinoma (EFO_0001061), Urethra Cancer (MONDO_0004192), Thyroid Neoplasm (EFO_0003841), Soft Tissue Sarcoma (EFO_1001968), Renal Cell Carcinoma (EFO_0000681), Kidney Neoplasm (EFO_0003865), Carcinoma Of Liver And Intrahepatic Biliary Tract (MONDO_0018531), Ovarian Neoplasm (EFO_0003893), Fallopian Tube Cancer (MONDO_0002158), Squamous Cell Carcinoma (EFO_0000707), Nasopharyngeal Neoplasm (EFO_0004252), Adrenal Cortex Carcinoma (EFO_1000796), Kaposi'S Sarcoma (EFO_0000558), Kidney Cancer (MONDO_0002367), Melanoma (EFO_0000756), Follicular Thyroid Carcinoma (EFO_0000501), Pancreatic Neoplasm (EFO_0003860), Esophageal Cancer (MONDO_0007576), Desmoid-Type Fibromatosis (EFO_0009907)", 'newLinkedTargets_string': 'BRAF (ENSG00000157764), RET (ENSG00000165731), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), KIT (ENSG00000157404), FLT3 (ENSG00000122025), RAF1 (ENSG00000132155), PDGFRB (ENSG00000113721)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2005, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_80', 'tradeNames_string': 'Nexavar', 'drugName': 'Sorafenib', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Vascular endothelial growth factor receptor inhibitor', 'linkedDiseasesDrug_string': "Multiple Myeloma (EFO_0001378), Papillary Thyroid Carcinoma (EFO_0000641), Verrucous Carcinoma (EFO_0007535), Liver Disease (EFO_0001421), Small Cell Carcinoma (EFO_0008524), Malignant Colon Neoplasm (MONDO_0021063), Papillary Renal Cell Carcinoma (EFO_0000640), Chromophobe Renal Cell Carcinoma (EFO_0000335), Neuroendocrine Neoplasm (EFO_1001901), Urinary Bladder Carcinoma (MONDO_0004986), Clear Cell Renal Carcinoma (EFO_0000349), Brain Neoplasm (EFO_0003833), Carcinoma (EFO_0000313), Liver Cancer (MONDO_0002691), Osteosarcoma (EFO_0000637), Lung Cancer (MONDO_0008903), Leukemia (EFO_0000565), Colorectal Adenocarcinoma (EFO_0000365), Kidney Disease (EFO_0003086), Glioblastoma Multiforme (EFO_0000519), Cancer (MONDO_0004992), Chronic Lymphocytic Leukemia (EFO_0000095), Anaplastic Large Cell Lymphoma (EFO_0003032), Gastrointestinal Stromal Tumor (MONDO_0011719), Myelodysplastic Syndrome (EFO_0000198), Colorectal Carcinoma (EFO_1001951), Gliosarcoma (EFO_1001465), Hepatocellular Carcinoma (EFO_0000182), Mantle Cell Lymphoma (EFO_1001469), Medullary Thyroid Gland Carcinoma (MONDO_0015277), Acute Lymphoblastic Leukemia (EFO_0000220), Acute Myeloid Leukemia (EFO_0000222), Diffuse Large B-Cell Lymphoma (EFO_0000403), Tongue Neoplasm (EFO_0003871), Anaplastic Oligodendroglioma (EFO_0002501), Hypopharyngeal Carcinoma (EFO_0002938), Small Cell Lung Carcinoma (EFO_0000702), Thyroid Cancer (MONDO_0002108), Portal Hypertension (EFO_0000666), Rectum Cancer (EFO_1000657), Non-Small Cell Lung Carcinoma (EFO_0003060), Acute Monocytic Leukemia (EFO_0000221), Neuroblastoma (EFO_0000621), Pulmonary Arterial Hypertension (EFO_0001361), Upper Aerodigestive Tract Neoplasm (EFO_0004284), Hepatoblastoma (EFO_1000292), Laryngeal Squamous Cell Carcinoma (EFO_0006352), Gastric Cancer (MONDO_0001056), Ovarian Cancer (MONDO_0008170), Anaplastic Astrocytoma (EFO_0002499), Breast Cancer (MONDO_0007254), Lymphoma (EFO_0000574), Cholangiocarcinoma (EFO_0005221), Keloid (EFO_0004212), Pancreatic Carcinoma (EFO_0002618), Central Nervous System Neoplasm (EFO_1000158), Rhabdomyosarcoma (EFO_0002918), Mesothelioma (EFO_0000588), Peritoneum Cancer (MONDO_0002087), Biliary Tract Neoplasm (EFO_0003891), Hepatopulmonary Syndrome (EFO_1001346), Cutaneous Melanoma (EFO_0000389), Oropharyngeal Carcinoma (MONDO_0044926), Neoplasm (EFO_0000616), Testicular Carcinoma (EFO_0005088), Urinary Bladder Cancer (MONDO_0001187), Adenocarcinoma (EFO_0000228), Uterine Carcinosarcoma (EFO_1000613), Metastatic Prostate Cancer (EFO_0000196), Sarcoma (EFO_0000691), Thyroid Carcinoma (EFO_0002892), Rectal Carcinoma (MONDO_0044937), Chronic Myelogenous Leukemia (EFO_0000339), Myeloid Sarcoma (EFO_1001052), Prostate Adenocarcinoma (EFO_0000673), Acute Promyelocytic Leukemia (EFO_0000224), Prostate Cancer (MONDO_0008315), Colorectal Neoplasm (EFO_0004142), Male Breast Carcinoma (EFO_0006861), Thrombotic Disease (MONDO_0000831), Cervical Carcinoma (EFO_0001061), Urethra Cancer (MONDO_0004192), Thyroid Neoplasm (EFO_0003841), Soft Tissue Sarcoma (EFO_1001968), Renal Cell Carcinoma (EFO_0000681), Kidney Neoplasm (EFO_0003865), Carcinoma Of Liver And Intrahepatic Biliary Tract (MONDO_0018531), Ovarian Neoplasm (EFO_0003893), Fallopian Tube Cancer (MONDO_0002158), Squamous Cell Carcinoma (EFO_0000707), Nasopharyngeal Neoplasm (EFO_0004252), Adrenal Cortex Carcinoma (EFO_1000796), Kaposi'S Sarcoma (EFO_0000558), Kidney Cancer (MONDO_0002367), Melanoma (EFO_0000756), Follicular Thyroid Carcinoma (EFO_0000501), Pancreatic Neoplasm (EFO_0003860), Esophageal Cancer (MONDO_0007576), Desmoid-Type Fibromatosis (EFO_0009907)", 'newLinkedTargets_string': 'BRAF (ENSG00000157764), RET (ENSG00000165731), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), KIT (ENSG00000157404), FLT3 (ENSG00000122025), RAF1 (ENSG00000132155), PDGFRB (ENSG00000113721)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2005, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_81', 'tradeNames_string': 'Nexavar', 'drugName': 'Sorafenib', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Stem cell growth factor receptor inhibitor', 'linkedDiseasesDrug_string': "Multiple Myeloma (EFO_0001378), Papillary Thyroid Carcinoma (EFO_0000641), Verrucous Carcinoma (EFO_0007535), Liver Disease (EFO_0001421), Small Cell Carcinoma (EFO_0008524), Malignant Colon Neoplasm (MONDO_0021063), Papillary Renal Cell Carcinoma (EFO_0000640), Chromophobe Renal Cell Carcinoma (EFO_0000335), Neuroendocrine Neoplasm (EFO_1001901), Urinary Bladder Carcinoma (MONDO_0004986), Clear Cell Renal Carcinoma (EFO_0000349), Brain Neoplasm (EFO_0003833), Carcinoma (EFO_0000313), Liver Cancer (MONDO_0002691), Osteosarcoma (EFO_0000637), Lung Cancer (MONDO_0008903), Leukemia (EFO_0000565), Colorectal Adenocarcinoma (EFO_0000365), Kidney Disease (EFO_0003086), Glioblastoma Multiforme (EFO_0000519), Cancer (MONDO_0004992), Chronic Lymphocytic Leukemia (EFO_0000095), Anaplastic Large Cell Lymphoma (EFO_0003032), Gastrointestinal Stromal Tumor (MONDO_0011719), Myelodysplastic Syndrome (EFO_0000198), Colorectal Carcinoma (EFO_1001951), Gliosarcoma (EFO_1001465), Hepatocellular Carcinoma (EFO_0000182), Mantle Cell Lymphoma (EFO_1001469), Medullary Thyroid Gland Carcinoma (MONDO_0015277), Acute Lymphoblastic Leukemia (EFO_0000220), Acute Myeloid Leukemia (EFO_0000222), Diffuse Large B-Cell Lymphoma (EFO_0000403), Tongue Neoplasm (EFO_0003871), Anaplastic Oligodendroglioma (EFO_0002501), Hypopharyngeal Carcinoma (EFO_0002938), Small Cell Lung Carcinoma (EFO_0000702), Thyroid Cancer (MONDO_0002108), Portal Hypertension (EFO_0000666), Rectum Cancer (EFO_1000657), Non-Small Cell Lung Carcinoma (EFO_0003060), Acute Monocytic Leukemia (EFO_0000221), Neuroblastoma (EFO_0000621), Pulmonary Arterial Hypertension (EFO_0001361), Upper Aerodigestive Tract Neoplasm (EFO_0004284), Hepatoblastoma (EFO_1000292), Laryngeal Squamous Cell Carcinoma (EFO_0006352), Gastric Cancer (MONDO_0001056), Ovarian Cancer (MONDO_0008170), Anaplastic Astrocytoma (EFO_0002499), Breast Cancer (MONDO_0007254), Lymphoma (EFO_0000574), Cholangiocarcinoma (EFO_0005221), Keloid (EFO_0004212), Pancreatic Carcinoma (EFO_0002618), Central Nervous System Neoplasm (EFO_1000158), Rhabdomyosarcoma (EFO_0002918), Mesothelioma (EFO_0000588), Peritoneum Cancer (MONDO_0002087), Biliary Tract Neoplasm (EFO_0003891), Hepatopulmonary Syndrome (EFO_1001346), Cutaneous Melanoma (EFO_0000389), Oropharyngeal Carcinoma (MONDO_0044926), Neoplasm (EFO_0000616), Testicular Carcinoma (EFO_0005088), Urinary Bladder Cancer (MONDO_0001187), Adenocarcinoma (EFO_0000228), Uterine Carcinosarcoma (EFO_1000613), Metastatic Prostate Cancer (EFO_0000196), Sarcoma (EFO_0000691), Thyroid Carcinoma (EFO_0002892), Rectal Carcinoma (MONDO_0044937), Chronic Myelogenous Leukemia (EFO_0000339), Myeloid Sarcoma (EFO_1001052), Prostate Adenocarcinoma (EFO_0000673), Acute Promyelocytic Leukemia (EFO_0000224), Prostate Cancer (MONDO_0008315), Colorectal Neoplasm (EFO_0004142), Male Breast Carcinoma (EFO_0006861), Thrombotic Disease (MONDO_0000831), Cervical Carcinoma (EFO_0001061), Urethra Cancer (MONDO_0004192), Thyroid Neoplasm (EFO_0003841), Soft Tissue Sarcoma (EFO_1001968), Renal Cell Carcinoma (EFO_0000681), Kidney Neoplasm (EFO_0003865), Carcinoma Of Liver And Intrahepatic Biliary Tract (MONDO_0018531), Ovarian Neoplasm (EFO_0003893), Fallopian Tube Cancer (MONDO_0002158), Squamous Cell Carcinoma (EFO_0000707), Nasopharyngeal Neoplasm (EFO_0004252), Adrenal Cortex Carcinoma (EFO_1000796), Kaposi'S Sarcoma (EFO_0000558), Kidney Cancer (MONDO_0002367), Melanoma (EFO_0000756), Follicular Thyroid Carcinoma (EFO_0000501), Pancreatic Neoplasm (EFO_0003860), Esophageal Cancer (MONDO_0007576), Desmoid-Type Fibromatosis (EFO_0009907)", 'newLinkedTargets_string': 'BRAF (ENSG00000157764), RET (ENSG00000165731), FLT1 (ENSG00000102755), FLT4 (ENSG00000037280), KDR (ENSG00000128052), KIT (ENSG00000157404), FLT3 (ENSG00000122025), RAF1 (ENSG00000132155), PDGFRB (ENSG00000113721)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2005, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.110 | Q22 | What is Forfivo Xl? | Forfivo Xl, also known generically as Bupropion Hydrochloride, was approved by the FDA in 1985 to treat unipolar depression, mood disorder, major depressive disorder, and depressive disorder. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%forfivo xl%" OR LOWER(tradeNames_string) LIKE "%forfivo xl%" OR LOWER(drugSynonyms_string) LIKE "%forfivo xl%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_771', 'tradeNames_string': 'Bupropion hydrochloride, Forfivo xl, Wellbutrin, Wellbutrin 100, Wellbutrin 75, Wellbutrin sr, Wellbutrin xl, Zyban', 'drugName': 'Bupropion Hydrochloride', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Norepinephrine transporter inhibitor', 'linkedDiseasesDrug_string': 'Smoking Cessation (EFO_0004319), Unipolar Depression (EFO_0003761), Lung Cancer (MONDO_0008903), Bipolar I Disorder (EFO_0009963), Nicotine Dependence (EFO_0003768), Mood Disorder (EFO_0004247), Obesity (EFO_0001073), Wilson Disease (MONDO_0010200), Major Depressive Disorder (MONDO_0002009), Bipolar Disorder (MONDO_0004985), Depressive Disorder (MONDO_0002050), Eating Disorder (EFO_0005203), Alcohol Dependence (MONDO_0007079)', 'newLinkedTargets_string': 'SLC6A2 (ENSG00000103546), SLC6A3 (ENSG00000142319)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1985, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_772', 'tradeNames_string': 'Bupropion hydrochloride, Forfivo xl, Wellbutrin, Wellbutrin 100, Wellbutrin 75, Wellbutrin sr, Wellbutrin xl, Zyban', 'drugName': 'Bupropion Hydrochloride', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Dopamine transporter inhibitor', 'linkedDiseasesDrug_string': 'Smoking Cessation (EFO_0004319), Unipolar Depression (EFO_0003761), Lung Cancer (MONDO_0008903), Bipolar I Disorder (EFO_0009963), Nicotine Dependence (EFO_0003768), Mood Disorder (EFO_0004247), Obesity (EFO_0001073), Wilson Disease (MONDO_0010200), Major Depressive Disorder (MONDO_0002009), Bipolar Disorder (MONDO_0004985), Depressive Disorder (MONDO_0002050), Eating Disorder (EFO_0005203), Alcohol Dependence (MONDO_0007079)', 'newLinkedTargets_string': 'SLC6A2 (ENSG00000103546), SLC6A3 (ENSG00000142319)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1985, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.468 | Q22 | What is Ocaliva? | Ocaliva, also known generically as Obeticholic Acid, was approved by the FDA in 2016 to treat Cholangitis, biliary liver cirrhosis, and primary biliary cirrhosis. It is a small molecule therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%ocaliva%" OR LOWER(tradeNames_string) LIKE "%ocaliva%" OR LOWER(drugSynonyms_string) LIKE "%ocaliva%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3863', 'tradeNames_string': 'Ocaliva', 'drugName': 'Obeticholic Acid', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Bile acid receptor FXR agonist', 'linkedDiseasesDrug_string': "Familial Adenomatous Polyposis (Orphanet_733), Hepatitis, Alcoholic (EFO_1001345), Diarrhea (HP_0002014), Cholangitis (HP_0030151), Liver Disease (EFO_0001421), Biliary Liver Cirrhosis (EFO_0004267), Obesity (EFO_0001073), Non-Alcoholic Steatohepatitis (EFO_1001249), Non-Alcoholic Fatty Liver Disease (EFO_0003095), Cholestasis (MONDO_0001751), Barrett'S Esophagus (EFO_0000280), Sclerosing Cholangitis (EFO_0004268), Pruritus (HP_0000989), Primary Biliary Cirrhosis (EFO_1001486), Familial Partial Lipodystrophy (MONDO_0020088)", 'newLinkedTargets_string': 'NR1H4 (ENSG00000012504)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2016, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.616 | Q22 | What is Arazlo? | Arazlo, also known generically as Tazarotene, was approved by the FDA in 1997 to treat psoriasis, acne, psoriasis vulgaris, lentigo, and Genetic hypopigmentation of the skin. It is a small molecule therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%arazlo%" OR LOWER(tradeNames_string) LIKE "%arazlo%" OR LOWER(drugSynonyms_string) LIKE "%arazlo%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5124', 'tradeNames_string': 'Arazlo, Avage, Fabior, Tazorac, Zorac', 'drugName': 'Tazarotene', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Retinoic acid receptor agonist', 'linkedDiseasesDrug_string': 'Psoriasis (EFO_0000676), Genetic Hypopigmentation Of The Skin (Orphanet_183469), Skin Carcinoma (EFO_0009259), Skin Disease (EFO_0000701), Acne (EFO_0003894), Cutaneous T-Cell Lymphoma (EFO_0002913), Lentigo (MONDO_0021582), Psoriasis Vulgaris (EFO_1001494)', 'newLinkedTargets_string': 'RARG (ENSG00000172819), RARB (ENSG00000077092), RARA (ENSG00000131759)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1997, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.538 | Q22 | What is Hemangeol? | Hemangeol, also known generically as Propranolol Hydrochloride, was approved by the FDA in 1967 to treat hypertension, stroke, angina pectoris, cardiac arrhythmia, Wolff-Parkinson-White Syndrome, migraine disorder, and coronary atherosclerosis. It is a small molecule therapy that acts as a(n) antagonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%hemangeol%" OR LOWER(tradeNames_string) LIKE "%hemangeol%" OR LOWER(drugSynonyms_string) LIKE "%hemangeol%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4718', 'tradeNames_string': 'Angilol, Apsolol, Avlocardyl, Bedranol, Bedranol s.r., Berkolol, Beta-prograne mr, Betadur cr, Cardinol, Dupromex, Half beta-prograne mr, Half propanix la, Half propatard la, Half-beprane cr, Half-betadur cr, Half-inderal la, Hemangeol, Inderal, Inderal la, Innopran, Innopran xl, Lederpronol, Lopranol la, Probeta la, Propanix la, Propanix-10, Propanix-160, Propanix-160 sr, Propanix-40, Propanix-80, Propatard la, Propranolol hydrochloride, Propranolol hydrochloride intensol, Rapranol sr, Sagittol, Slo-blok, Slo-pro, Sloprolol, Syprol, Tesnol', 'drugName': 'Propranolol Hydrochloride', 'drugMolecularType': 'Small molecule', 'drugActionType': 'antagonist', 'drugMechanismOfAction': 'Beta-1 adrenergic receptor antagonist', 'linkedDiseasesDrug_string': 'Migraine Disorder (MONDO_0005277), Obesity (EFO_0001073), Movement Disorder (EFO_0004280), Prostate Carcinoma (EFO_0001663), Post-Traumatic Stress Disorder (EFO_0001358), Wolff-Parkinson-White Syndrome (EFO_1001450), Angina Pectoris (EFO_0003913), Colorectal Neoplasm (EFO_0004142), Coronary Atherosclerosis (MONDO_0021661), Hypertension (EFO_0000537), Cardiac Arrhythmia (EFO_0004269), Cocaine Dependence (EFO_0002610), Stroke (EFO_0000712), Hemangioma (EFO_1000635), Soft Tissue Sarcoma (EFO_1001968), Esophageal Varices (EFO_0009545), Cutaneous Melanoma (EFO_0000389), Urinary Bladder Cancer (MONDO_0001187), Tetralogy Of Fallot (HP_0001636), Type 2 Diabetes Mellitus (MONDO_0005148), Pancreatic Neoplasm (EFO_0003860), Hypoxia (EFO_0009444), Cirrhosis Of Liver (EFO_0001422)', 'newLinkedTargets_string': 'ADRB2 (ENSG00000169252), ADRB1 (ENSG00000043591)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1967, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_4719', 'tradeNames_string': 'Angilol, Apsolol, Avlocardyl, Bedranol, Bedranol s.r., Berkolol, Beta-prograne mr, Betadur cr, Cardinol, Dupromex, Half beta-prograne mr, Half propanix la, Half propatard la, Half-beprane cr, Half-betadur cr, Half-inderal la, Hemangeol, Inderal, Inderal la, Innopran, Innopran xl, Lederpronol, Lopranol la, Probeta la, Propanix la, Propanix-10, Propanix-160, Propanix-160 sr, Propanix-40, Propanix-80, Propatard la, Propranolol hydrochloride, Propranolol hydrochloride intensol, Rapranol sr, Sagittol, Slo-blok, Slo-pro, Sloprolol, Syprol, Tesnol', 'drugName': 'Propranolol Hydrochloride', 'drugMolecularType': 'Small molecule', 'drugActionType': 'antagonist', 'drugMechanismOfAction': 'Beta-2 adrenergic receptor antagonist', 'linkedDiseasesDrug_string': 'Migraine Disorder (MONDO_0005277), Obesity (EFO_0001073), Movement Disorder (EFO_0004280), Prostate Carcinoma (EFO_0001663), Post-Traumatic Stress Disorder (EFO_0001358), Wolff-Parkinson-White Syndrome (EFO_1001450), Angina Pectoris (EFO_0003913), Colorectal Neoplasm (EFO_0004142), Coronary Atherosclerosis (MONDO_0021661), Hypertension (EFO_0000537), Cardiac Arrhythmia (EFO_0004269), Cocaine Dependence (EFO_0002610), Stroke (EFO_0000712), Hemangioma (EFO_1000635), Soft Tissue Sarcoma (EFO_1001968), Esophageal Varices (EFO_0009545), Cutaneous Melanoma (EFO_0000389), Urinary Bladder Cancer (MONDO_0001187), Tetralogy Of Fallot (HP_0001636), Type 2 Diabetes Mellitus (MONDO_0005148), Pancreatic Neoplasm (EFO_0003860), Hypoxia (EFO_0009444), Cirrhosis Of Liver (EFO_0001422)', 'newLinkedTargets_string': 'ADRB2 (ENSG00000169252), ADRB1 (ENSG00000043591)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1967, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.103 | Q22 | What is Prolensa? | Prolensa, also known generically as Bromfenac Sodium, was approved by the FDA in 1997 to treat Ocular pain, inflammation, and cataract. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%prolensa%" OR LOWER(tradeNames_string) LIKE "%prolensa%" OR LOWER(drugSynonyms_string) LIKE "%prolensa%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_989', 'tradeNames_string': 'Bromday, Bromfenac sodium, Bromsite, Prolensa, Xibrom', 'drugName': 'Bromfenac Sodium', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Cyclooxygenase inhibitor', 'linkedDiseasesDrug_string': 'Cataract (MONDO_0005129), Ocular Pain (HP_0200026), Inflammation (MP_0001845)', 'newLinkedTargets_string': 'PTGS2 (ENSG00000073756), PTGS1 (ENSG00000095303)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1997, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.356 | Q22 | What is Xyzal Allergy 24Hr? | Xyzal Allergy 24Hr, also known generically as Levocetirizine Dihydrochloride, was approved by the FDA in 2007 to treat Pruritus, seasonal allergic rhinitis, urticaria, allergic conjunctivitis, and Rhinitis, Allergic, Perennial. It is a small molecule therapy that acts as a(n) antagonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%xyzal allergy 24hr%" OR LOWER(tradeNames_string) LIKE "%xyzal allergy 24hr%" OR LOWER(drugSynonyms_string) LIKE "%xyzal allergy 24hr%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5631', 'tradeNames_string': 'Levocetirizine dihydrochloride, Xusal, Xyzal, Xyzal allergy 24hr, Xyzall', 'drugName': 'Levocetirizine Dihydrochloride', 'drugMolecularType': 'Small molecule', 'drugActionType': 'antagonist', 'drugMechanismOfAction': 'Histamine H1 receptor antagonist', 'linkedDiseasesDrug_string': 'Allergic Conjunctivitis (EFO_0007141), Rhinitis, Allergic, Perennial (EFO_1001417), Seasonal Allergic Rhinitis (EFO_0003956), Cough (HP_0012735), Fish-Eye Disease (Orphanet_79292), Urticaria (EFO_0005531), Pruritus (HP_0000989), Rhinitis (EFO_0008521)', 'newLinkedTargets_string': 'HRH1 (ENSG00000196639)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2007, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.631 | Q22 | What is Vogelxo? | Vogelxo, also known generically as Testosterone, was approved by the FDA in 1972 to treat Hypogonadotropic hypogonadism, Klinefelter's syndrome, orchitis, hypogonadism, and hypogonadotropic hypogonadism. It is a small molecule therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%vogelxo%" OR LOWER(tradeNames_string) LIKE "%vogelxo%" OR LOWER(drugSynonyms_string) LIKE "%vogelxo%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5308', 'tradeNames_string': 'Androderm, Androgel, Androgel 1%, Andropatch, Axiron, Fortesta, Intrinsa, Natesto, Striant, Striant sr, Testim, Testim 1%, Testoderm, Testoderm tts, Testogel, Testopatch, Testopel, Testoral, Testosterone, Tostran, Vogelxo', 'drugName': 'Testosterone', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Androgen Receptor agonist', 'linkedDiseasesDrug_string': "Erectile Dysfunction (EFO_0004234), Cancer (MONDO_0004992), Hip Fracture (EFO_0003964), Coronary Artery Disease (EFO_0001645), Multiple Sclerosis (MONDO_0005301), Obesity (EFO_0001073), Aids (EFO_0000765), Hypogonadotropic Hypogonadism (MONDO_0018555), Klinefelter'S Syndrome (EFO_1001006), Aging (GO_0007568), Anorexia Nervosa (MONDO_0005351), Prostate Carcinoma (EFO_0001663), Spinal Cord Injury (EFO_1001919), Orchitis (EFO_1001078), Polycystic Ovary Syndrome (EFO_0000660), Prostate Cancer (MONDO_0008315), Cerebral Arterial Disease (EFO_1000859), Growth Delay (HP_0001510), Muscular Disease (EFO_0002970), Hypogonadotropic Hypogonadism (HP_0000044), Sexual Dysfunction (EFO_0004714), Hypogonadism (MONDO_0002146), Insulin Resistance (EFO_0002614), Abnormality Of Connective Tissue (HP_0003549), Sarcopenia (EFO_1000653), Menopause (EFO_0003922), Infertility (EFO_0000545), Chronic Kidney Disease (EFO_0003884), Kallmann Syndrome (MONDO_0018800), Testicular Carcinoma (EFO_0005088), Heart Failure (EFO_0003144), Metastatic Prostate Cancer (EFO_0000196), Metabolic Syndrome (EFO_0000195), Dyspareunia (HP_0030016), Hereditary Breast And Ovarian Cancer Syndrome (Orphanet_145), Genetic Disorder Of Sex Development (Orphanet_325690)", 'newLinkedTargets_string': 'AR (ENSG00000169083)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1972, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.339 | Q22 | What is Vitrakvi? | Vitrakvi, also known generically as Larotrectinib Sulfate, was approved by the FDA in 2018 to treat cancer, neoplasm, and metastasis. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%vitrakvi%" OR LOWER(tradeNames_string) LIKE "%vitrakvi%" OR LOWER(drugSynonyms_string) LIKE "%vitrakvi%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3998', 'tradeNames_string': 'Vitrakvi', 'drugName': 'Larotrectinib Sulfate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Neurotrophic tyrosine kinase receptor inhibitor', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Metastasis (EFO_0009708), Neoplasm (EFO_0000616)', 'newLinkedTargets_string': 'NTRK1 (ENSG00000198400), NTRK2 (ENSG00000148053), NTRK3 (ENSG00000140538)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2018, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.182 | Q22 | What is Verdeso? | Verdeso, also known generically as Desonide, was approved by the FDA in 1972 to treat atopic eczema, skin disease, and eye inflammation. It is a small molecule therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%verdeso%" OR LOWER(tradeNames_string) LIKE "%verdeso%" OR LOWER(drugSynonyms_string) LIKE "%verdeso%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1842', 'tradeNames_string': 'Cortalone, Dekotil, Delta-cortef, Deltacortril, Deltalone, Dilacort, Fernisolone-p, Hydeltra, Meti-derm, Meticortelone, Pevanti, Precortisyl, Precortisyl fte, Prednisolone, Prelone, Scheriproct, Servisone, Sterane', 'drugName': 'Prednisolone', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Glucocorticoid receptor agonist', 'linkedDiseasesDrug_string': "Psoriasis (EFO_0000676), Multiple Myeloma (EFO_0001378), Allergic Bronchopulmonary Aspergillosis (EFO_0007140), Ankylosing Spondylitis (EFO_0003898), Hemophagocytic Syndrome (MONDO_0015540), Iga Glomerulonephritis (EFO_0004194), Allergic Rhinitis (EFO_0005854), Eosinophilic Pneumonia (EFO_0007257), Iridocyclitis (HP_0001094), Temporal Arteritis (EFO_1001209), Ischemic Stroke (HP_0002140), Dermatitis Herpetiformis (EFO_1000684), Atopic Eczema (EFO_0000274), Childhood Acute Lymphoblastic Leukemia (MONDO_0000870), Hypereosinophilic Syndrome (EFO_1001467), Aplastic Anemia (HP_0001915), Granulomatosis With Polyangiitis (EFO_0005297), Keratitis (EFO_0009449), Primary Adrenal Insufficiency (MONDO_0015128), Optic Neuritis (EFO_0007405), Biliary Atresia (MONDO_0008867), Hemangioma (EFO_1000635), Habitual Abortion (EFO_1000954), Ocular Hypertension (EFO_1001069), Hemolytic Anemia (EFO_0005558), Choroiditis (MONDO_0001280), Gout (EFO_0004274), Orbital Plasma Cell Granuloma (EFO_1001077), Iritis (EFO_1000997), Follicular Lymphoma (MONDO_0018906), Churg-Strauss Syndrome (EFO_0007208), Leukemia (EFO_0000565), Pericarditis (EFO_0007427), Adrenocortical Insufficiency (EFO_0009491), Kidney Disease (EFO_0003086), Lipoma (EFO_0000759), Myocarditis (EFO_0009609), Schizophrenia (MONDO_0005090), Lupus Nephritis (EFO_0005761), Thrombotic Thrombocytopenic Purpura (MONDO_0018896), Cancer (MONDO_0004992), Non-Hodgkins Lymphoma (EFO_0005952), Autoimmune Thrombocytopenic Purpura (EFO_0007160), Multiple Sclerosis (MONDO_0005301), Sympathetic Ophthalmia (EFO_1001205), Pure Red-Cell Aplasia (MONDO_0001705), Anaplastic Large Cell Lymphoma (EFO_0003032), Pulmonary Tuberculosis (EFO_1000049), Familial Lipoprotein Lipase Deficiency (MONDO_0009387), Prostate Carcinoma (EFO_0001663), Classic Congenital Adrenal Hyperplasia Due To 21-Hydroxylase Deficiency (MONDO_0008728), Uveitis (EFO_1001231), Hepatocellular Carcinoma (EFO_0000182), Headache (HP_0002315), Cataract (MONDO_0005129), Acute Lymphoblastic Leukemia (EFO_0000220), Vestibular Neuronitis (EFO_0007537), Acute Myeloid Leukemia (EFO_0000222), Polymyalgia Rheumatica (EFO_0008518), Peptic Ulcer (HP_0004398), Dermatomyositis (EFO_0000398), Diffuse Large B-Cell Lymphoma (EFO_0000403), Allergic Conjunctivitis (EFO_0007141), Sinusitis (EFO_0007486), Asthma (MONDO_0004979), West Syndrome (MONDO_0018097), Hemorrhoid (EFO_0009552), Duchenne Muscular Dystrophy (MONDO_0010679), Anemia, Hemolytic, Autoimmune (EFO_1001264), Hodgkins Lymphoma (EFO_0000183), Epicondylitis (EFO_1001887), Chronic Kidney Disease (EFO_0003884), T-Cell Acute Lymphoblastic Leukemia (EFO_0000209), Hiv Infection (EFO_0000764), Pulpitis (EFO_1001139), Osteoarthritis (MONDO_0005178), Type Iii Hypersensitivity Reaction Disease (EFO_1001222), Posterior Uveitis (EFO_1001119), Unspecified Peripheral T-Cell Lymphoma (EFO_0000211), Chorioretinitis (HP_0012424), Mucous Membrane Pemphigoid (EFO_1000680), Open-Angle Glaucoma (EFO_0004190), Glomerulonephritis (MONDO_0002462), Glaucoma (MONDO_0005041), Idiopathic Pulmonary Fibrosis (EFO_0000768), Focal Segmental Glomerulosclerosis (EFO_0004236), Leprosy (EFO_0001054), Hepatitis, Alcoholic (EFO_1001345), Breast Cancer (MONDO_0007254), Juvenile Idiopathic Arthritis (EFO_0002609), Aphthous Ulcer (EFO_0003938), Psoriatic Arthritis (EFO_0003778), Lymphoma (EFO_0000574), Frozen Shoulder (EFO_1000941), Mycosis Fungoides (EFO_1001051), Tenosynovitis (EFO_1001435), Hypercalcemia (HP_0003072), Exfoliative Dermatitis (EFO_0009456), Microscopic Polyangiitis (EFO_1000784), Contact Dermatitis (EFO_0005319), Neoplasm Of Mature B-Cells (EFO_0000096), Infertility (EFO_0000545), Chronic Obstructive Pulmonary Disease (EFO_0000341), Allergic Disease (MONDO_0005271), Erythema Multiforme (EFO_1000694), Age-Related Macular Degeneration (EFO_0001365), Eczema (HP_0000964), Sarcoidosis (MONDO_0019338), Pituitary-Dependent Cushing'S Disease (EFO_1001110), Croup (EFO_0007227), Pemphigus (EFO_1000749), Ophthalmic Herpes Zoster (EFO_0007403), Metastatic Prostate Cancer (EFO_0000196), Seborrheic Dermatitis (EFO_1000764), Type 2 Diabetes Mellitus (MONDO_0005148), Anti-Neutrophil Antibody Associated Vasculitis (EFO_0004826), Lateral Epicondylitis (EFO_1001896), Pneumonia (EFO_0003106), Covid-19 (MONDO_0100096), Systemic Lupus Erythematosus (MONDO_0007915), Angioimmunoblastic T-Cell Lymphoma (EFO_0000255), Celiac Disease (EFO_0001060), Ulcerative Colitis (EFO_0000729), Prostate Adenocarcinoma (EFO_0000673), Nephrotic Syndrome (EFO_0004255), Familial Atrioventricular Septal Defect (MONDO_0020290), Prostate Cancer (MONDO_0008315), Crohn'S Disease (EFO_0000384), Eye Inflammation (EFO_0005752), Membranous Glomerulonephritis (EFO_0004254), Thrombocytopenia (HP_0001873), Language Disorder (MONDO_0004750), Lichen Planus (EFO_1000726), Synovitis (EFO_0008997), Graves Disease (EFO_0004237), Lymphoblastic Lymphoma (MONDO_0000873), Soft Tissue Sarcoma (EFO_1001968), Inflammation (MP_0001845), Extrinsic Allergic Alveolitis (EFO_1001321), Nasal Congestion (HP_0001742), Rheumatoid Arthritis (EFO_0000685), Subacute Thyroiditis (EFO_1001194), Systemic Scleroderma (EFO_0000717), Meningeal Tuberculosis (EFO_1000039), Eye Infection (EFO_1001888), Mucocutaneous Lymph Node Syndrome (EFO_0004246), Trichinosis (EFO_0007520), Colitis (EFO_0003872), Melanoma (EFO_0000756)", 'newLinkedTargets_string': 'NR3C1 (ENSG00000113580)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1955, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_3983', 'tradeNames_string': 'Desonate, Desonide, Desowen, Tridesilon, Verdeso', 'drugName': 'Desonide', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Glucocorticoid receptor agonist', 'linkedDiseasesDrug_string': 'Eye Inflammation (EFO_0005752), Skin Disease (EFO_0000701), Atopic Eczema (EFO_0000274)', 'newLinkedTargets_string': 'NR3C1 (ENSG00000113580)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1972, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.308 | Q22 | What is Dilaudid? | Dilaudid, also known generically as Hydromorphone Hydrochloride, was approved by the FDA in 1984 to treat pain and drug dependence. It is a small molecule therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%dilaudid%" OR LOWER(tradeNames_string) LIKE "%dilaudid%" OR LOWER(drugSynonyms_string) LIKE "%dilaudid%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3034', 'tradeNames_string': '', 'drugName': 'Hydromorphone', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Mu opioid receptor agonist', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Opioid Use Disorder (EFO_0010702), Drug Dependence (EFO_0003890), Osteoarthritis, Hip (EFO_1000786), Liver Disease (EFO_0001421), Pain (EFO_0003843), Chronic Pain (HP_0012532), Sickle Cell Anemia (MONDO_0011382), Osteoarthritis, Knee (EFO_0004616), Back Pain (HP_0003418), Heroin Dependence (EFO_0004240), Constipation (HP_0002019), Mucositis (EFO_1001898), Low Back Pain (HP_0003419), Injury (EFO_0000546), Ileus (MONDO_0004567), Opioid Dependence (EFO_0005611)', 'newLinkedTargets_string': 'OPRM1 (ENSG00000112038)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1984, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_4427', 'tradeNames_string': 'Dilaudid, Dilaudid-hp, Exalgo, Hydromorphone hydrochloride, Palladone, Palladone-sr', 'drugName': 'Hydromorphone Hydrochloride', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Mu opioid receptor agonist', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Drug Dependence (EFO_0003890), Osteoarthritis, Hip (EFO_1000786), Liver Disease (EFO_0001421), Pain (EFO_0003843), Chronic Pain (HP_0012532), Osteoarthritis, Knee (EFO_0004616), Back Pain (HP_0003418)', 'newLinkedTargets_string': 'OPRM1 (ENSG00000112038)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1984, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.355 | Q22 | What is Spritam? | Spritam, also known generically as Levetiracetam, was approved by the FDA in 1999 to treat Seizure, Bilateral tonic-clonic seizure, Focal-onset seizure, epilepsy, and epilepsy with generalized tonic-clonic seizures. It is a small molecule therapy that acts as a(n) modulator and blocker. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%spritam%" OR LOWER(tradeNames_string) LIKE "%spritam%" OR LOWER(drugSynonyms_string) LIKE "%spritam%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_283', 'tradeNames_string': 'Desitrend, Elepsia xr, Keppra, Keppra xr, Levetiracetam, Levetiracetam in sodium chloride, Matever, Spritam', 'drugName': 'Levetiracetam', 'drugMolecularType': 'Small molecule', 'drugActionType': 'modulator', 'drugMechanismOfAction': 'Synaptic vesicle glycoprotein 2A modulator', 'linkedDiseasesDrug_string': 'Canavan Disease (MONDO_0010079), Neuroblastoma (EFO_0000621), Alzheimer Disease (MONDO_0004975), Movement Disorder (EFO_0004280), Focal-Onset Seizure (HP_0007359), Central Nervous System Cancer (EFO_0000326), Panic Disorder (EFO_0004262), Status Epilepticus (EFO_0008526), Drug-Induced Dyskinesia (EFO_1000904), Post-Traumatic Stress Disorder (EFO_0001358), Alcohol Abuse (MONDO_0002046), Aphasia (HP_0002381), Dementia (HP_0000726), Parkinson Disease (MONDO_0005180), Anxiety (EFO_0005230), Partial Epilepsy (EFO_0004263), Epilepsy With Generalized Tonic-Clonic Seizures (EFO_0007262), Cocaine Dependence (EFO_0002610), Epilepsy (EFO_0000474), Photosensitive Epilepsy (MONDO_0015643), Seizure (HP_0001250), Acute Myeloid Leukemia (EFO_0000222), Alcohol Withdrawal (EFO_0004777), Restless Legs Syndrome (EFO_0004270), Obsessive-Compulsive Disorder (EFO_0004242), Stroke (EFO_0000712), Sickle Cell Anemia (MONDO_0011382), Subarachnoid Hemorrhage (EFO_0000713), Brain Neoplasm (EFO_0003833), Glioma (EFO_0005543), Bipolar Disorder (MONDO_0004985), Depressive Disorder (MONDO_0002050), Alcohol Dependence (MONDO_0007079), Bilateral Tonic-Clonic Seizure (HP_0002069), Opioid Dependence (EFO_0005611), Psychosis (EFO_0005407), Cognitive Impairment (HP_0100543), Essential Tremor (EFO_0003108), Postherpetic Neuralgia (MONDO_0041052), Torticollis (HP_0000473), Polyneuropathy (EFO_0009562), Generalized Non-Motor (Absence) Seizure (HP_0002121), Glioblastoma Multiforme (EFO_0000519), Schizophrenia (MONDO_0005090)', 'newLinkedTargets_string': 'CACNA1B (ENSG00000148408), SV2A (ENSG00000159164)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1999, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_284', 'tradeNames_string': 'Desitrend, Elepsia xr, Keppra, Keppra xr, Levetiracetam, Levetiracetam in sodium chloride, Matever, Spritam', 'drugName': 'Levetiracetam', 'drugMolecularType': 'Small molecule', 'drugActionType': 'blocker', 'drugMechanismOfAction': 'Voltage-gated N-type calcium channel alpha-1B subunit blocker', 'linkedDiseasesDrug_string': 'Canavan Disease (MONDO_0010079), Neuroblastoma (EFO_0000621), Alzheimer Disease (MONDO_0004975), Movement Disorder (EFO_0004280), Focal-Onset Seizure (HP_0007359), Central Nervous System Cancer (EFO_0000326), Panic Disorder (EFO_0004262), Status Epilepticus (EFO_0008526), Drug-Induced Dyskinesia (EFO_1000904), Post-Traumatic Stress Disorder (EFO_0001358), Alcohol Abuse (MONDO_0002046), Aphasia (HP_0002381), Dementia (HP_0000726), Parkinson Disease (MONDO_0005180), Anxiety (EFO_0005230), Partial Epilepsy (EFO_0004263), Epilepsy With Generalized Tonic-Clonic Seizures (EFO_0007262), Cocaine Dependence (EFO_0002610), Epilepsy (EFO_0000474), Photosensitive Epilepsy (MONDO_0015643), Seizure (HP_0001250), Acute Myeloid Leukemia (EFO_0000222), Alcohol Withdrawal (EFO_0004777), Restless Legs Syndrome (EFO_0004270), Obsessive-Compulsive Disorder (EFO_0004242), Stroke (EFO_0000712), Sickle Cell Anemia (MONDO_0011382), Subarachnoid Hemorrhage (EFO_0000713), Brain Neoplasm (EFO_0003833), Glioma (EFO_0005543), Bipolar Disorder (MONDO_0004985), Depressive Disorder (MONDO_0002050), Alcohol Dependence (MONDO_0007079), Bilateral Tonic-Clonic Seizure (HP_0002069), Opioid Dependence (EFO_0005611), Psychosis (EFO_0005407), Cognitive Impairment (HP_0100543), Essential Tremor (EFO_0003108), Postherpetic Neuralgia (MONDO_0041052), Torticollis (HP_0000473), Polyneuropathy (EFO_0009562), Generalized Non-Motor (Absence) Seizure (HP_0002121), Glioblastoma Multiforme (EFO_0000519), Schizophrenia (MONDO_0005090)', 'newLinkedTargets_string': 'CACNA1B (ENSG00000148408), SV2A (ENSG00000159164)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1999, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.152 | Q22 | What is Cotellic? | Cotellic, also known generically as Cobimetinib Fumarate, was approved by the FDA in 2015 to treat metastatic melanoma. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%cotellic%" OR LOWER(tradeNames_string) LIKE "%cotellic%" OR LOWER(drugSynonyms_string) LIKE "%cotellic%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3656', 'tradeNames_string': 'Cotellic', 'drugName': 'Cobimetinib', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Dual specificity mitogen-activated protein kinase kinase 1 inhibitor', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Multiple Myeloma (EFO_0001378), Cerebral Arteriovenous Malformation (Orphanet_46724), Skin Cancer (MONDO_0002898), Thyroid Carcinoma (EFO_0002892), Metastatic Melanoma (EFO_0002617), Colorectal Carcinoma (EFO_1001951), Esophageal Carcinoma (EFO_0002916), Ovarian Cancer (MONDO_0008170), Breast Carcinoma (EFO_0000305), Breast Cancer (MONDO_0007254), Gastric Adenocarcinoma (EFO_0000503), Gallbladder Carcinoma (EFO_1001956), Chronic Myelomonocytic Leukemia (EFO_1001779), Acute Myeloid Leukemia (EFO_0000222), Pancreatic Ductal Adenocarcinoma (EFO_0002517), Skin Carcinoma (EFO_0009259), Craniopharyngioma (EFO_1000209), Cutaneous Melanoma (EFO_0000389), Neoplasm (EFO_0000616), Non-Small Cell Lung Carcinoma (EFO_0003060), Sarcoma (EFO_0000691), Melanoma (EFO_0000756)', 'newLinkedTargets_string': 'MAP2K1 (ENSG00000169032), MAP2K2 (ENSG00000126934)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2015, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_3657', 'tradeNames_string': 'Cotellic', 'drugName': 'Cobimetinib', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Dual specificity mitogen-activated protein kinase kinase 2 inhibitor', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Multiple Myeloma (EFO_0001378), Cerebral Arteriovenous Malformation (Orphanet_46724), Skin Cancer (MONDO_0002898), Thyroid Carcinoma (EFO_0002892), Metastatic Melanoma (EFO_0002617), Colorectal Carcinoma (EFO_1001951), Esophageal Carcinoma (EFO_0002916), Ovarian Cancer (MONDO_0008170), Breast Carcinoma (EFO_0000305), Breast Cancer (MONDO_0007254), Gastric Adenocarcinoma (EFO_0000503), Gallbladder Carcinoma (EFO_1001956), Chronic Myelomonocytic Leukemia (EFO_1001779), Acute Myeloid Leukemia (EFO_0000222), Pancreatic Ductal Adenocarcinoma (EFO_0002517), Skin Carcinoma (EFO_0009259), Craniopharyngioma (EFO_1000209), Cutaneous Melanoma (EFO_0000389), Neoplasm (EFO_0000616), Non-Small Cell Lung Carcinoma (EFO_0003060), Sarcoma (EFO_0000691), Melanoma (EFO_0000756)', 'newLinkedTargets_string': 'MAP2K1 (ENSG00000169032), MAP2K2 (ENSG00000126934)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2015, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_6004', 'tradeNames_string': 'Cotellic', 'drugName': 'Cobimetinib Fumarate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Dual specificity mitogen-activated protein kinase kinase 1 inhibitor', 'linkedDiseasesDrug_string': 'Metastatic Melanoma (EFO_0002617)', 'newLinkedTargets_string': 'MAP2K1 (ENSG00000169032), MAP2K2 (ENSG00000126934)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2015, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_6005', 'tradeNames_string': 'Cotellic', 'drugName': 'Cobimetinib Fumarate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Dual specificity mitogen-activated protein kinase kinase 2 inhibitor', 'linkedDiseasesDrug_string': 'Metastatic Melanoma (EFO_0002617)', 'newLinkedTargets_string': 'MAP2K1 (ENSG00000169032), MAP2K2 (ENSG00000126934)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2015, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.127 | Q22 | What is Vraylar? | Vraylar, also known generically as Cariprazine Hydrochloride, was approved by the FDA in 2015 to treat bipolar disorder, bipolar I disorder, and schizophrenia. It is a small molecule therapy that acts as a(n) modulator. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%vraylar%" OR LOWER(tradeNames_string) LIKE "%vraylar%" OR LOWER(drugSynonyms_string) LIKE "%vraylar%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4947', 'tradeNames_string': 'Vraylar', 'drugName': 'Cariprazine Hydrochloride', 'drugMolecularType': 'Small molecule', 'drugActionType': 'modulator', 'drugMechanismOfAction': 'Dopamine D3 receptor modulator', 'linkedDiseasesDrug_string': 'Schizophrenia (MONDO_0005090), Bipolar Disorder (MONDO_0004985), Bipolar I Disorder (EFO_0009963)', 'newLinkedTargets_string': 'DRD2 (ENSG00000149295), DRD3 (ENSG00000151577)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2015, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_4948', 'tradeNames_string': 'Vraylar', 'drugName': 'Cariprazine Hydrochloride', 'drugMolecularType': 'Small molecule', 'drugActionType': 'modulator', 'drugMechanismOfAction': 'Dopamine D2 receptor modulator', 'linkedDiseasesDrug_string': 'Schizophrenia (MONDO_0005090), Bipolar Disorder (MONDO_0004985), Bipolar I Disorder (EFO_0009963)', 'newLinkedTargets_string': 'DRD2 (ENSG00000149295), DRD3 (ENSG00000151577)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2015, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.558 | Q22 | What is Daliresp? | Daliresp, also known generically as Roflumilast, was approved by the FDA in 2011 to treat Airway obstruction, chronic obstructive pulmonary disease, and chronic bronchitis. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%daliresp%" OR LOWER(tradeNames_string) LIKE "%daliresp%" OR LOWER(drugSynonyms_string) LIKE "%daliresp%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5055', 'tradeNames_string': 'Daliresp, Daxas, Zoryve', 'drugName': 'Roflumilast', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Phosphodiesterase 4 inhibitor', 'linkedDiseasesDrug_string': 'Psoriasis (EFO_0000676), Cancer (MONDO_0004992), Rosacea (EFO_1000760), Nervous System Disease (EFO_0000618), Obesity (EFO_0001073), Fragile X Syndrome (MONDO_0010383), Atopic Eczema (EFO_0000274), Dementia (HP_0000726), Lymphoma (EFO_0000574), Adult Acute Respiratory Distress Syndrome (MONDO_0100130), Non-Alcoholic Fatty Liver Disease (EFO_0003095), Asthma (MONDO_0004979), Bronchiectasis (HP_0002110), Chronic Obstructive Pulmonary Disease (EFO_0000341), Airway Obstruction (HP_0006536), Chronic Bronchitis (EFO_0006505), Diabetic Nephropathy (EFO_0000401), Major Depressive Disorder (MONDO_0002009), Type 2 Diabetes Mellitus (MONDO_0005148), Schizophrenia (MONDO_0005090), Dermatitis (MONDO_0002406)', 'newLinkedTargets_string': 'PDE4A (ENSG00000065989), PDE4D (ENSG00000113448), PDE4B (ENSG00000184588), PDE4C (ENSG00000105650)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2011, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.612 | Q22 | What is Nucynta Er? | Nucynta Er, also known generically as Tapentadol Hydrochloride, was approved by the FDA in 2008 to treat Chronic pain, pain, and neuropathic pain. It is a small molecule therapy that acts as a(n) agonist and inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%nucynta er%" OR LOWER(tradeNames_string) LIKE "%nucynta er%" OR LOWER(drugSynonyms_string) LIKE "%nucynta er%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_6372', 'tradeNames_string': 'Nucynta, Nucynta er, Palexia', 'drugName': 'Tapentadol Hydrochloride', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Mu opioid receptor agonist', 'linkedDiseasesDrug_string': 'Pain (EFO_0003843), Chronic Pain (HP_0012532), Low Back Pain (HP_0003419), Neuropathic Pain (EFO_0005762)', 'newLinkedTargets_string': 'SLC6A2 (ENSG00000103546), OPRM1 (ENSG00000112038)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2008, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_6373', 'tradeNames_string': 'Nucynta, Nucynta er, Palexia', 'drugName': 'Tapentadol Hydrochloride', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Norepinephrine transporter inhibitor', 'linkedDiseasesDrug_string': 'Pain (EFO_0003843), Chronic Pain (HP_0012532), Low Back Pain (HP_0003419), Neuropathic Pain (EFO_0005762)', 'newLinkedTargets_string': 'SLC6A2 (ENSG00000103546), OPRM1 (ENSG00000112038)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2008, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.188 | Q22 | What is Xelstrym? | Xelstrym, also known generically as Dextroamphetamine, was approved by the FDA in 1955 to treat obesity, attention deficit hyperactivity disorder, drug dependence, arteriosclerosis disorder, and narcolepsy-cataplexy syndrome. It is a small molecule therapy that acts as a(n) inhibitor and releasing agent. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%xelstrym%" OR LOWER(tradeNames_string) LIKE "%xelstrym%" OR LOWER(drugSynonyms_string) LIKE "%xelstrym%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5075', 'tradeNames_string': 'Dexedrine, Dextrostat, Xelstrym', 'drugName': 'Dextroamphetamine', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Synaptic vesicular amine transporter inhibitor', 'linkedDiseasesDrug_string': 'Methamphetamine Dependence (EFO_0004701), Drug Dependence (EFO_0003890), Multiple Sclerosis (MONDO_0005301), Stroke (EFO_0000712), Obesity (EFO_0001073), Attention Deficit Hyperactivity Disorder (EFO_0003888), Narcolepsy-Cataplexy Syndrome (MONDO_0016158), Arteriosclerosis Disorder (MONDO_0002277), Glioma (EFO_0005543), Bipolar Disorder (MONDO_0004985), Cocaine Dependence (EFO_0002610), Schizophrenia (MONDO_0005090), Opioid Dependence (EFO_0005611)', 'newLinkedTargets_string': 'SLC6A3 (ENSG00000142319), SLC6A2 (ENSG00000103546), SLC18A2 (ENSG00000165646)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1955, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_5076', 'tradeNames_string': 'Dexedrine, Dextrostat, Xelstrym', 'drugName': 'Dextroamphetamine', 'drugMolecularType': 'Small molecule', 'drugActionType': 'releasing agent', 'drugMechanismOfAction': 'Dopamine transporter releasing agent', 'linkedDiseasesDrug_string': 'Methamphetamine Dependence (EFO_0004701), Drug Dependence (EFO_0003890), Multiple Sclerosis (MONDO_0005301), Stroke (EFO_0000712), Obesity (EFO_0001073), Attention Deficit Hyperactivity Disorder (EFO_0003888), Narcolepsy-Cataplexy Syndrome (MONDO_0016158), Arteriosclerosis Disorder (MONDO_0002277), Glioma (EFO_0005543), Bipolar Disorder (MONDO_0004985), Cocaine Dependence (EFO_0002610), Schizophrenia (MONDO_0005090), Opioid Dependence (EFO_0005611)', 'newLinkedTargets_string': 'SLC6A3 (ENSG00000142319), SLC6A2 (ENSG00000103546), SLC18A2 (ENSG00000165646)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1955, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_5077', 'tradeNames_string': 'Dexedrine, Dextrostat, Xelstrym', 'drugName': 'Dextroamphetamine', 'drugMolecularType': 'Small molecule', 'drugActionType': 'releasing agent', 'drugMechanismOfAction': 'Norepinephrine transporter releasing agent', 'linkedDiseasesDrug_string': 'Methamphetamine Dependence (EFO_0004701), Drug Dependence (EFO_0003890), Multiple Sclerosis (MONDO_0005301), Stroke (EFO_0000712), Obesity (EFO_0001073), Attention Deficit Hyperactivity Disorder (EFO_0003888), Narcolepsy-Cataplexy Syndrome (MONDO_0016158), Arteriosclerosis Disorder (MONDO_0002277), Glioma (EFO_0005543), Bipolar Disorder (MONDO_0004985), Cocaine Dependence (EFO_0002610), Schizophrenia (MONDO_0005090), Opioid Dependence (EFO_0005611)', 'newLinkedTargets_string': 'SLC6A3 (ENSG00000142319), SLC6A2 (ENSG00000103546), SLC18A2 (ENSG00000165646)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1955, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.434 | Q22 | What is Bafiertam? | Bafiertam, also known generically as Monomethyl Fumarate, was approved by the FDA in 2020 to treat multiple sclerosis. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%bafiertam%" OR LOWER(tradeNames_string) LIKE "%bafiertam%" OR LOWER(drugSynonyms_string) LIKE "%bafiertam%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_313', 'tradeNames_string': 'Bafiertam', 'drugName': 'Monomethyl Fumarate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Kelch-like ECH-associated protein 1 inhibitor', 'linkedDiseasesDrug_string': 'Multiple Sclerosis (MONDO_0005301), Relapsing-Remitting Multiple Sclerosis (EFO_0003929)', 'newLinkedTargets_string': 'KEAP1 (ENSG00000079999)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2020, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.565 | Q22 | What is Rubraca? | Rubraca, also known generically as Rucaparib Camsylate, was approved by the FDA in 2016 to treat ovarian carcinoma and ovarian cancer. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%rubraca%" OR LOWER(tradeNames_string) LIKE "%rubraca%" OR LOWER(drugSynonyms_string) LIKE "%rubraca%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_6042', 'tradeNames_string': 'Rubraca', 'drugName': 'Rucaparib Camsylate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'PARP 1, 2 and 3 inhibitor', 'linkedDiseasesDrug_string': 'Ovarian Carcinoma (EFO_0001075), Ovarian Cancer (MONDO_0008170), Prostate Adenocarcinoma (EFO_0000673), Neoplasm (EFO_0000616)', 'newLinkedTargets_string': 'PARP1 (ENSG00000143799), PARP3 (ENSG00000041880), PARP2 (ENSG00000129484)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2016, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.696 | Q22 | What is Trintellix? | Trintellix, also known generically as Vortioxetine Hydrobromide, was approved by the FDA in 2013 to treat unipolar depression and major depressive disorder. It is a small molecule therapy that acts as a(n) agonist, inhibitor, and antagonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%trintellix%" OR LOWER(tradeNames_string) LIKE "%trintellix%" OR LOWER(drugSynonyms_string) LIKE "%trintellix%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_776', 'tradeNames_string': 'Trintellix', 'drugName': 'Vortioxetine Hydrobromide', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Serotonin transporter inhibitor', 'linkedDiseasesDrug_string': 'Unipolar Depression (EFO_0003761), Major Depressive Disorder (MONDO_0002009)', 'newLinkedTargets_string': 'SLC6A4 (ENSG00000108576), HTR3A (ENSG00000166736), HTR1A (ENSG00000178394)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2013, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_777', 'tradeNames_string': 'Trintellix', 'drugName': 'Vortioxetine Hydrobromide', 'drugMolecularType': 'Small molecule', 'drugActionType': 'antagonist', 'drugMechanismOfAction': 'Serotonin 3a (5-HT3a) receptor antagonist', 'linkedDiseasesDrug_string': 'Unipolar Depression (EFO_0003761), Major Depressive Disorder (MONDO_0002009)', 'newLinkedTargets_string': 'SLC6A4 (ENSG00000108576), HTR3A (ENSG00000166736), HTR1A (ENSG00000178394)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2013, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_778', 'tradeNames_string': 'Trintellix', 'drugName': 'Vortioxetine Hydrobromide', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Serotonin 1a (5-HT1a) receptor agonist', 'linkedDiseasesDrug_string': 'Unipolar Depression (EFO_0003761), Major Depressive Disorder (MONDO_0002009)', 'newLinkedTargets_string': 'SLC6A4 (ENSG00000108576), HTR3A (ENSG00000166736), HTR1A (ENSG00000178394)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2013, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.350 | Q22 | What is Lupron Depot? | Lupron Depot, also known generically as Leuprolide Acetate, was approved by the FDA in 1985 to treat metastatic prostate cancer, prostate adenocarcinoma, prostate carcinoma, Central precocious puberty, precocious puberty, prostate cancer, and central precocious puberty. It is a protein therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%lupron depot%" OR LOWER(tradeNames_string) LIKE "%lupron depot%" OR LOWER(drugSynonyms_string) LIKE "%lupron depot%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4802', 'tradeNames_string': 'Carcinil, Eligard, Eligard kit, Fensolvi kit, Leuprolide acetate, Leuprorelin, Lupron, Lupron Depot Ped, Lupron depot, Lupron depot-ped, Lupron depot-ped kit, Lutrate depot kit, Viadur', 'drugName': 'Leuprolide Acetate', 'drugMolecularType': 'Protein', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Gonadotropin-releasing hormone receptor agonist', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Multiple Myeloma (EFO_0001378), Alzheimer Disease (MONDO_0004975), Male Infertility (EFO_0004248), Uterine Fibroid (EFO_0000731), Obesity (EFO_0001073), Prostate Carcinoma (EFO_0001663), Prostate Adenocarcinoma (EFO_0000673), Breast Neoplasm (EFO_0003869), Central Precocious Puberty (EFO_0009029), Prostate Cancer (MONDO_0008315), Mantle Cell Lymphoma (EFO_1001469), Breast Cancer (MONDO_0007254), Postpartum Depression (EFO_0007453), Hypertension (EFO_0000537), Endometriosis (EFO_0001065), Precocious Puberty (MONDO_0000088), Hodgkins Lymphoma (EFO_0000183), Cognitive Impairment (HP_0100543), Metastatic Prostate Cancer (EFO_0000196), Bulimia Nervosa (EFO_0005204)', 'newLinkedTargets_string': 'GNRHR (ENSG00000109163)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1985, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.651 | Q22 | What is Qudexy Xr? | Qudexy Xr, also known generically as Topiramate, was approved by the FDA in 1996 to treat Seizure, epilepsy, migraine disorder, and Lennox-Gastaut syndrome. It is a small molecule therapy that acts as a(n) inhibitor, positive modulator, blocker, and antagonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%qudexy xr%" OR LOWER(tradeNames_string) LIKE "%qudexy xr%" OR LOWER(drugSynonyms_string) LIKE "%qudexy xr%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1592', 'tradeNames_string': 'Epitomax, Eprontia, Qudexy xr, Topamax, Topamax sprinkle, Topiramate, Trokendi xr', 'drugName': 'Topiramate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'blocker', 'drugMechanismOfAction': 'Sodium channel alpha subunit blocker', 'linkedDiseasesDrug_string': 'Diabetes Mellitus (EFO_0000400), Hyperlipidemia (MONDO_0021187), Hypertriglyceridemia (EFO_0004211), Multiple Sclerosis (MONDO_0005301), Liver Disease (EFO_0001421), Migraine Disorder (MONDO_0005277), Tourette Syndrome (EFO_0004895), Obesity (EFO_0001073), Pain (EFO_0003843), Lennox-Gastaut Syndrome (MONDO_0016532), Cannabis Dependence (EFO_0007191), Prader-Willi Syndrome (MONDO_0008300), Eating Disorder (EFO_0005203), Deafness (EFO_0001063), Post-Traumatic Stress Disorder (EFO_0001358), Alcohol Abuse (MONDO_0002046), Sciatica (HP_0011868), Headache (HP_0002315), Nicotine Dependence (EFO_0003768), Hypertension (EFO_0000537), Dementia (HP_0000726), Parkinson Disease (MONDO_0005180), Anxiety (EFO_0005230), Brain Ischemia (MONDO_0005299), Epilepsy With Generalized Tonic-Clonic Seizures (EFO_0007262), Partial Epilepsy (EFO_0004263), Cocaine Dependence (EFO_0002610), Epilepsy (EFO_0000474), Seizure (HP_0001250), Alcohol Drinking (EFO_0004329), Methamphetamine Dependence (EFO_0004701), Binge Eating (EFO_0005924), Obsessive-Compulsive Disorder (EFO_0004242), Bipolar Disorder (MONDO_0004985), Depressive Disorder (MONDO_0002050), Alcohol Dependence (MONDO_0007079), Congenital Heart Disease (EFO_0005207), Gambling Behaviour (EFO_0004699), Smoking Cessation (EFO_0004319), Cognitive Impairment (HP_0100543), Essential Tremor (EFO_0003108), Metabolic Syndrome (EFO_0000195), Bulimia Nervosa (EFO_0005204), Type 2 Diabetes Mellitus (MONDO_0005148), Schizophrenia (MONDO_0005090)', 'newLinkedTargets_string': 'GRIK1 (ENSG00000171189), GRIK5 (ENSG00000105737), GRIK4 (ENSG00000149403), GRIK2 (ENSG00000164418), GRIK3 (ENSG00000163873), CA4 (ENSG00000167434), SCN1A (ENSG00000144285), SCN5A (ENSG00000183873), SCN4A (ENSG00000007314), SCN7A (ENSG00000136546), SCN2A (ENSG00000136531), SCN9A (ENSG00000169432), SCN3A (ENSG00000153253), SCN11A (ENSG00000168356), SCN8A (ENSG00000196876), SCN10A (ENSG00000185313), GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863), CA2 (ENSG00000104267), GRIA4 (ENSG00000152578), GRIA3 (ENSG00000125675), GRIA2 (ENSG00000120251), GRIA1 (ENSG00000155511)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1996, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_1593', 'tradeNames_string': 'Epitomax, Eprontia, Qudexy xr, Topamax, Topamax sprinkle, Topiramate, Trokendi xr', 'drugName': 'Topiramate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'positive modulator', 'drugMechanismOfAction': 'GABA-A receptor; anion channel positive modulator', 'linkedDiseasesDrug_string': 'Diabetes Mellitus (EFO_0000400), Hyperlipidemia (MONDO_0021187), Hypertriglyceridemia (EFO_0004211), Multiple Sclerosis (MONDO_0005301), Liver Disease (EFO_0001421), Migraine Disorder (MONDO_0005277), Tourette Syndrome (EFO_0004895), Obesity (EFO_0001073), Pain (EFO_0003843), Lennox-Gastaut Syndrome (MONDO_0016532), Cannabis Dependence (EFO_0007191), Prader-Willi Syndrome (MONDO_0008300), Eating Disorder (EFO_0005203), Deafness (EFO_0001063), Post-Traumatic Stress Disorder (EFO_0001358), Alcohol Abuse (MONDO_0002046), Sciatica (HP_0011868), Headache (HP_0002315), Nicotine Dependence (EFO_0003768), Hypertension (EFO_0000537), Dementia (HP_0000726), Parkinson Disease (MONDO_0005180), Anxiety (EFO_0005230), Brain Ischemia (MONDO_0005299), Epilepsy With Generalized Tonic-Clonic Seizures (EFO_0007262), Partial Epilepsy (EFO_0004263), Cocaine Dependence (EFO_0002610), Epilepsy (EFO_0000474), Seizure (HP_0001250), Alcohol Drinking (EFO_0004329), Methamphetamine Dependence (EFO_0004701), Binge Eating (EFO_0005924), Obsessive-Compulsive Disorder (EFO_0004242), Bipolar Disorder (MONDO_0004985), Depressive Disorder (MONDO_0002050), Alcohol Dependence (MONDO_0007079), Congenital Heart Disease (EFO_0005207), Gambling Behaviour (EFO_0004699), Smoking Cessation (EFO_0004319), Cognitive Impairment (HP_0100543), Essential Tremor (EFO_0003108), Metabolic Syndrome (EFO_0000195), Bulimia Nervosa (EFO_0005204), Type 2 Diabetes Mellitus (MONDO_0005148), Schizophrenia (MONDO_0005090)', 'newLinkedTargets_string': 'GRIK1 (ENSG00000171189), GRIK5 (ENSG00000105737), GRIK4 (ENSG00000149403), GRIK2 (ENSG00000164418), GRIK3 (ENSG00000163873), CA4 (ENSG00000167434), SCN1A (ENSG00000144285), SCN5A (ENSG00000183873), SCN4A (ENSG00000007314), SCN7A (ENSG00000136546), SCN2A (ENSG00000136531), SCN9A (ENSG00000169432), SCN3A (ENSG00000153253), SCN11A (ENSG00000168356), SCN8A (ENSG00000196876), SCN10A (ENSG00000185313), GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863), CA2 (ENSG00000104267), GRIA4 (ENSG00000152578), GRIA3 (ENSG00000125675), GRIA2 (ENSG00000120251), GRIA1 (ENSG00000155511)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1996, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_1594', 'tradeNames_string': 'Epitomax, Eprontia, Qudexy xr, Topamax, Topamax sprinkle, Topiramate, Trokendi xr', 'drugName': 'Topiramate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'antagonist', 'drugMechanismOfAction': 'Glutamate receptor ionotropic kainate antagonist', 'linkedDiseasesDrug_string': 'Diabetes Mellitus (EFO_0000400), Hyperlipidemia (MONDO_0021187), Hypertriglyceridemia (EFO_0004211), Multiple Sclerosis (MONDO_0005301), Liver Disease (EFO_0001421), Migraine Disorder (MONDO_0005277), Tourette Syndrome (EFO_0004895), Obesity (EFO_0001073), Pain (EFO_0003843), Lennox-Gastaut Syndrome (MONDO_0016532), Cannabis Dependence (EFO_0007191), Prader-Willi Syndrome (MONDO_0008300), Eating Disorder (EFO_0005203), Deafness (EFO_0001063), Post-Traumatic Stress Disorder (EFO_0001358), Alcohol Abuse (MONDO_0002046), Sciatica (HP_0011868), Headache (HP_0002315), Nicotine Dependence (EFO_0003768), Hypertension (EFO_0000537), Dementia (HP_0000726), Parkinson Disease (MONDO_0005180), Anxiety (EFO_0005230), Brain Ischemia (MONDO_0005299), Epilepsy With Generalized Tonic-Clonic Seizures (EFO_0007262), Partial Epilepsy (EFO_0004263), Cocaine Dependence (EFO_0002610), Epilepsy (EFO_0000474), Seizure (HP_0001250), Alcohol Drinking (EFO_0004329), Methamphetamine Dependence (EFO_0004701), Binge Eating (EFO_0005924), Obsessive-Compulsive Disorder (EFO_0004242), Bipolar Disorder (MONDO_0004985), Depressive Disorder (MONDO_0002050), Alcohol Dependence (MONDO_0007079), Congenital Heart Disease (EFO_0005207), Gambling Behaviour (EFO_0004699), Smoking Cessation (EFO_0004319), Cognitive Impairment (HP_0100543), Essential Tremor (EFO_0003108), Metabolic Syndrome (EFO_0000195), Bulimia Nervosa (EFO_0005204), Type 2 Diabetes Mellitus (MONDO_0005148), Schizophrenia (MONDO_0005090)', 'newLinkedTargets_string': 'GRIK1 (ENSG00000171189), GRIK5 (ENSG00000105737), GRIK4 (ENSG00000149403), GRIK2 (ENSG00000164418), GRIK3 (ENSG00000163873), CA4 (ENSG00000167434), SCN1A (ENSG00000144285), SCN5A (ENSG00000183873), SCN4A (ENSG00000007314), SCN7A (ENSG00000136546), SCN2A (ENSG00000136531), SCN9A (ENSG00000169432), SCN3A (ENSG00000153253), SCN11A (ENSG00000168356), SCN8A (ENSG00000196876), SCN10A (ENSG00000185313), GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863), CA2 (ENSG00000104267), GRIA4 (ENSG00000152578), GRIA3 (ENSG00000125675), GRIA2 (ENSG00000120251), GRIA1 (ENSG00000155511)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1996, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_1595', 'tradeNames_string': 'Epitomax, Eprontia, Qudexy xr, Topamax, Topamax sprinkle, Topiramate, Trokendi xr', 'drugName': 'Topiramate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Carbonic anhydrase IV inhibitor', 'linkedDiseasesDrug_string': 'Diabetes Mellitus (EFO_0000400), Hyperlipidemia (MONDO_0021187), Hypertriglyceridemia (EFO_0004211), Multiple Sclerosis (MONDO_0005301), Liver Disease (EFO_0001421), Migraine Disorder (MONDO_0005277), Tourette Syndrome (EFO_0004895), Obesity (EFO_0001073), Pain (EFO_0003843), Lennox-Gastaut Syndrome (MONDO_0016532), Cannabis Dependence (EFO_0007191), Prader-Willi Syndrome (MONDO_0008300), Eating Disorder (EFO_0005203), Deafness (EFO_0001063), Post-Traumatic Stress Disorder (EFO_0001358), Alcohol Abuse (MONDO_0002046), Sciatica (HP_0011868), Headache (HP_0002315), Nicotine Dependence (EFO_0003768), Hypertension (EFO_0000537), Dementia (HP_0000726), Parkinson Disease (MONDO_0005180), Anxiety (EFO_0005230), Brain Ischemia (MONDO_0005299), Epilepsy With Generalized Tonic-Clonic Seizures (EFO_0007262), Partial Epilepsy (EFO_0004263), Cocaine Dependence (EFO_0002610), Epilepsy (EFO_0000474), Seizure (HP_0001250), Alcohol Drinking (EFO_0004329), Methamphetamine Dependence (EFO_0004701), Binge Eating (EFO_0005924), Obsessive-Compulsive Disorder (EFO_0004242), Bipolar Disorder (MONDO_0004985), Depressive Disorder (MONDO_0002050), Alcohol Dependence (MONDO_0007079), Congenital Heart Disease (EFO_0005207), Gambling Behaviour (EFO_0004699), Smoking Cessation (EFO_0004319), Cognitive Impairment (HP_0100543), Essential Tremor (EFO_0003108), Metabolic Syndrome (EFO_0000195), Bulimia Nervosa (EFO_0005204), Type 2 Diabetes Mellitus (MONDO_0005148), Schizophrenia (MONDO_0005090)', 'newLinkedTargets_string': 'GRIK1 (ENSG00000171189), GRIK5 (ENSG00000105737), GRIK4 (ENSG00000149403), GRIK2 (ENSG00000164418), GRIK3 (ENSG00000163873), CA4 (ENSG00000167434), SCN1A (ENSG00000144285), SCN5A (ENSG00000183873), SCN4A (ENSG00000007314), SCN7A (ENSG00000136546), SCN2A (ENSG00000136531), SCN9A (ENSG00000169432), SCN3A (ENSG00000153253), SCN11A (ENSG00000168356), SCN8A (ENSG00000196876), SCN10A (ENSG00000185313), GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863), CA2 (ENSG00000104267), GRIA4 (ENSG00000152578), GRIA3 (ENSG00000125675), GRIA2 (ENSG00000120251), GRIA1 (ENSG00000155511)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1996, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_1596', 'tradeNames_string': 'Epitomax, Eprontia, Qudexy xr, Topamax, Topamax sprinkle, Topiramate, Trokendi xr', 'drugName': 'Topiramate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Carbonic anhydrase II inhibitor', 'linkedDiseasesDrug_string': 'Diabetes Mellitus (EFO_0000400), Hyperlipidemia (MONDO_0021187), Hypertriglyceridemia (EFO_0004211), Multiple Sclerosis (MONDO_0005301), Liver Disease (EFO_0001421), Migraine Disorder (MONDO_0005277), Tourette Syndrome (EFO_0004895), Obesity (EFO_0001073), Pain (EFO_0003843), Lennox-Gastaut Syndrome (MONDO_0016532), Cannabis Dependence (EFO_0007191), Prader-Willi Syndrome (MONDO_0008300), Eating Disorder (EFO_0005203), Deafness (EFO_0001063), Post-Traumatic Stress Disorder (EFO_0001358), Alcohol Abuse (MONDO_0002046), Sciatica (HP_0011868), Headache (HP_0002315), Nicotine Dependence (EFO_0003768), Hypertension (EFO_0000537), Dementia (HP_0000726), Parkinson Disease (MONDO_0005180), Anxiety (EFO_0005230), Brain Ischemia (MONDO_0005299), Epilepsy With Generalized Tonic-Clonic Seizures (EFO_0007262), Partial Epilepsy (EFO_0004263), Cocaine Dependence (EFO_0002610), Epilepsy (EFO_0000474), Seizure (HP_0001250), Alcohol Drinking (EFO_0004329), Methamphetamine Dependence (EFO_0004701), Binge Eating (EFO_0005924), Obsessive-Compulsive Disorder (EFO_0004242), Bipolar Disorder (MONDO_0004985), Depressive Disorder (MONDO_0002050), Alcohol Dependence (MONDO_0007079), Congenital Heart Disease (EFO_0005207), Gambling Behaviour (EFO_0004699), Smoking Cessation (EFO_0004319), Cognitive Impairment (HP_0100543), Essential Tremor (EFO_0003108), Metabolic Syndrome (EFO_0000195), Bulimia Nervosa (EFO_0005204), Type 2 Diabetes Mellitus (MONDO_0005148), Schizophrenia (MONDO_0005090)', 'newLinkedTargets_string': 'GRIK1 (ENSG00000171189), GRIK5 (ENSG00000105737), GRIK4 (ENSG00000149403), GRIK2 (ENSG00000164418), GRIK3 (ENSG00000163873), CA4 (ENSG00000167434), SCN1A (ENSG00000144285), SCN5A (ENSG00000183873), SCN4A (ENSG00000007314), SCN7A (ENSG00000136546), SCN2A (ENSG00000136531), SCN9A (ENSG00000169432), SCN3A (ENSG00000153253), SCN11A (ENSG00000168356), SCN8A (ENSG00000196876), SCN10A (ENSG00000185313), GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863), CA2 (ENSG00000104267), GRIA4 (ENSG00000152578), GRIA3 (ENSG00000125675), GRIA2 (ENSG00000120251), GRIA1 (ENSG00000155511)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1996, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_1597', 'tradeNames_string': 'Epitomax, Eprontia, Qudexy xr, Topamax, Topamax sprinkle, Topiramate, Trokendi xr', 'drugName': 'Topiramate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'antagonist', 'drugMechanismOfAction': 'Glutamate receptor ionotropic AMPA antagonist', 'linkedDiseasesDrug_string': 'Diabetes Mellitus (EFO_0000400), Hyperlipidemia (MONDO_0021187), Hypertriglyceridemia (EFO_0004211), Multiple Sclerosis (MONDO_0005301), Liver Disease (EFO_0001421), Migraine Disorder (MONDO_0005277), Tourette Syndrome (EFO_0004895), Obesity (EFO_0001073), Pain (EFO_0003843), Lennox-Gastaut Syndrome (MONDO_0016532), Cannabis Dependence (EFO_0007191), Prader-Willi Syndrome (MONDO_0008300), Eating Disorder (EFO_0005203), Deafness (EFO_0001063), Post-Traumatic Stress Disorder (EFO_0001358), Alcohol Abuse (MONDO_0002046), Sciatica (HP_0011868), Headache (HP_0002315), Nicotine Dependence (EFO_0003768), Hypertension (EFO_0000537), Dementia (HP_0000726), Parkinson Disease (MONDO_0005180), Anxiety (EFO_0005230), Brain Ischemia (MONDO_0005299), Epilepsy With Generalized Tonic-Clonic Seizures (EFO_0007262), Partial Epilepsy (EFO_0004263), Cocaine Dependence (EFO_0002610), Epilepsy (EFO_0000474), Seizure (HP_0001250), Alcohol Drinking (EFO_0004329), Methamphetamine Dependence (EFO_0004701), Binge Eating (EFO_0005924), Obsessive-Compulsive Disorder (EFO_0004242), Bipolar Disorder (MONDO_0004985), Depressive Disorder (MONDO_0002050), Alcohol Dependence (MONDO_0007079), Congenital Heart Disease (EFO_0005207), Gambling Behaviour (EFO_0004699), Smoking Cessation (EFO_0004319), Cognitive Impairment (HP_0100543), Essential Tremor (EFO_0003108), Metabolic Syndrome (EFO_0000195), Bulimia Nervosa (EFO_0005204), Type 2 Diabetes Mellitus (MONDO_0005148), Schizophrenia (MONDO_0005090)', 'newLinkedTargets_string': 'GRIK1 (ENSG00000171189), GRIK5 (ENSG00000105737), GRIK4 (ENSG00000149403), GRIK2 (ENSG00000164418), GRIK3 (ENSG00000163873), CA4 (ENSG00000167434), SCN1A (ENSG00000144285), SCN5A (ENSG00000183873), SCN4A (ENSG00000007314), SCN7A (ENSG00000136546), SCN2A (ENSG00000136531), SCN9A (ENSG00000169432), SCN3A (ENSG00000153253), SCN11A (ENSG00000168356), SCN8A (ENSG00000196876), SCN10A (ENSG00000185313), GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863), CA2 (ENSG00000104267), GRIA4 (ENSG00000152578), GRIA3 (ENSG00000125675), GRIA2 (ENSG00000120251), GRIA1 (ENSG00000155511)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1996, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.145 | Q22 | What is Clobex? | Clobex, also known generically as Clobetasol Propionate, was approved by the FDA in 1985 to treat psoriasis, skin disease, and psoriasis vulgaris. It is a small molecule therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%clobex%" OR LOWER(tradeNames_string) LIKE "%clobex%" OR LOWER(drugSynonyms_string) LIKE "%clobex%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5376', 'tradeNames_string': 'Clarelux, Clobaderm, Clobetasol propionate, Clobetasol propionate (emollient), Clobex, Cormax, Dermovate, Dermovate nn, Embeline, Embeline e, Etrivex, Impeklo, Impoyz, Olux, Olux e, Temovate, Temovate e', 'drugName': 'Clobetasol Propionate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Glucocorticoid receptor agonist', 'linkedDiseasesDrug_string': 'Psoriasis (EFO_0000676), Oral Lichen Planus (EFO_0008517), Graft Versus Host Disease (MONDO_0013730), Scleroderma (EFO_1001993), Psoriasis Vulgaris (EFO_1001494), Herpes Labialis (EFO_1001347), Vulvar Lichen Sclerosus (EFO_1000623), Cataract (MONDO_0005129), Atopic Eczema (EFO_0000274), Bullous Pemphigoid (EFO_0007187), Lichen Planus (EFO_1000726), Alopecia Areata (EFO_0004192), Rheumatoid Arthritis (EFO_0000685), Toxic Epidermal Necrolysis (EFO_0004775), Rectum Cancer (EFO_1000657), Colon Adenocarcinoma (EFO_1001949), Lichen Disease (EFO_1000724), Skin Disease (EFO_0000701), Seborrheic Dermatitis (EFO_1000764), Phlebitis (EFO_1001395)', 'newLinkedTargets_string': 'NR3C1 (ENSG00000113580)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1985, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.144 | Q22 | What is Sympazan? | Sympazan, also known generically as Clobazam, was approved by the FDA in 2005 to treat Seizure, anxiety, and Lennox-Gastaut syndrome. It is a small molecule therapy that acts as a(n) positive allosteric modulator. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%sympazan%" OR LOWER(tradeNames_string) LIKE "%sympazan%" OR LOWER(drugSynonyms_string) LIKE "%sympazan%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5981', 'tradeNames_string': 'Frisium, Onfi, Perizam, Sympazan, Tapclob, Urbanyl', 'drugName': 'Clobazam', 'drugMolecularType': 'Small molecule', 'drugActionType': 'positive allosteric modulator', 'drugMechanismOfAction': 'GABA-A receptor; anion channel positive allosteric modulator', 'linkedDiseasesDrug_string': 'Pain (EFO_0003843), Dravet Syndrome (Orphanet_33069), Lennox-Gastaut Syndrome (MONDO_0016532), Dementia (HP_0000726), Neuropathic Pain (EFO_0005762), Anxiety (EFO_0005230), Epilepsy (EFO_0000474), Depressive Disorder (MONDO_0002050), Seizure (HP_0001250), Low Back Pain (HP_0003419), Schizophrenia (MONDO_0005090), Epilepsia Partialis Continua (EFO_1000924)', 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2005, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.399 | Q22 | What is Camzyos? | Camzyos, also known generically as Mavacamten, was approved by the FDA in 2022 to treat hypertrophic cardiomyopathy. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%camzyos%" OR LOWER(tradeNames_string) LIKE "%camzyos%" OR LOWER(drugSynonyms_string) LIKE "%camzyos%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1036', 'tradeNames_string': 'Camzyos', 'drugName': 'Mavacamten', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Cardiac myosin inhibitor', 'linkedDiseasesDrug_string': 'Heart Failure (EFO_0003144), Hypertrophic Cardiomyopathy (EFO_0000538)', 'newLinkedTargets_string': 'MYH7 (ENSG00000092054), MYH6 (ENSG00000197616), MYH7B (ENSG00000078814), MYL3 (ENSG00000160808), MYL2 (ENSG00000111245), MYL7 (ENSG00000106631), MYL4 (ENSG00000198336)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2022, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.325 | Q22 | What is Absorica Ld? | Absorica Ld, also known generically as Isotretinoin, was approved by the FDA in 1982 to treat acne. It is a small molecule therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%absorica ld%" OR LOWER(tradeNames_string) LIKE "%absorica ld%" OR LOWER(drugSynonyms_string) LIKE "%absorica ld%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3116', 'tradeNames_string': 'Absorica, Absorica ld, Accutane, Amnesteem, Claravis, Isotrex, Myorisan, Roaccutane, Sotret, Zenatane', 'drugName': 'Isotretinoin', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Retinoic acid receptor agonist', 'linkedDiseasesDrug_string': "Neuroblastoma (EFO_0000621), Multiple Myeloma (EFO_0001378), Alzheimer Disease (MONDO_0004975), Medulloblastoma (EFO_0002939), Infection (EFO_0000544), Rosacea (EFO_1000760), Mixed Glioma (MONDO_0003268), Covid-19 (MONDO_0100096), Oligodendroglioma (EFO_0000632), Azoospermia (EFO_0000279), Klinefelter'S Syndrome (EFO_1001006), Burkitts Lymphoma (EFO_0000309), Myelodysplastic Syndrome (EFO_0000198), Focal Segmental Glomerulosclerosis (EFO_0004236), Chronic Myelogenous Leukemia (EFO_0000339), Juvenile Myelomonocytic Leukemia (EFO_1000309), Acute Promyelocytic Leukemia (EFO_0000224), Anaplastic Astrocytoma (EFO_0002499), Gliosarcoma (EFO_1001465), Tinea Pedis (EFO_0007512), Prostate Cancer (MONDO_0008315), Breast Cancer (MONDO_0007254), Childhood Acute Lymphoblastic Leukemia (MONDO_0000870), Acute Myeloid Leukemia (EFO_0000222), Wilms Tumor (MONDO_0006058), Mycosis Fungoides (EFO_1001051), Acne (EFO_0003894), Emphysema (EFO_0000464), Diffuse Large B-Cell Lymphoma (EFO_0000403), Central Nervous System Neoplasm (EFO_1000158), Anaplastic Oligodendroglioma (EFO_0002501), Ganglioneuroblastoma (EFO_0000502), Actinic Keratosis (EFO_0002496), Lymphoblastic Lymphoma (MONDO_0000873), Renal Cell Carcinoma (EFO_0000681), Hiv-1 Infection (EFO_0000180), Brain Neoplasm (EFO_0003833), Dysplasia Of Cervix (EFO_1000910), Hodgkins Lymphoma (EFO_0000183), Cervical Cancer (MONDO_0002974), Head And Neck Malignant Neoplasia (EFO_0006859), Lung Cancer (MONDO_0008903), Neoplasm (EFO_0000616), Leukemia (EFO_0000565), Kidney Cancer (MONDO_0002367), Ichthyosis (MONDO_0019269), Epidermolysis Bullosa (EFO_1000690), Glioblastoma Multiforme (EFO_0000519)", 'newLinkedTargets_string': 'RARG (ENSG00000172819), RARB (ENSG00000077092), RARA (ENSG00000131759)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1982, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.20 | Q22 | What is Alecensa? | Alecensa, also known generically as Alectinib Hydrochloride, was approved by the FDA in 2015 to treat non-small cell lung carcinoma. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%alecensa%" OR LOWER(tradeNames_string) LIKE "%alecensa%" OR LOWER(drugSynonyms_string) LIKE "%alecensa%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4671', 'tradeNames_string': 'Alecensa', 'drugName': 'Alectinib', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'ALK tyrosine kinase receptor inhibitor', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Papillary Thyroid Carcinoma (EFO_0000641), Liver Disease (EFO_0001421), Upper Aerodigestive Tract Neoplasm (EFO_0004284), Anaplastic Large Cell Lymphoma (EFO_0003032), Central Nervous System Cancer (EFO_0000326), Colorectal Neoplasm (EFO_0004142), Cholangiocarcinoma (EFO_0005221), Lung Neoplasm (MONDO_0021117), Brain Neoplasm (EFO_0003833), Bronchial Neoplasm (EFO_1000849), Ovarian Neoplasm (EFO_0003893), Neoplasm (EFO_0000616), Salivary Gland Neoplasm (EFO_0003826), Non-Small Cell Lung Carcinoma (EFO_0003060), Sarcoma (EFO_0000691), Melanoma (EFO_0000756), Glioblastoma Multiforme (EFO_0000519), Pancreatic Neoplasm (EFO_0003860)', 'newLinkedTargets_string': 'ALK (ENSG00000171094), RET (ENSG00000165731), EML4 (ENSG00000143924)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2015, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_4672', 'tradeNames_string': 'Alecensa', 'drugName': 'Alectinib', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Tyrosine-protein kinase receptor RET inhibitor', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Papillary Thyroid Carcinoma (EFO_0000641), Liver Disease (EFO_0001421), Upper Aerodigestive Tract Neoplasm (EFO_0004284), Anaplastic Large Cell Lymphoma (EFO_0003032), Central Nervous System Cancer (EFO_0000326), Colorectal Neoplasm (EFO_0004142), Cholangiocarcinoma (EFO_0005221), Lung Neoplasm (MONDO_0021117), Brain Neoplasm (EFO_0003833), Bronchial Neoplasm (EFO_1000849), Ovarian Neoplasm (EFO_0003893), Neoplasm (EFO_0000616), Salivary Gland Neoplasm (EFO_0003826), Non-Small Cell Lung Carcinoma (EFO_0003060), Sarcoma (EFO_0000691), Melanoma (EFO_0000756), Glioblastoma Multiforme (EFO_0000519), Pancreatic Neoplasm (EFO_0003860)', 'newLinkedTargets_string': 'ALK (ENSG00000171094), RET (ENSG00000165731), EML4 (ENSG00000143924)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2015, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_4673', 'tradeNames_string': 'Alecensa', 'drugName': 'Alectinib', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'EML4-ALK', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Papillary Thyroid Carcinoma (EFO_0000641), Liver Disease (EFO_0001421), Upper Aerodigestive Tract Neoplasm (EFO_0004284), Anaplastic Large Cell Lymphoma (EFO_0003032), Central Nervous System Cancer (EFO_0000326), Colorectal Neoplasm (EFO_0004142), Cholangiocarcinoma (EFO_0005221), Lung Neoplasm (MONDO_0021117), Brain Neoplasm (EFO_0003833), Bronchial Neoplasm (EFO_1000849), Ovarian Neoplasm (EFO_0003893), Neoplasm (EFO_0000616), Salivary Gland Neoplasm (EFO_0003826), Non-Small Cell Lung Carcinoma (EFO_0003060), Sarcoma (EFO_0000691), Melanoma (EFO_0000756), Glioblastoma Multiforme (EFO_0000519), Pancreatic Neoplasm (EFO_0003860)', 'newLinkedTargets_string': 'ALK (ENSG00000171094), RET (ENSG00000165731), EML4 (ENSG00000143924)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2015, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_1249', 'tradeNames_string': 'Alecensa', 'drugName': 'Alectinib Hydrochloride', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'ALK tyrosine kinase receptor inhibitor', 'linkedDiseasesDrug_string': 'Non-Small Cell Lung Carcinoma (EFO_0003060)', 'newLinkedTargets_string': 'ALK (ENSG00000171094), RET (ENSG00000165731), EML4 (ENSG00000143924)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2015, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_1250', 'tradeNames_string': 'Alecensa', 'drugName': 'Alectinib Hydrochloride', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Tyrosine-protein kinase receptor RET inhibitor', 'linkedDiseasesDrug_string': 'Non-Small Cell Lung Carcinoma (EFO_0003060)', 'newLinkedTargets_string': 'ALK (ENSG00000171094), RET (ENSG00000165731), EML4 (ENSG00000143924)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2015, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_1251', 'tradeNames_string': 'Alecensa', 'drugName': 'Alectinib Hydrochloride', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'EML4-ALK', 'linkedDiseasesDrug_string': 'Non-Small Cell Lung Carcinoma (EFO_0003060)', 'newLinkedTargets_string': 'ALK (ENSG00000171094), RET (ENSG00000165731), EML4 (ENSG00000143924)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2015, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.175 | Q22 | What is Zegalogue? | Zegalogue, also known generically as Dasiglucagon Hydrochloride, was approved by the FDA in 2021 to treat Hypoglycemia and type 1 diabetes mellitus. It is a unknown therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%zegalogue%" OR LOWER(tradeNames_string) LIKE "%zegalogue%" OR LOWER(drugSynonyms_string) LIKE "%zegalogue%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4736', 'tradeNames_string': 'Zegalogue, Zegalogue (autoinjector)', 'drugName': 'Dasiglucagon Hydrochloride', 'drugMolecularType': 'Unknown', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Glucagon receptor agonist', 'linkedDiseasesDrug_string': 'Hypoglycemia (HP_0001943), Type 1 Diabetes Mellitus (MONDO_0005147)', 'newLinkedTargets_string': 'GCGR (ENSG00000215644)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2021, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.639 | Q22 | What is Brilinta? | Brilinta, also known generically as Ticagrelor, was approved by the FDA in 2011 to treat Recurrent thrombophlebitis, myocardial infarction, stroke, coronary artery disease, acute coronary syndrome, acute myocardial infarction, thrombotic disease, and type 2 diabetes mellitus. It is a small molecule therapy that acts as a(n) negative allosteric modulator. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%brilinta%" OR LOWER(tradeNames_string) LIKE "%brilinta%" OR LOWER(drugSynonyms_string) LIKE "%brilinta%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4496', 'tradeNames_string': 'Brilinta, Brilique', 'drugName': 'Ticagrelor', 'drugMolecularType': 'Small molecule', 'drugActionType': 'negative allosteric modulator', 'drugMechanismOfAction': 'Purinergic receptor P2Y12 negative allosteric modulator', 'linkedDiseasesDrug_string': 'Coronary Artery Disease (EFO_0001645), Pneumonia (EFO_0003106), Non-St Elevation Myocardial Infarction (EFO_0008586), Peripheral Arterial Disease (EFO_0004265), Covid-19 (MONDO_0100096), St Elevation Myocardial Infarction (EFO_0008585), Abdominal Aortic Aneurysm (EFO_0004214), Atrial Fibrillation (EFO_0000275), Recurrent Thrombophlebitis (HP_0004419), Angina Pectoris (EFO_0003913), Cardiovascular Disease (EFO_0000319), Acute Myocardial Infarction (EFO_0008583), Acute Coronary Syndrome (EFO_0005672), Thrombotic Disease (MONDO_0000831), Aortic Stenosis (EFO_0000266), Stroke (EFO_0000712), Brain Aneurysm (EFO_0003870), Sickle Cell Anemia (MONDO_0011382), Chronic Obstructive Pulmonary Disease (EFO_0000341), Myocardial Infarction (EFO_0000612), Influenza (EFO_0007328), Chronic Kidney Disease (EFO_0003884), Internal Carotid Artery Stenosis (EFO_0002615), Kidney Disease (EFO_0003086), Type 2 Diabetes Mellitus (MONDO_0005148), Ischemia (EFO_0000556)', 'newLinkedTargets_string': 'P2RY12 (ENSG00000169313)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2011, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.316 | Q22 | What is Gleevec? | Gleevec, also known generically as Imatinib Mesylate, was approved by the FDA in 2001 to treat chronic myelogenous leukemia. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%gleevec%" OR LOWER(tradeNames_string) LIKE "%gleevec%" OR LOWER(drugSynonyms_string) LIKE "%gleevec%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2515', 'tradeNames_string': '', 'drugName': 'Imatinib', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Tyrosine-protein kinase ABL inhibitor', 'linkedDiseasesDrug_string': 'Papillary Thyroid Carcinoma (EFO_0000641), Wet Macular Degeneration (EFO_0004683), Malignant Colon Neoplasm (MONDO_0021063), Scleroderma (EFO_1001993), Spinal Cord Injury (EFO_1001919), Lymphangioleiomyomatosis (MONDO_0011705), Seasonal Allergic Rhinitis (EFO_0003956), Childhood Acute Lymphoblastic Leukemia (MONDO_0000870), Hypereosinophilic Syndrome (EFO_1001467), Eosinophilia (HP_0001880), Sickle Cell Anemia (MONDO_0011382), Clear Cell Renal Carcinoma (EFO_0000349), Pulmonary Venoocclusive Disease (MONDO_0009937), Malignant Epithelial Tumor Of Ovary (MONDO_0018364), Fibrosarcoma (EFO_0002087), Carcinoma (EFO_0000313), T-Lymphoblastic Lymphoma (MONDO_0044917), Lung Cancer (MONDO_0008903), Leukemia (EFO_0000565), Colorectal Adenocarcinoma (EFO_0000365), Glioblastoma Multiforme (EFO_0000519), Cancer (MONDO_0004992), Non-Hodgkins Lymphoma (EFO_0005952), Multiple Sclerosis (MONDO_0005301), Thymic Carcinoma (EFO_1000576), Anaplastic Large Cell Lymphoma (EFO_0003032), Gastrointestinal Stromal Tumor (MONDO_0011719), Colorectal Carcinoma (EFO_1001951), Gliosarcoma (EFO_1001465), Fibromatosis (EFO_0000497), Acute Lung Injury (EFO_0004610), Gastric Adenocarcinoma (EFO_0000503), B-Cell Acute Lymphoblastic Leukemia (EFO_0000094), Acute Lymphoblastic Leukemia (EFO_0000220), Acute Myeloid Leukemia (EFO_0000222), Asthma (MONDO_0004979), Small Cell Lung Carcinoma (EFO_0000702), Stroke (EFO_0000712), Thyroid Cancer (MONDO_0002108), Malignant Peripheral Nerve Sheath Tumor (EFO_0000760), Rectum Cancer (EFO_1000657), T-Cell Acute Lymphoblastic Leukemia (EFO_0000209), Merkel Cell Skin Cancer (EFO_1001471), Non-Small Cell Lung Carcinoma (EFO_0003060), Colonic Neoplasm (EFO_0004288), Primary Myelofibrosis (EFO_0002430), Pulmonary Hypertension (MONDO_0005149), Plasmodium Falciparum Malaria (EFO_0007444), Hematopoietic And Lymphoid Cell Neoplasm (MONDO_0044881), Pulmonary Arterial Hypertension (EFO_0001361), Idiopathic Pulmonary Fibrosis (EFO_0000768), Gastric Cancer (MONDO_0001056), Ovarian Cancer (MONDO_0008170), Breast Cancer (MONDO_0007254), Lymphoma (EFO_0000574), Loiasis (EFO_1000729), Pancreatic Carcinoma (EFO_0002618), Central Nervous System Neoplasm (EFO_1000158), Colorectal Cancer (MONDO_0005575), Neurofibromatosis Type 1 (MONDO_0018975), Mesothelioma (EFO_0000588), Peritoneum Cancer (MONDO_0002087), Cutaneous Melanoma (EFO_0000389), Chronic Myeloproliferative Disorder (EFO_0002428), Neoplasm (EFO_0000616), Chordoma (MONDO_0008978), Uterine Carcinosarcoma (EFO_1000613), Sarcoma (EFO_0000691), Tuberculosis (MONDO_0018076), Synovial Sarcoma (EFO_0001376), Type 1 Diabetes Mellitus (MONDO_0005147), Stomach Neoplasm (EFO_0003897), Uterine Cancer (MONDO_0002715), Graft Versus Host Disease (MONDO_0013730), Covid-19 (MONDO_0100096), Myeloid Leukemia (MONDO_0004643), Metastatic Melanoma (EFO_0002617), Endometrial Cancer (MONDO_0011962), Desmoplastic Small Round Cell Tumor (EFO_1000895), Polycythemia Vera (EFO_0002429), Chronic Myelogenous Leukemia (EFO_0000339), Prostate Adenocarcinoma (EFO_0000673), Prostate Cancer (MONDO_0008315), Male Breast Carcinoma (EFO_0006861), Dermatofibrosarcoma Protuberans (MONDO_0011934), Nephrogenic Fibrosing Dermopathy (EFO_1001814), Lymphoblastic Lymphoma (MONDO_0000873), Plexiform Neurofibroma (EFO_0000658), Skin Neoplasm (EFO_0004198), Rheumatoid Arthritis (EFO_0000685), Systemic Scleroderma (EFO_0000717), Chondrosarcoma (EFO_0000333), Localised Scleroderma (EFO_1001361), Lymphoid Leukemia (EFO_0004289), Head And Neck Malignant Neoplasia (EFO_0006859), Fallopian Tube Cancer (MONDO_0002158), Kidney Cancer (MONDO_0002367), Melanoma (EFO_0000756), Cirrhosis Of Liver (EFO_0001422), Desmoid-Type Fibromatosis (EFO_0009907)', 'newLinkedTargets_string': 'ABL1 (ENSG00000097007), PDGFRB (ENSG00000113721), BCR (ENSG00000186716), KIT (ENSG00000157404)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2001, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_2516', 'tradeNames_string': '', 'drugName': 'Imatinib', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Bcr/Abl fusion protein', 'linkedDiseasesDrug_string': 'Papillary Thyroid Carcinoma (EFO_0000641), Wet Macular Degeneration (EFO_0004683), Malignant Colon Neoplasm (MONDO_0021063), Scleroderma (EFO_1001993), Spinal Cord Injury (EFO_1001919), Lymphangioleiomyomatosis (MONDO_0011705), Seasonal Allergic Rhinitis (EFO_0003956), Childhood Acute Lymphoblastic Leukemia (MONDO_0000870), Hypereosinophilic Syndrome (EFO_1001467), Eosinophilia (HP_0001880), Sickle Cell Anemia (MONDO_0011382), Clear Cell Renal Carcinoma (EFO_0000349), Pulmonary Venoocclusive Disease (MONDO_0009937), Malignant Epithelial Tumor Of Ovary (MONDO_0018364), Fibrosarcoma (EFO_0002087), Carcinoma (EFO_0000313), T-Lymphoblastic Lymphoma (MONDO_0044917), Lung Cancer (MONDO_0008903), Leukemia (EFO_0000565), Colorectal Adenocarcinoma (EFO_0000365), Glioblastoma Multiforme (EFO_0000519), Cancer (MONDO_0004992), Non-Hodgkins Lymphoma (EFO_0005952), Multiple Sclerosis (MONDO_0005301), Thymic Carcinoma (EFO_1000576), Anaplastic Large Cell Lymphoma (EFO_0003032), Gastrointestinal Stromal Tumor (MONDO_0011719), Colorectal Carcinoma (EFO_1001951), Gliosarcoma (EFO_1001465), Fibromatosis (EFO_0000497), Acute Lung Injury (EFO_0004610), Gastric Adenocarcinoma (EFO_0000503), B-Cell Acute Lymphoblastic Leukemia (EFO_0000094), Acute Lymphoblastic Leukemia (EFO_0000220), Acute Myeloid Leukemia (EFO_0000222), Asthma (MONDO_0004979), Small Cell Lung Carcinoma (EFO_0000702), Stroke (EFO_0000712), Thyroid Cancer (MONDO_0002108), Malignant Peripheral Nerve Sheath Tumor (EFO_0000760), Rectum Cancer (EFO_1000657), T-Cell Acute Lymphoblastic Leukemia (EFO_0000209), Merkel Cell Skin Cancer (EFO_1001471), Non-Small Cell Lung Carcinoma (EFO_0003060), Colonic Neoplasm (EFO_0004288), Primary Myelofibrosis (EFO_0002430), Pulmonary Hypertension (MONDO_0005149), Plasmodium Falciparum Malaria (EFO_0007444), Hematopoietic And Lymphoid Cell Neoplasm (MONDO_0044881), Pulmonary Arterial Hypertension (EFO_0001361), Idiopathic Pulmonary Fibrosis (EFO_0000768), Gastric Cancer (MONDO_0001056), Ovarian Cancer (MONDO_0008170), Breast Cancer (MONDO_0007254), Lymphoma (EFO_0000574), Loiasis (EFO_1000729), Pancreatic Carcinoma (EFO_0002618), Central Nervous System Neoplasm (EFO_1000158), Colorectal Cancer (MONDO_0005575), Neurofibromatosis Type 1 (MONDO_0018975), Mesothelioma (EFO_0000588), Peritoneum Cancer (MONDO_0002087), Cutaneous Melanoma (EFO_0000389), Chronic Myeloproliferative Disorder (EFO_0002428), Neoplasm (EFO_0000616), Chordoma (MONDO_0008978), Uterine Carcinosarcoma (EFO_1000613), Sarcoma (EFO_0000691), Tuberculosis (MONDO_0018076), Synovial Sarcoma (EFO_0001376), Type 1 Diabetes Mellitus (MONDO_0005147), Stomach Neoplasm (EFO_0003897), Uterine Cancer (MONDO_0002715), Graft Versus Host Disease (MONDO_0013730), Covid-19 (MONDO_0100096), Myeloid Leukemia (MONDO_0004643), Metastatic Melanoma (EFO_0002617), Endometrial Cancer (MONDO_0011962), Desmoplastic Small Round Cell Tumor (EFO_1000895), Polycythemia Vera (EFO_0002429), Chronic Myelogenous Leukemia (EFO_0000339), Prostate Adenocarcinoma (EFO_0000673), Prostate Cancer (MONDO_0008315), Male Breast Carcinoma (EFO_0006861), Dermatofibrosarcoma Protuberans (MONDO_0011934), Nephrogenic Fibrosing Dermopathy (EFO_1001814), Lymphoblastic Lymphoma (MONDO_0000873), Plexiform Neurofibroma (EFO_0000658), Skin Neoplasm (EFO_0004198), Rheumatoid Arthritis (EFO_0000685), Systemic Scleroderma (EFO_0000717), Chondrosarcoma (EFO_0000333), Localised Scleroderma (EFO_1001361), Lymphoid Leukemia (EFO_0004289), Head And Neck Malignant Neoplasia (EFO_0006859), Fallopian Tube Cancer (MONDO_0002158), Kidney Cancer (MONDO_0002367), Melanoma (EFO_0000756), Cirrhosis Of Liver (EFO_0001422), Desmoid-Type Fibromatosis (EFO_0009907)', 'newLinkedTargets_string': 'ABL1 (ENSG00000097007), PDGFRB (ENSG00000113721), BCR (ENSG00000186716), KIT (ENSG00000157404)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2001, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_2517', 'tradeNames_string': '', 'drugName': 'Imatinib', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Platelet-derived growth factor receptor beta inhibitor', 'linkedDiseasesDrug_string': 'Papillary Thyroid Carcinoma (EFO_0000641), Wet Macular Degeneration (EFO_0004683), Malignant Colon Neoplasm (MONDO_0021063), Scleroderma (EFO_1001993), Spinal Cord Injury (EFO_1001919), Lymphangioleiomyomatosis (MONDO_0011705), Seasonal Allergic Rhinitis (EFO_0003956), Childhood Acute Lymphoblastic Leukemia (MONDO_0000870), Hypereosinophilic Syndrome (EFO_1001467), Eosinophilia (HP_0001880), Sickle Cell Anemia (MONDO_0011382), Clear Cell Renal Carcinoma (EFO_0000349), Pulmonary Venoocclusive Disease (MONDO_0009937), Malignant Epithelial Tumor Of Ovary (MONDO_0018364), Fibrosarcoma (EFO_0002087), Carcinoma (EFO_0000313), T-Lymphoblastic Lymphoma (MONDO_0044917), Lung Cancer (MONDO_0008903), Leukemia (EFO_0000565), Colorectal Adenocarcinoma (EFO_0000365), Glioblastoma Multiforme (EFO_0000519), Cancer (MONDO_0004992), Non-Hodgkins Lymphoma (EFO_0005952), Multiple Sclerosis (MONDO_0005301), Thymic Carcinoma (EFO_1000576), Anaplastic Large Cell Lymphoma (EFO_0003032), Gastrointestinal Stromal Tumor (MONDO_0011719), Colorectal Carcinoma (EFO_1001951), Gliosarcoma (EFO_1001465), Fibromatosis (EFO_0000497), Acute Lung Injury (EFO_0004610), Gastric Adenocarcinoma (EFO_0000503), B-Cell Acute Lymphoblastic Leukemia (EFO_0000094), Acute Lymphoblastic Leukemia (EFO_0000220), Acute Myeloid Leukemia (EFO_0000222), Asthma (MONDO_0004979), Small Cell Lung Carcinoma (EFO_0000702), Stroke (EFO_0000712), Thyroid Cancer (MONDO_0002108), Malignant Peripheral Nerve Sheath Tumor (EFO_0000760), Rectum Cancer (EFO_1000657), T-Cell Acute Lymphoblastic Leukemia (EFO_0000209), Merkel Cell Skin Cancer (EFO_1001471), Non-Small Cell Lung Carcinoma (EFO_0003060), Colonic Neoplasm (EFO_0004288), Primary Myelofibrosis (EFO_0002430), Pulmonary Hypertension (MONDO_0005149), Plasmodium Falciparum Malaria (EFO_0007444), Hematopoietic And Lymphoid Cell Neoplasm (MONDO_0044881), Pulmonary Arterial Hypertension (EFO_0001361), Idiopathic Pulmonary Fibrosis (EFO_0000768), Gastric Cancer (MONDO_0001056), Ovarian Cancer (MONDO_0008170), Breast Cancer (MONDO_0007254), Lymphoma (EFO_0000574), Loiasis (EFO_1000729), Pancreatic Carcinoma (EFO_0002618), Central Nervous System Neoplasm (EFO_1000158), Colorectal Cancer (MONDO_0005575), Neurofibromatosis Type 1 (MONDO_0018975), Mesothelioma (EFO_0000588), Peritoneum Cancer (MONDO_0002087), Cutaneous Melanoma (EFO_0000389), Chronic Myeloproliferative Disorder (EFO_0002428), Neoplasm (EFO_0000616), Chordoma (MONDO_0008978), Uterine Carcinosarcoma (EFO_1000613), Sarcoma (EFO_0000691), Tuberculosis (MONDO_0018076), Synovial Sarcoma (EFO_0001376), Type 1 Diabetes Mellitus (MONDO_0005147), Stomach Neoplasm (EFO_0003897), Uterine Cancer (MONDO_0002715), Graft Versus Host Disease (MONDO_0013730), Covid-19 (MONDO_0100096), Myeloid Leukemia (MONDO_0004643), Metastatic Melanoma (EFO_0002617), Endometrial Cancer (MONDO_0011962), Desmoplastic Small Round Cell Tumor (EFO_1000895), Polycythemia Vera (EFO_0002429), Chronic Myelogenous Leukemia (EFO_0000339), Prostate Adenocarcinoma (EFO_0000673), Prostate Cancer (MONDO_0008315), Male Breast Carcinoma (EFO_0006861), Dermatofibrosarcoma Protuberans (MONDO_0011934), Nephrogenic Fibrosing Dermopathy (EFO_1001814), Lymphoblastic Lymphoma (MONDO_0000873), Plexiform Neurofibroma (EFO_0000658), Skin Neoplasm (EFO_0004198), Rheumatoid Arthritis (EFO_0000685), Systemic Scleroderma (EFO_0000717), Chondrosarcoma (EFO_0000333), Localised Scleroderma (EFO_1001361), Lymphoid Leukemia (EFO_0004289), Head And Neck Malignant Neoplasia (EFO_0006859), Fallopian Tube Cancer (MONDO_0002158), Kidney Cancer (MONDO_0002367), Melanoma (EFO_0000756), Cirrhosis Of Liver (EFO_0001422), Desmoid-Type Fibromatosis (EFO_0009907)', 'newLinkedTargets_string': 'ABL1 (ENSG00000097007), PDGFRB (ENSG00000113721), BCR (ENSG00000186716), KIT (ENSG00000157404)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2001, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_2518', 'tradeNames_string': '', 'drugName': 'Imatinib', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Stem cell growth factor receptor inhibitor', 'linkedDiseasesDrug_string': 'Papillary Thyroid Carcinoma (EFO_0000641), Wet Macular Degeneration (EFO_0004683), Malignant Colon Neoplasm (MONDO_0021063), Scleroderma (EFO_1001993), Spinal Cord Injury (EFO_1001919), Lymphangioleiomyomatosis (MONDO_0011705), Seasonal Allergic Rhinitis (EFO_0003956), Childhood Acute Lymphoblastic Leukemia (MONDO_0000870), Hypereosinophilic Syndrome (EFO_1001467), Eosinophilia (HP_0001880), Sickle Cell Anemia (MONDO_0011382), Clear Cell Renal Carcinoma (EFO_0000349), Pulmonary Venoocclusive Disease (MONDO_0009937), Malignant Epithelial Tumor Of Ovary (MONDO_0018364), Fibrosarcoma (EFO_0002087), Carcinoma (EFO_0000313), T-Lymphoblastic Lymphoma (MONDO_0044917), Lung Cancer (MONDO_0008903), Leukemia (EFO_0000565), Colorectal Adenocarcinoma (EFO_0000365), Glioblastoma Multiforme (EFO_0000519), Cancer (MONDO_0004992), Non-Hodgkins Lymphoma (EFO_0005952), Multiple Sclerosis (MONDO_0005301), Thymic Carcinoma (EFO_1000576), Anaplastic Large Cell Lymphoma (EFO_0003032), Gastrointestinal Stromal Tumor (MONDO_0011719), Colorectal Carcinoma (EFO_1001951), Gliosarcoma (EFO_1001465), Fibromatosis (EFO_0000497), Acute Lung Injury (EFO_0004610), Gastric Adenocarcinoma (EFO_0000503), B-Cell Acute Lymphoblastic Leukemia (EFO_0000094), Acute Lymphoblastic Leukemia (EFO_0000220), Acute Myeloid Leukemia (EFO_0000222), Asthma (MONDO_0004979), Small Cell Lung Carcinoma (EFO_0000702), Stroke (EFO_0000712), Thyroid Cancer (MONDO_0002108), Malignant Peripheral Nerve Sheath Tumor (EFO_0000760), Rectum Cancer (EFO_1000657), T-Cell Acute Lymphoblastic Leukemia (EFO_0000209), Merkel Cell Skin Cancer (EFO_1001471), Non-Small Cell Lung Carcinoma (EFO_0003060), Colonic Neoplasm (EFO_0004288), Primary Myelofibrosis (EFO_0002430), Pulmonary Hypertension (MONDO_0005149), Plasmodium Falciparum Malaria (EFO_0007444), Hematopoietic And Lymphoid Cell Neoplasm (MONDO_0044881), Pulmonary Arterial Hypertension (EFO_0001361), Idiopathic Pulmonary Fibrosis (EFO_0000768), Gastric Cancer (MONDO_0001056), Ovarian Cancer (MONDO_0008170), Breast Cancer (MONDO_0007254), Lymphoma (EFO_0000574), Loiasis (EFO_1000729), Pancreatic Carcinoma (EFO_0002618), Central Nervous System Neoplasm (EFO_1000158), Colorectal Cancer (MONDO_0005575), Neurofibromatosis Type 1 (MONDO_0018975), Mesothelioma (EFO_0000588), Peritoneum Cancer (MONDO_0002087), Cutaneous Melanoma (EFO_0000389), Chronic Myeloproliferative Disorder (EFO_0002428), Neoplasm (EFO_0000616), Chordoma (MONDO_0008978), Uterine Carcinosarcoma (EFO_1000613), Sarcoma (EFO_0000691), Tuberculosis (MONDO_0018076), Synovial Sarcoma (EFO_0001376), Type 1 Diabetes Mellitus (MONDO_0005147), Stomach Neoplasm (EFO_0003897), Uterine Cancer (MONDO_0002715), Graft Versus Host Disease (MONDO_0013730), Covid-19 (MONDO_0100096), Myeloid Leukemia (MONDO_0004643), Metastatic Melanoma (EFO_0002617), Endometrial Cancer (MONDO_0011962), Desmoplastic Small Round Cell Tumor (EFO_1000895), Polycythemia Vera (EFO_0002429), Chronic Myelogenous Leukemia (EFO_0000339), Prostate Adenocarcinoma (EFO_0000673), Prostate Cancer (MONDO_0008315), Male Breast Carcinoma (EFO_0006861), Dermatofibrosarcoma Protuberans (MONDO_0011934), Nephrogenic Fibrosing Dermopathy (EFO_1001814), Lymphoblastic Lymphoma (MONDO_0000873), Plexiform Neurofibroma (EFO_0000658), Skin Neoplasm (EFO_0004198), Rheumatoid Arthritis (EFO_0000685), Systemic Scleroderma (EFO_0000717), Chondrosarcoma (EFO_0000333), Localised Scleroderma (EFO_1001361), Lymphoid Leukemia (EFO_0004289), Head And Neck Malignant Neoplasia (EFO_0006859), Fallopian Tube Cancer (MONDO_0002158), Kidney Cancer (MONDO_0002367), Melanoma (EFO_0000756), Cirrhosis Of Liver (EFO_0001422), Desmoid-Type Fibromatosis (EFO_0009907)', 'newLinkedTargets_string': 'ABL1 (ENSG00000097007), PDGFRB (ENSG00000113721), BCR (ENSG00000186716), KIT (ENSG00000157404)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2001, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_3269', 'tradeNames_string': 'Gleevec, Glivec, Imatinib mesylate', 'drugName': 'Imatinib Mesylate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Tyrosine-protein kinase ABL inhibitor', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Non-Hodgkins Lymphoma (EFO_0005952), Pulmonary Hypertension (MONDO_0005149), Primary Myelofibrosis (EFO_0002430), Uterine Cancer (MONDO_0002715), Multiple Sclerosis (MONDO_0005301), Graft Versus Host Disease (MONDO_0013730), Pulmonary Arterial Hypertension (EFO_0001361), Wet Macular Degeneration (EFO_0004683), Merkel Cell Skin Cancer (EFO_1001471), Gastrointestinal Stromal Tumor (MONDO_0011719), Idiopathic Pulmonary Fibrosis (EFO_0000768), Colorectal Carcinoma (EFO_1001951), Polycythemia Vera (EFO_0002429), Chronic Myelogenous Leukemia (EFO_0000339), Scleroderma (EFO_1001993), Prostate Adenocarcinoma (EFO_0000673), Malignant Colon Neoplasm (MONDO_0021063), Endometrial Cancer (MONDO_0011962), Gliosarcoma (EFO_1001465), Ovarian Cancer (MONDO_0008170), Gastric Cancer (MONDO_0001056), Prostate Cancer (MONDO_0008315), Breast Cancer (MONDO_0007254), Gastric Adenocarcinoma (EFO_0000503), Lymphangioleiomyomatosis (MONDO_0011705), B-Cell Acute Lymphoblastic Leukemia (EFO_0000094), Acute Lymphoblastic Leukemia (EFO_0000220), Male Breast Carcinoma (EFO_0006861), Childhood Acute Lymphoblastic Leukemia (MONDO_0000870), Lymphoma (EFO_0000574), Hypereosinophilic Syndrome (EFO_1001467), Acute Myeloid Leukemia (EFO_0000222), Dermatofibrosarcoma Protuberans (MONDO_0011934), Central Nervous System Neoplasm (EFO_1000158), Loiasis (EFO_1000729), Eosinophilia (HP_0001880), Asthma (MONDO_0004979), Pancreatic Carcinoma (EFO_0002618), Small Cell Lung Carcinoma (EFO_0000702), Nephrogenic Fibrosing Dermopathy (EFO_1001814), Neurofibromatosis Type 1 (MONDO_0018975), Sickle Cell Anemia (MONDO_0011382), Mesothelioma (EFO_0000588), Lymphoblastic Lymphoma (MONDO_0000873), Plexiform Neurofibroma (EFO_0000658), Thyroid Cancer (MONDO_0002108), Pulmonary Venoocclusive Disease (MONDO_0009937), Peritoneum Cancer (MONDO_0002087), Malignant Peripheral Nerve Sheath Tumor (EFO_0000760), Malignant Epithelial Tumor Of Ovary (MONDO_0018364), Skin Neoplasm (EFO_0004198), Carcinoma (EFO_0000313), Cutaneous Melanoma (EFO_0000389), Systemic Scleroderma (EFO_0000717), T-Lymphoblastic Lymphoma (MONDO_0044917), Chondrosarcoma (EFO_0000333), Localised Scleroderma (EFO_1001361), Rectum Cancer (EFO_1000657), Head And Neck Malignant Neoplasia (EFO_0006859), Chronic Myeloproliferative Disorder (EFO_0002428), Fallopian Tube Cancer (MONDO_0002158), Lung Cancer (MONDO_0008903), Neoplasm (EFO_0000616), Glioblastoma Multiforme (EFO_0000519), Lymphoid Leukemia (EFO_0004289), T-Cell Acute Lymphoblastic Leukemia (EFO_0000209), Non-Small Cell Lung Carcinoma (EFO_0003060), Leukemia (EFO_0000565), Uterine Carcinosarcoma (EFO_1000613), Kidney Cancer (MONDO_0002367), Sarcoma (EFO_0000691), Melanoma (EFO_0000756), Synovial Sarcoma (EFO_0001376), Type 1 Diabetes Mellitus (MONDO_0005147), Desmoid-Type Fibromatosis (EFO_0009907)', 'newLinkedTargets_string': 'ABL1 (ENSG00000097007), PDGFRB (ENSG00000113721), KIT (ENSG00000157404), BCR (ENSG00000186716)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2001, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_3270', 'tradeNames_string': 'Gleevec, Glivec, Imatinib mesylate', 'drugName': 'Imatinib Mesylate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Bcr/Abl fusion protein', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Non-Hodgkins Lymphoma (EFO_0005952), Pulmonary Hypertension (MONDO_0005149), Primary Myelofibrosis (EFO_0002430), Uterine Cancer (MONDO_0002715), Multiple Sclerosis (MONDO_0005301), Graft Versus Host Disease (MONDO_0013730), Pulmonary Arterial Hypertension (EFO_0001361), Wet Macular Degeneration (EFO_0004683), Merkel Cell Skin Cancer (EFO_1001471), Gastrointestinal Stromal Tumor (MONDO_0011719), Idiopathic Pulmonary Fibrosis (EFO_0000768), Colorectal Carcinoma (EFO_1001951), Polycythemia Vera (EFO_0002429), Chronic Myelogenous Leukemia (EFO_0000339), Scleroderma (EFO_1001993), Prostate Adenocarcinoma (EFO_0000673), Malignant Colon Neoplasm (MONDO_0021063), Endometrial Cancer (MONDO_0011962), Gliosarcoma (EFO_1001465), Ovarian Cancer (MONDO_0008170), Gastric Cancer (MONDO_0001056), Prostate Cancer (MONDO_0008315), Breast Cancer (MONDO_0007254), Gastric Adenocarcinoma (EFO_0000503), Lymphangioleiomyomatosis (MONDO_0011705), B-Cell Acute Lymphoblastic Leukemia (EFO_0000094), Acute Lymphoblastic Leukemia (EFO_0000220), Male Breast Carcinoma (EFO_0006861), Childhood Acute Lymphoblastic Leukemia (MONDO_0000870), Lymphoma (EFO_0000574), Hypereosinophilic Syndrome (EFO_1001467), Acute Myeloid Leukemia (EFO_0000222), Dermatofibrosarcoma Protuberans (MONDO_0011934), Central Nervous System Neoplasm (EFO_1000158), Loiasis (EFO_1000729), Eosinophilia (HP_0001880), Asthma (MONDO_0004979), Pancreatic Carcinoma (EFO_0002618), Small Cell Lung Carcinoma (EFO_0000702), Nephrogenic Fibrosing Dermopathy (EFO_1001814), Neurofibromatosis Type 1 (MONDO_0018975), Sickle Cell Anemia (MONDO_0011382), Mesothelioma (EFO_0000588), Lymphoblastic Lymphoma (MONDO_0000873), Plexiform Neurofibroma (EFO_0000658), Thyroid Cancer (MONDO_0002108), Pulmonary Venoocclusive Disease (MONDO_0009937), Peritoneum Cancer (MONDO_0002087), Malignant Peripheral Nerve Sheath Tumor (EFO_0000760), Malignant Epithelial Tumor Of Ovary (MONDO_0018364), Skin Neoplasm (EFO_0004198), Carcinoma (EFO_0000313), Cutaneous Melanoma (EFO_0000389), Systemic Scleroderma (EFO_0000717), T-Lymphoblastic Lymphoma (MONDO_0044917), Chondrosarcoma (EFO_0000333), Localised Scleroderma (EFO_1001361), Rectum Cancer (EFO_1000657), Head And Neck Malignant Neoplasia (EFO_0006859), Chronic Myeloproliferative Disorder (EFO_0002428), Fallopian Tube Cancer (MONDO_0002158), Lung Cancer (MONDO_0008903), Neoplasm (EFO_0000616), Glioblastoma Multiforme (EFO_0000519), Lymphoid Leukemia (EFO_0004289), T-Cell Acute Lymphoblastic Leukemia (EFO_0000209), Non-Small Cell Lung Carcinoma (EFO_0003060), Leukemia (EFO_0000565), Uterine Carcinosarcoma (EFO_1000613), Kidney Cancer (MONDO_0002367), Sarcoma (EFO_0000691), Melanoma (EFO_0000756), Synovial Sarcoma (EFO_0001376), Type 1 Diabetes Mellitus (MONDO_0005147), Desmoid-Type Fibromatosis (EFO_0009907)', 'newLinkedTargets_string': 'ABL1 (ENSG00000097007), PDGFRB (ENSG00000113721), KIT (ENSG00000157404), BCR (ENSG00000186716)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2001, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_3271', 'tradeNames_string': 'Gleevec, Glivec, Imatinib mesylate', 'drugName': 'Imatinib Mesylate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Platelet-derived growth factor receptor beta inhibitor', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Non-Hodgkins Lymphoma (EFO_0005952), Pulmonary Hypertension (MONDO_0005149), Primary Myelofibrosis (EFO_0002430), Uterine Cancer (MONDO_0002715), Multiple Sclerosis (MONDO_0005301), Graft Versus Host Disease (MONDO_0013730), Pulmonary Arterial Hypertension (EFO_0001361), Wet Macular Degeneration (EFO_0004683), Merkel Cell Skin Cancer (EFO_1001471), Gastrointestinal Stromal Tumor (MONDO_0011719), Idiopathic Pulmonary Fibrosis (EFO_0000768), Colorectal Carcinoma (EFO_1001951), Polycythemia Vera (EFO_0002429), Chronic Myelogenous Leukemia (EFO_0000339), Scleroderma (EFO_1001993), Prostate Adenocarcinoma (EFO_0000673), Malignant Colon Neoplasm (MONDO_0021063), Endometrial Cancer (MONDO_0011962), Gliosarcoma (EFO_1001465), Ovarian Cancer (MONDO_0008170), Gastric Cancer (MONDO_0001056), Prostate Cancer (MONDO_0008315), Breast Cancer (MONDO_0007254), Gastric Adenocarcinoma (EFO_0000503), Lymphangioleiomyomatosis (MONDO_0011705), B-Cell Acute Lymphoblastic Leukemia (EFO_0000094), Acute Lymphoblastic Leukemia (EFO_0000220), Male Breast Carcinoma (EFO_0006861), Childhood Acute Lymphoblastic Leukemia (MONDO_0000870), Lymphoma (EFO_0000574), Hypereosinophilic Syndrome (EFO_1001467), Acute Myeloid Leukemia (EFO_0000222), Dermatofibrosarcoma Protuberans (MONDO_0011934), Central Nervous System Neoplasm (EFO_1000158), Loiasis (EFO_1000729), Eosinophilia (HP_0001880), Asthma (MONDO_0004979), Pancreatic Carcinoma (EFO_0002618), Small Cell Lung Carcinoma (EFO_0000702), Nephrogenic Fibrosing Dermopathy (EFO_1001814), Neurofibromatosis Type 1 (MONDO_0018975), Sickle Cell Anemia (MONDO_0011382), Mesothelioma (EFO_0000588), Lymphoblastic Lymphoma (MONDO_0000873), Plexiform Neurofibroma (EFO_0000658), Thyroid Cancer (MONDO_0002108), Pulmonary Venoocclusive Disease (MONDO_0009937), Peritoneum Cancer (MONDO_0002087), Malignant Peripheral Nerve Sheath Tumor (EFO_0000760), Malignant Epithelial Tumor Of Ovary (MONDO_0018364), Skin Neoplasm (EFO_0004198), Carcinoma (EFO_0000313), Cutaneous Melanoma (EFO_0000389), Systemic Scleroderma (EFO_0000717), T-Lymphoblastic Lymphoma (MONDO_0044917), Chondrosarcoma (EFO_0000333), Localised Scleroderma (EFO_1001361), Rectum Cancer (EFO_1000657), Head And Neck Malignant Neoplasia (EFO_0006859), Chronic Myeloproliferative Disorder (EFO_0002428), Fallopian Tube Cancer (MONDO_0002158), Lung Cancer (MONDO_0008903), Neoplasm (EFO_0000616), Glioblastoma Multiforme (EFO_0000519), Lymphoid Leukemia (EFO_0004289), T-Cell Acute Lymphoblastic Leukemia (EFO_0000209), Non-Small Cell Lung Carcinoma (EFO_0003060), Leukemia (EFO_0000565), Uterine Carcinosarcoma (EFO_1000613), Kidney Cancer (MONDO_0002367), Sarcoma (EFO_0000691), Melanoma (EFO_0000756), Synovial Sarcoma (EFO_0001376), Type 1 Diabetes Mellitus (MONDO_0005147), Desmoid-Type Fibromatosis (EFO_0009907)', 'newLinkedTargets_string': 'ABL1 (ENSG00000097007), PDGFRB (ENSG00000113721), KIT (ENSG00000157404), BCR (ENSG00000186716)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2001, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_3272', 'tradeNames_string': 'Gleevec, Glivec, Imatinib mesylate', 'drugName': 'Imatinib Mesylate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Stem cell growth factor receptor inhibitor', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Non-Hodgkins Lymphoma (EFO_0005952), Pulmonary Hypertension (MONDO_0005149), Primary Myelofibrosis (EFO_0002430), Uterine Cancer (MONDO_0002715), Multiple Sclerosis (MONDO_0005301), Graft Versus Host Disease (MONDO_0013730), Pulmonary Arterial Hypertension (EFO_0001361), Wet Macular Degeneration (EFO_0004683), Merkel Cell Skin Cancer (EFO_1001471), Gastrointestinal Stromal Tumor (MONDO_0011719), Idiopathic Pulmonary Fibrosis (EFO_0000768), Colorectal Carcinoma (EFO_1001951), Polycythemia Vera (EFO_0002429), Chronic Myelogenous Leukemia (EFO_0000339), Scleroderma (EFO_1001993), Prostate Adenocarcinoma (EFO_0000673), Malignant Colon Neoplasm (MONDO_0021063), Endometrial Cancer (MONDO_0011962), Gliosarcoma (EFO_1001465), Ovarian Cancer (MONDO_0008170), Gastric Cancer (MONDO_0001056), Prostate Cancer (MONDO_0008315), Breast Cancer (MONDO_0007254), Gastric Adenocarcinoma (EFO_0000503), Lymphangioleiomyomatosis (MONDO_0011705), B-Cell Acute Lymphoblastic Leukemia (EFO_0000094), Acute Lymphoblastic Leukemia (EFO_0000220), Male Breast Carcinoma (EFO_0006861), Childhood Acute Lymphoblastic Leukemia (MONDO_0000870), Lymphoma (EFO_0000574), Hypereosinophilic Syndrome (EFO_1001467), Acute Myeloid Leukemia (EFO_0000222), Dermatofibrosarcoma Protuberans (MONDO_0011934), Central Nervous System Neoplasm (EFO_1000158), Loiasis (EFO_1000729), Eosinophilia (HP_0001880), Asthma (MONDO_0004979), Pancreatic Carcinoma (EFO_0002618), Small Cell Lung Carcinoma (EFO_0000702), Nephrogenic Fibrosing Dermopathy (EFO_1001814), Neurofibromatosis Type 1 (MONDO_0018975), Sickle Cell Anemia (MONDO_0011382), Mesothelioma (EFO_0000588), Lymphoblastic Lymphoma (MONDO_0000873), Plexiform Neurofibroma (EFO_0000658), Thyroid Cancer (MONDO_0002108), Pulmonary Venoocclusive Disease (MONDO_0009937), Peritoneum Cancer (MONDO_0002087), Malignant Peripheral Nerve Sheath Tumor (EFO_0000760), Malignant Epithelial Tumor Of Ovary (MONDO_0018364), Skin Neoplasm (EFO_0004198), Carcinoma (EFO_0000313), Cutaneous Melanoma (EFO_0000389), Systemic Scleroderma (EFO_0000717), T-Lymphoblastic Lymphoma (MONDO_0044917), Chondrosarcoma (EFO_0000333), Localised Scleroderma (EFO_1001361), Rectum Cancer (EFO_1000657), Head And Neck Malignant Neoplasia (EFO_0006859), Chronic Myeloproliferative Disorder (EFO_0002428), Fallopian Tube Cancer (MONDO_0002158), Lung Cancer (MONDO_0008903), Neoplasm (EFO_0000616), Glioblastoma Multiforme (EFO_0000519), Lymphoid Leukemia (EFO_0004289), T-Cell Acute Lymphoblastic Leukemia (EFO_0000209), Non-Small Cell Lung Carcinoma (EFO_0003060), Leukemia (EFO_0000565), Uterine Carcinosarcoma (EFO_1000613), Kidney Cancer (MONDO_0002367), Sarcoma (EFO_0000691), Melanoma (EFO_0000756), Synovial Sarcoma (EFO_0001376), Type 1 Diabetes Mellitus (MONDO_0005147), Desmoid-Type Fibromatosis (EFO_0009907)', 'newLinkedTargets_string': 'ABL1 (ENSG00000097007), PDGFRB (ENSG00000113721), KIT (ENSG00000157404), BCR (ENSG00000186716)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2001, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.657 | Q22 | What is Qdolo? | Qdolo, also known generically as Tramadol Hydrochloride, was approved by the FDA in 1995 to treat Chronic pain, pain, and drug dependence. It is a small molecule therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%qdolo%" OR LOWER(tradeNames_string) LIKE "%qdolo%" OR LOWER(drugSynonyms_string) LIKE "%qdolo%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3268', 'tradeNames_string': 'Aceon, Conzip, Dromadol sr, Dromadol xl, Invodol sr, Larapam sr, Mabron, Maneo, Marol, Maxitram sr, Nobligan ret, Oldaram, Qdolo, Rybix odt, Ryzolt, Tilodol sr, Tradorec xl, Tramacet, Tramadol hydrochloride, Tramake, Tramake insts, Tramquel sr, Tramulief sr, Ultram, Ultram er, Zamadol, Zamadol 24hr, Zamadol melt, Zamadol sr, Zeridame sr, Zydol, Zydol sr, Zydol xl', 'drugName': 'Tramadol Hydrochloride', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Mu opioid receptor agonist', 'linkedDiseasesDrug_string': 'Toothache (EFO_0010072), Cancer (MONDO_0004992), Drug Dependence (EFO_0003890), Pain (EFO_0003843), Chronic Pain (HP_0012532), Low Back Pain (HP_0003419)', 'newLinkedTargets_string': 'OPRM1 (ENSG00000112038)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1995, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.13 | Q22 | What is Ventolin Hfa? | Ventolin Hfa, also known generically as Albuterol, was approved by the FDA in 1981 to treat Airway obstruction, Bronchospasm, chronic obstructive pulmonary disease, and asthma. It is a small molecule therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%ventolin hfa%" OR LOWER(tradeNames_string) LIKE "%ventolin hfa%" OR LOWER(drugSynonyms_string) LIKE "%ventolin hfa%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1434', 'tradeNames_string': 'Aerolin, Aerolin 400, Aerolin auto, Airomir, Airsalb, Albuterol, Asmasal clickhaler, Asmasal spacehaler, Asmaven, Asmavent, Cobutolin, Combivent, Combivent udvs, Ipramol steri-neb, Kentamol, Libetist, Maxivent, Proair Hfa, Proventil, Proventil Hfa, Rimasal, Salamol e-breathe, Salapin, Salbulin novolizer, Salbuvent, Salipraneb, Steri-neb salamol, Ventmax sr, Ventodisks, Ventolin, Ventolin Hfa, Ventolin cr, Ventolin e-breathe, Volmax', 'drugName': 'Albuterol', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Beta-2 adrenergic receptor agonist', 'linkedDiseasesDrug_string': 'Diabetes Mellitus (EFO_0000400), Status Asthmaticus (EFO_0008590), Pulmonary Hypertension (MONDO_0005149), Cough (HP_0012735), Pulmonary Arterial Hypertension (EFO_0001361), Idiopathic Pulmonary Fibrosis (EFO_0000768), Lung Disease (EFO_0003818), Spinal Cord Injury (EFO_1001919), Bronchiolitis (HP_0011950), Idiopathic Pulmonary Arterial Hypertension (MONDO_0017147), Bronchospasm (HP_0025428), Congestive Heart Failure (EFO_0000373), Lymphangioleiomyomatosis (MONDO_0011705), Seasonal Allergic Rhinitis (EFO_0003956), Cardiovascular Disease (EFO_0000319), Adult Acute Respiratory Distress Syndrome (MONDO_0100130), Pulmonary Edema (EFO_1001134), Organophosphate Poisoning (EFO_0010581), Familial Dysautonomia (Orphanet_1764), Asthma (MONDO_0004979), Memory Impairment (EFO_0001072), Tachypnea (EFO_0009840), Chronic Obstructive Pulmonary Disease (EFO_0000341), Primary Ciliary Dyskinesia (MONDO_0016575), Airway Obstruction (HP_0006536), Glycogen Storage Disease Due To Acid Maltase Deficiency (Orphanet_365), Allergic Disease (MONDO_0005271), Congenital Myasthenic Syndromes (Orphanet_590), Respiratory Failure (EFO_0009686), Major Depressive Disorder (MONDO_0002009)', 'newLinkedTargets_string': 'ADRB2 (ENSG00000169252)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1981, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_6278', 'tradeNames_string': 'Accuneb, Albuterol sulfate, Proair, Proair digihaler, Proair hfa, Proair respiclick, Proventil, Proventil-hfa, Ventolin, Ventolin hfa, Ventolin rotacaps, Volmax, Vospire er', 'drugName': 'Albuterol Sulfate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Beta-2 adrenergic receptor agonist', 'linkedDiseasesDrug_string': 'Status Asthmaticus (EFO_0008590), Bronchospasm (HP_0025428), Asthma (MONDO_0004979), Chronic Obstructive Pulmonary Disease (EFO_0000341), Cardiovascular Disease (EFO_0000319), Adult Acute Respiratory Distress Syndrome (MONDO_0100130), Lung Disease (EFO_0003818)', 'newLinkedTargets_string': 'ADRB2 (ENSG00000169252)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1982, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.309 | Q22 | What is Dilaudid-Hp? | Dilaudid-Hp, also known generically as Hydromorphone Hydrochloride, was approved by the FDA in 1984 to treat pain and drug dependence. It is a small molecule therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%dilaudid-hp%" OR LOWER(tradeNames_string) LIKE "%dilaudid-hp%" OR LOWER(drugSynonyms_string) LIKE "%dilaudid-hp%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3034', 'tradeNames_string': '', 'drugName': 'Hydromorphone', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Mu opioid receptor agonist', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Opioid Use Disorder (EFO_0010702), Drug Dependence (EFO_0003890), Osteoarthritis, Hip (EFO_1000786), Liver Disease (EFO_0001421), Pain (EFO_0003843), Chronic Pain (HP_0012532), Sickle Cell Anemia (MONDO_0011382), Osteoarthritis, Knee (EFO_0004616), Back Pain (HP_0003418), Heroin Dependence (EFO_0004240), Constipation (HP_0002019), Mucositis (EFO_1001898), Low Back Pain (HP_0003419), Injury (EFO_0000546), Ileus (MONDO_0004567), Opioid Dependence (EFO_0005611)', 'newLinkedTargets_string': 'OPRM1 (ENSG00000112038)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1984, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_4427', 'tradeNames_string': 'Dilaudid, Dilaudid-hp, Exalgo, Hydromorphone hydrochloride, Palladone, Palladone-sr', 'drugName': 'Hydromorphone Hydrochloride', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Mu opioid receptor agonist', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Drug Dependence (EFO_0003890), Osteoarthritis, Hip (EFO_1000786), Liver Disease (EFO_0001421), Pain (EFO_0003843), Chronic Pain (HP_0012532), Osteoarthritis, Knee (EFO_0004616), Back Pain (HP_0003418)', 'newLinkedTargets_string': 'OPRM1 (ENSG00000112038)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1984, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.26 | Q22 | What is Vijoice? | Vijoice, also known generically as Alpelisib, was approved by the FDA in 2019 to treat breast carcinoma, cancer, neoplasm, breast neoplasm, and breast cancer. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%vijoice%" OR LOWER(tradeNames_string) LIKE "%vijoice%" OR LOWER(drugSynonyms_string) LIKE "%vijoice%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_722', 'tradeNames_string': 'Piqray, Vijoice', 'drugName': 'Alpelisib', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'PI3-kinase p110-alpha subunit inhibitor', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Multiple Myeloma (EFO_0001378), Liver Disease (EFO_0001421), Upper Aerodigestive Tract Neoplasm (EFO_0004284), Gastrointestinal Stromal Tumor (MONDO_0011719), Endometrial Cancer (MONDO_0011962), Colorectal Carcinoma (EFO_1001951), Gastric Cancer (MONDO_0001056), Ovarian Cancer (MONDO_0008170), Breast Carcinoma (EFO_0000305), Breast Neoplasm (EFO_0003869), Breast Cancer (MONDO_0007254), Head And Neck Squamous Cell Carcinoma (EFO_0000181), Pancreatic Carcinoma (EFO_0002618), Oropharynx Cancer (EFO_1001931), Oropharynx Squamous Cell Carcinoma (MONDO_0044704), Rectum Cancer (EFO_1000657), Squamous Cell Carcinoma (EFO_0000707), Esophageal Squamous Cell Carcinoma (EFO_0005922), Neoplasm (EFO_0000616), Meningioma (MONDO_0016642)', 'newLinkedTargets_string': 'PIK3CA (ENSG00000121879)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2019, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.525 | Q22 | What is Wakix? | Wakix, also known generically as Pitolisant Hydrochloride, was approved by the FDA in 2019 to treat hypersomnia and narcolepsy-cataplexy syndrome. It is a small molecule therapy that acts as a(n) inverse agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%wakix%" OR LOWER(tradeNames_string) LIKE "%wakix%" OR LOWER(drugSynonyms_string) LIKE "%wakix%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1748', 'tradeNames_string': 'Wakix, Wakix, europe', 'drugName': 'Pitolisant', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inverse agonist', 'drugMechanismOfAction': 'Histamine H3 receptor inverse agonist', 'linkedDiseasesDrug_string': 'Idiopathic Hypersomnia (MONDO_0018044), Drug Dependence (EFO_0003890), Hypersomnia (EFO_0005246), Narcolepsy (MONDO_0021107), Kidney Disease (EFO_0003086), Narcolepsy-Cataplexy Syndrome (MONDO_0016158), Parkinson Disease (MONDO_0005180), Prader-Willi Syndrome (MONDO_0008300), Schizophrenia (MONDO_0005090), Alcohol Dependence (MONDO_0007079)', 'newLinkedTargets_string': 'HRH3 (ENSG00000101180)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2019, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_1676', 'tradeNames_string': 'Wakix', 'drugName': 'Pitolisant Hydrochloride', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inverse agonist', 'drugMechanismOfAction': 'Histamine H3 receptor inverse agonist', 'linkedDiseasesDrug_string': 'Narcolepsy-Cataplexy Syndrome (MONDO_0016158), Hypersomnia (EFO_0005246)', 'newLinkedTargets_string': 'HRH3 (ENSG00000101180)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2019, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.172 | Q22 | What is Quviviq? | Quviviq, also known generically as Daridorexant Hydrochloride, was approved by the FDA in 2022 to treat insomnia. It is a small molecule therapy that acts as a(n) antagonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%quviviq%" OR LOWER(tradeNames_string) LIKE "%quviviq%" OR LOWER(drugSynonyms_string) LIKE "%quviviq%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5696', 'tradeNames_string': 'Quviviq', 'drugName': 'Daridorexant Hydrochloride', 'drugMolecularType': 'Small molecule', 'drugActionType': 'antagonist', 'drugMechanismOfAction': 'Orexin receptor 2 antagonist', 'linkedDiseasesDrug_string': 'Insomnia (EFO_0004698)', 'newLinkedTargets_string': 'HCRTR2 (ENSG00000137252), HCRTR1 (ENSG00000121764)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2022, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_5697', 'tradeNames_string': 'Quviviq', 'drugName': 'Daridorexant Hydrochloride', 'drugMolecularType': 'Small molecule', 'drugActionType': 'antagonist', 'drugMechanismOfAction': 'Orexin receptor 1 antagonist', 'linkedDiseasesDrug_string': 'Insomnia (EFO_0004698)', 'newLinkedTargets_string': 'HCRTR2 (ENSG00000137252), HCRTR1 (ENSG00000121764)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2022, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.486 | Q22 | What is Oxycontin? | Oxycontin, also known generically as Oxycodone, was approved by the FDA in 1950 to treat Chronic pain, pain, drug dependence, and substance abuse. It is a small molecule therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%oxycontin%" OR LOWER(tradeNames_string) LIKE "%oxycontin%" OR LOWER(drugSynonyms_string) LIKE "%oxycontin%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_6046', 'tradeNames_string': 'Oxycontin, Proladone, Xtampza er', 'drugName': 'Oxycodone', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Mu opioid receptor agonist', 'linkedDiseasesDrug_string': 'Toothache (EFO_0010072), Cancer (MONDO_0004992), Genital Neoplasm, Female (EFO_1001331), Substance Abuse (MONDO_0002491), Pain (EFO_0003843), Injury (EFO_0000546), Colorectal Carcinoma (EFO_1001951), Nephrolithiasis (EFO_0004253), Spinal Cord Injury (EFO_1001919), Hypospadias (EFO_0004209), Preeclampsia (EFO_0000668), Intervertebral Disc Degeneration (HP_0008419), Osteoarthritis, Knee (EFO_0004616), Parkinson Disease (MONDO_0005180), Neuropathic Pain (EFO_0005762), Respiratory Depression (EFO_0009842), Pruritus (HP_0000989), Restless Legs Syndrome (EFO_0004270), Sinusitis (EFO_0007486), Nutritional Disorder (EFO_0001069), Neck Pain (HP_0030833), Drug Dependence (EFO_0003890), Diabetic Polyneuropathy (MONDO_0001583), Osteoarthritis, Hip (EFO_1000786), Back Pain (HP_0003418), Joint Disease (EFO_1000999), Opioid Dependence (EFO_0005611), Head And Neck Malignant Neoplasia (EFO_0006859), Opioid Use Disorder (EFO_0010702), Osteoarthritis (MONDO_0005178), Chronic Pain (HP_0012532), Low Back Pain (HP_0003419)', 'newLinkedTargets_string': 'OPRM1 (ENSG00000112038)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1950, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_4049', 'tradeNames_string': 'Abtard, Candox, Carexil, Dolocodon pr, Leveraxo, Longtec, Lynlor, Oxaydo, Oxecta, Oxeltra, Oxycodone hydrochloride, Oxycontin, Oxylan, Oxynorm, Reltebon, Roxicodone, Roxybond, Shortec, Zomestine', 'drugName': 'Oxycodone Hydrochloride', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Mu opioid receptor agonist', 'linkedDiseasesDrug_string': 'Osteoarthritis, Hip (EFO_1000786), Pain (EFO_0003843), Chronic Pain (HP_0012532), Osteoarthritis, Knee (EFO_0004616), Low Back Pain (HP_0003419)', 'newLinkedTargets_string': 'OPRM1 (ENSG00000112038)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1950, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.417 | Q22 | What is Quillichew Er? | Quillichew Er, also known generically as Methylphenidate Hydrochloride, was approved by the FDA in 1955 to treat attention deficit hyperactivity disorder. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%quillichew er%" OR LOWER(tradeNames_string) LIKE "%quillichew er%" OR LOWER(drugSynonyms_string) LIKE "%quillichew er%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_845', 'tradeNames_string': 'Adhansia xr, Aptensio xr, Concerta, Delmosart, Equasym, Equasym xl, Jornay pm, Matoride xl, Medikinet, Medikinet xl, Metadate cd, Metadate er, Methylin, Methylin er, Methylphenidate hydrochloride, Quillichew er, Quillivant xr, Relexxii, Ritalin, Ritalin la, Ritalin sr, Ritalin-sr, Tranquilyn, Xenidate xl', 'drugName': 'Methylphenidate Hydrochloride', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Norepinephrine transporter inhibitor', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Sleep Disorder (EFO_0008568), Conduct Disorder (EFO_0004216), Nicotine Dependence (EFO_0003768), Chronic Progressive Multiple Sclerosis (EFO_0003840), Attention Deficit Hyperactivity Disorder (EFO_0003888), Relapsing-Remitting Multiple Sclerosis (EFO_0003929), Fatigue (HP_0012378), Depressive Disorder (MONDO_0002050), Schizophrenia (MONDO_0005090), Childhood Apraxia Of Speech (MONDO_0011184)', 'newLinkedTargets_string': 'SLC6A3 (ENSG00000142319), SLC6A2 (ENSG00000103546)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1955, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_846', 'tradeNames_string': 'Adhansia xr, Aptensio xr, Concerta, Delmosart, Equasym, Equasym xl, Jornay pm, Matoride xl, Medikinet, Medikinet xl, Metadate cd, Metadate er, Methylin, Methylin er, Methylphenidate hydrochloride, Quillichew er, Quillivant xr, Relexxii, Ritalin, Ritalin la, Ritalin sr, Ritalin-sr, Tranquilyn, Xenidate xl', 'drugName': 'Methylphenidate Hydrochloride', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Dopamine transporter inhibitor', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Sleep Disorder (EFO_0008568), Conduct Disorder (EFO_0004216), Nicotine Dependence (EFO_0003768), Chronic Progressive Multiple Sclerosis (EFO_0003840), Attention Deficit Hyperactivity Disorder (EFO_0003888), Relapsing-Remitting Multiple Sclerosis (EFO_0003929), Fatigue (HP_0012378), Depressive Disorder (MONDO_0002050), Schizophrenia (MONDO_0005090), Childhood Apraxia Of Speech (MONDO_0011184)', 'newLinkedTargets_string': 'SLC6A3 (ENSG00000142319), SLC6A2 (ENSG00000103546)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1955, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.249 | Q22 | What is Inrebic? | Inrebic, also known generically as Fedratinib Hydrochloride, was approved by the FDA in 2019 to treat Myelofibrosis and primary myelofibrosis. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%inrebic%" OR LOWER(tradeNames_string) LIKE "%inrebic%" OR LOWER(drugSynonyms_string) LIKE "%inrebic%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4654', 'tradeNames_string': 'Inrebic', 'drugName': 'Fedratinib Hydrochloride', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Tyrosine-protein kinase JAK2 inhibitor', 'linkedDiseasesDrug_string': 'Myelofibrosis (HP_0011974), Primary Myelofibrosis (EFO_0002430)', 'newLinkedTargets_string': 'JAK2 (ENSG00000096968), FLT3 (ENSG00000122025)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2019, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_4655', 'tradeNames_string': 'Inrebic', 'drugName': 'Fedratinib Hydrochloride', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Tyrosine-protein kinase receptor FLT3 inhibitor', 'linkedDiseasesDrug_string': 'Myelofibrosis (HP_0011974), Primary Myelofibrosis (EFO_0002430)', 'newLinkedTargets_string': 'JAK2 (ENSG00000096968), FLT3 (ENSG00000122025)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2019, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.302 | Q22 | What is Ultravate? | Ultravate, also known generically as Halobetasol Propionate, was approved by the FDA in 1990 to treat psoriasis, skin disease, and psoriasis vulgaris. It is a small molecule therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%ultravate%" OR LOWER(tradeNames_string) LIKE "%ultravate%" OR LOWER(drugSynonyms_string) LIKE "%ultravate%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1442', 'tradeNames_string': 'Bryhali, Halobetasol propionate, Lexette, Ultravate', 'drugName': 'Halobetasol Propionate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Glucocorticoid receptor agonist', 'linkedDiseasesDrug_string': 'Psoriasis (EFO_0000676), Skin Disease (EFO_0000701), Atopic Eczema (EFO_0000274), Psoriasis Vulgaris (EFO_1001494)', 'newLinkedTargets_string': 'NR3C1 (ENSG00000113580)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1990, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.440 | Q22 | What is Symproic? | Symproic, also known generically as Naldemedine Tosylate, was approved by the FDA in 2017 to treat Constipation, pain, and constipation disorder. It is a small molecule therapy that acts as a(n) antagonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%symproic%" OR LOWER(tradeNames_string) LIKE "%symproic%" OR LOWER(drugSynonyms_string) LIKE "%symproic%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1003', 'tradeNames_string': 'Symproic', 'drugName': 'Naldemedine Tosylate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'antagonist', 'drugMechanismOfAction': 'Mu opioid receptor antagonist', 'linkedDiseasesDrug_string': 'Constipation (HP_0002019), Constipation Disorder (MONDO_0002203), Pain (EFO_0003843)', 'newLinkedTargets_string': 'OPRM1 (ENSG00000112038)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2017, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.276 | Q22 | What is Emend? | Emend, also known generically as Fosaprepitant Dimeglumine, was approved by the FDA in 2008 to treat Nausea and vomiting, cancer, post operative nausea and vomiting, and Chemotherapy-induced nausea and vomiting. It is a small molecule therapy that acts as a(n) antagonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%emend%" OR LOWER(tradeNames_string) LIKE "%emend%" OR LOWER(drugSynonyms_string) LIKE "%emend%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1299', 'tradeNames_string': 'Aprepitant, Cinvanti, Emend', 'drugName': 'Aprepitant', 'drugMolecularType': 'Small molecule', 'drugActionType': 'antagonist', 'drugMechanismOfAction': 'Neurokinin 1 receptor antagonist', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Multiple Myeloma (EFO_0001378), Nausea (HP_0002018), Chemotherapy-Induced Nausea And Vomiting (EFO_0006911), Pain (EFO_0003843), Covid-19 (MONDO_0100096), Cannabis Dependence (EFO_0007191), Post Operative Nausea And Vomiting (EFO_0004888), Gastroparesis (EFO_1000948), Acute Myeloid Leukemia (EFO_0000222), Cocaine Dependence (EFO_0002610), Pruritus (HP_0000989), Heroin Dependence (EFO_0004240), Alcohol Dependence (MONDO_0007079), Opioid Dependence (EFO_0005611), Hiv Infection (EFO_0000764), Nausea And Vomiting (HP_0002017), Non-Small Cell Lung Carcinoma (EFO_0003060), Major Depressive Disorder (MONDO_0002009), Vomiting (HP_0002013), Glioblastoma Multiforme (EFO_0000519), Germ Cell Tumor (EFO_0000514)', 'newLinkedTargets_string': 'TACR1 (ENSG00000115353)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2003, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_5495', 'tradeNames_string': 'Emend, Fosaprepitant dimeglumine', 'drugName': 'Fosaprepitant Dimeglumine', 'drugMolecularType': 'Small molecule', 'drugActionType': 'antagonist', 'drugMechanismOfAction': 'Neurokinin 1 receptor antagonist', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Chemotherapy-Induced Nausea And Vomiting (EFO_0006911), Nausea And Vomiting (HP_0002017), Sarcoma (EFO_0000691), Post Operative Nausea And Vomiting (EFO_0004888)', 'newLinkedTargets_string': 'TACR1 (ENSG00000115353)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2008, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_542', 'tradeNames_string': 'Ivemend', 'drugName': 'Fosaprepitant', 'drugMolecularType': 'Small molecule', 'drugActionType': 'antagonist', 'drugMechanismOfAction': 'Neurokinin 1 receptor antagonist', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Multiple Myeloma (EFO_0001378), Chemotherapy-Induced Nausea And Vomiting (EFO_0006911), Neoplasm (EFO_0000616), Nausea And Vomiting (HP_0002017), Nasopharyngeal Neoplasm (EFO_0004252), Sarcoma (EFO_0000691), Female Reproductive System Neoplasm (MONDO_0021148), Post Operative Nausea And Vomiting (EFO_0004888), Brain Injury (MONDO_0043510)', 'newLinkedTargets_string': 'TACR1 (ENSG00000115353)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2008, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.157 | Q22 | What is Aliqopa? | Aliqopa, also known generically as Copanlisib Hydrochloride, was approved by the FDA in 2017 to treat neoplasm of mature B-cells and follicular lymphoma. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%aliqopa%" OR LOWER(tradeNames_string) LIKE "%aliqopa%" OR LOWER(drugSynonyms_string) LIKE "%aliqopa%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1213', 'tradeNames_string': 'Aliqopa', 'drugName': 'Copanlisib Hydrochloride', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'PI3-kinase p110-delta subunit inhibitor', 'linkedDiseasesDrug_string': 'Multiple Myeloma (EFO_0001378), Follicular Lymphoma (MONDO_0018906), Mantle Cell Lymphoma (EFO_1001469), Neoplasm (EFO_0000616), Neoplasm Of Mature B-Cells (EFO_0000096), Mycosis Fungoides (EFO_1001051), Diffuse Large B-Cell Lymphoma (EFO_0000403), Hodgkins Lymphoma (EFO_0000183), Breast Carcinoma (EFO_0000305)', 'newLinkedTargets_string': 'PIK3CA (ENSG00000121879), PIK3CD (ENSG00000171608)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2017, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_1214', 'tradeNames_string': 'Aliqopa', 'drugName': 'Copanlisib Hydrochloride', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'PI3-kinase p110-alpha subunit inhibitor', 'linkedDiseasesDrug_string': 'Multiple Myeloma (EFO_0001378), Follicular Lymphoma (MONDO_0018906), Mantle Cell Lymphoma (EFO_1001469), Neoplasm (EFO_0000616), Neoplasm Of Mature B-Cells (EFO_0000096), Mycosis Fungoides (EFO_1001051), Diffuse Large B-Cell Lymphoma (EFO_0000403), Hodgkins Lymphoma (EFO_0000183), Breast Carcinoma (EFO_0000305)', 'newLinkedTargets_string': 'PIK3CA (ENSG00000121879), PIK3CD (ENSG00000171608)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2017, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.129 | Q22 | What is Coreg Cr? | Coreg Cr, also known generically as Carvedilol Phosphate, was approved by the FDA in 2006 to treat hypertension and myocardial infarction. It is a small molecule therapy that acts as a(n) antagonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%coreg cr%" OR LOWER(tradeNames_string) LIKE "%coreg cr%" OR LOWER(drugSynonyms_string) LIKE "%coreg cr%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3793', 'tradeNames_string': 'Carvedilol, Coreg, Coreg CR, Eucardic 12.5, Eucardic 25, Eucardic 3.125, Eucardic 6.25', 'drugName': 'Carvedilol', 'drugMolecularType': 'Small molecule', 'drugActionType': 'antagonist', 'drugMechanismOfAction': 'Adrenergic receptor beta antagonist', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Multiple Myeloma (EFO_0001378), Coronary Artery Disease (EFO_0001645), Pulmonary Hypertension (MONDO_0005149), Pulmonary Arterial Hypertension (EFO_0001361), Essential Hypertension (MONDO_0001134), Hypoglycemia (HP_0001943), Atrial Fibrillation (EFO_0000275), Post-Traumatic Stress Disorder (EFO_0001358), Congestive Heart Failure (EFO_0000373), Prostate Cancer (MONDO_0008315), Breast Cancer (MONDO_0007254), Angina Pectoris (EFO_0003913), Left Ventricular Hypertrophy (EFO_0003896), Hypertension (EFO_0000537), Cardiovascular Disease (EFO_0000319), Lymphoma (EFO_0000574), Acute Myeloid Leukemia (EFO_0000222), Cocaine Dependence (EFO_0002610), Epilepsy (EFO_0000474), Myocardial Infarction (EFO_0000612), Hypercholesterolemia (HP_0003124), Portal Hypertension (EFO_0000666), Esophageal Varices (EFO_0009545), Lymphoid Leukemia (EFO_0004289), Heart Failure (EFO_0003144), Kidney Disease (EFO_0003086), Vascular Disease (EFO_0004264), Glioblastoma Multiforme (EFO_0000519), Type 2 Diabetes Mellitus (MONDO_0005148), Atherosclerosis (EFO_0003914)', 'newLinkedTargets_string': 'ADRB1 (ENSG00000043591), ADRB2 (ENSG00000169252), ADRB3 (ENSG00000188778), ADRA1A (ENSG00000120907), ADRA1D (ENSG00000171873), ADRA1B (ENSG00000170214)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1995, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_3794', 'tradeNames_string': 'Carvedilol, Coreg, Coreg CR, Eucardic 12.5, Eucardic 25, Eucardic 3.125, Eucardic 6.25', 'drugName': 'Carvedilol', 'drugMolecularType': 'Small molecule', 'drugActionType': 'antagonist', 'drugMechanismOfAction': 'Adrenergic receptor alpha-1 antagonist', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Multiple Myeloma (EFO_0001378), Coronary Artery Disease (EFO_0001645), Pulmonary Hypertension (MONDO_0005149), Pulmonary Arterial Hypertension (EFO_0001361), Essential Hypertension (MONDO_0001134), Hypoglycemia (HP_0001943), Atrial Fibrillation (EFO_0000275), Post-Traumatic Stress Disorder (EFO_0001358), Congestive Heart Failure (EFO_0000373), Prostate Cancer (MONDO_0008315), Breast Cancer (MONDO_0007254), Angina Pectoris (EFO_0003913), Left Ventricular Hypertrophy (EFO_0003896), Hypertension (EFO_0000537), Cardiovascular Disease (EFO_0000319), Lymphoma (EFO_0000574), Acute Myeloid Leukemia (EFO_0000222), Cocaine Dependence (EFO_0002610), Epilepsy (EFO_0000474), Myocardial Infarction (EFO_0000612), Hypercholesterolemia (HP_0003124), Portal Hypertension (EFO_0000666), Esophageal Varices (EFO_0009545), Lymphoid Leukemia (EFO_0004289), Heart Failure (EFO_0003144), Kidney Disease (EFO_0003086), Vascular Disease (EFO_0004264), Glioblastoma Multiforme (EFO_0000519), Type 2 Diabetes Mellitus (MONDO_0005148), Atherosclerosis (EFO_0003914)', 'newLinkedTargets_string': 'ADRB1 (ENSG00000043591), ADRB2 (ENSG00000169252), ADRB3 (ENSG00000188778), ADRA1A (ENSG00000120907), ADRA1D (ENSG00000171873), ADRA1B (ENSG00000170214)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1995, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_906', 'tradeNames_string': 'Coreg cr', 'drugName': 'Carvedilol Phosphate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'antagonist', 'drugMechanismOfAction': 'Adrenergic receptor beta antagonist', 'linkedDiseasesDrug_string': 'Congestive Heart Failure (EFO_0000373), Hypertension (EFO_0000537), Myocardial Infarction (EFO_0000612)', 'newLinkedTargets_string': 'ADRB1 (ENSG00000043591), ADRB2 (ENSG00000169252), ADRB3 (ENSG00000188778), ADRA1A (ENSG00000120907), ADRA1D (ENSG00000171873), ADRA1B (ENSG00000170214)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2006, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_907', 'tradeNames_string': 'Coreg cr', 'drugName': 'Carvedilol Phosphate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'antagonist', 'drugMechanismOfAction': 'Adrenergic receptor alpha-1 antagonist', 'linkedDiseasesDrug_string': 'Congestive Heart Failure (EFO_0000373), Hypertension (EFO_0000537), Myocardial Infarction (EFO_0000612)', 'newLinkedTargets_string': 'ADRB1 (ENSG00000043591), ADRB2 (ENSG00000169252), ADRB3 (ENSG00000188778), ADRA1A (ENSG00000120907), ADRA1D (ENSG00000171873), ADRA1B (ENSG00000170214)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2006, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.545 | Q22 | What is Yupelri? | Yupelri, also known generically as Revefenacin, was approved by the FDA in 2018 to treat Airway obstruction and chronic obstructive pulmonary disease. It is a small molecule therapy that acts as a(n) antagonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%yupelri%" OR LOWER(tradeNames_string) LIKE "%yupelri%" OR LOWER(drugSynonyms_string) LIKE "%yupelri%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4223', 'tradeNames_string': 'Yupelri', 'drugName': 'Revefenacin', 'drugMolecularType': 'Small molecule', 'drugActionType': 'antagonist', 'drugMechanismOfAction': 'Muscarinic acetylcholine receptor M3 antagonist', 'linkedDiseasesDrug_string': 'Airway Obstruction (HP_0006536), Liver Disease (EFO_0001421), Kidney Disease (EFO_0003086), Chronic Obstructive Pulmonary Disease (EFO_0000341)', 'newLinkedTargets_string': 'CHRM3 (ENSG00000133019)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2018, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.347 | Q22 | What is Zurampic? | Zurampic, also known generically as Lesinurad, was approved by the FDA in 2015 to treat gout and hyperuricemia. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%zurampic%" OR LOWER(tradeNames_string) LIKE "%zurampic%" OR LOWER(drugSynonyms_string) LIKE "%zurampic%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1001', 'tradeNames_string': 'Zurampic', 'drugName': 'Lesinurad', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Solute carrier family 22 member 12 inhibitor', 'linkedDiseasesDrug_string': 'Gout (EFO_0004274), Hyperuricemia (EFO_0009104)', 'newLinkedTargets_string': 'SLC22A12 (ENSG00000197891)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2015, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.291 | Q22 | What is Lonhala Magnair Kit? | Lonhala Magnair Kit, also known generically as Glycopyrrolate, was approved by the FDA in 1961 to treat Airway obstruction and gastrointestinal disease. It is a small molecule therapy that acts as a(n) antagonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%lonhala magnair kit%" OR LOWER(tradeNames_string) LIKE "%lonhala magnair kit%" OR LOWER(drugSynonyms_string) LIKE "%lonhala magnair kit%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1138', 'tradeNames_string': 'Cuvposa, Dartisla odt, Glycopyrrolate, Glyrx-pf, Lonhala magnair kit, Robinul, Robinul forte, Robinul fte, Seebri, Sialanar', 'drugName': 'Glycopyrrolate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'antagonist', 'drugMechanismOfAction': 'Muscarinic acetylcholine receptor M3 antagonist', 'linkedDiseasesDrug_string': 'Asthma (MONDO_0004979), Burn (EFO_0009516), Drooling (HP_0002307), Chronic Obstructive Pulmonary Disease (EFO_0000341), Kidney Disease (EFO_0003086), Airway Obstruction (HP_0006536), Depressive Disorder (MONDO_0002050), Hyperhidrosis (HP_0000975), Gastrointestinal Disease (EFO_0010282)', 'newLinkedTargets_string': 'CHRM3 (ENSG00000133019), CHRM1 (ENSG00000168539)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1961, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_1139', 'tradeNames_string': 'Cuvposa, Dartisla odt, Glycopyrrolate, Glyrx-pf, Lonhala magnair kit, Robinul, Robinul forte, Robinul fte, Seebri, Sialanar', 'drugName': 'Glycopyrrolate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'antagonist', 'drugMechanismOfAction': 'Muscarinic acetylcholine receptor M1 antagonist', 'linkedDiseasesDrug_string': 'Asthma (MONDO_0004979), Burn (EFO_0009516), Drooling (HP_0002307), Chronic Obstructive Pulmonary Disease (EFO_0000341), Kidney Disease (EFO_0003086), Airway Obstruction (HP_0006536), Depressive Disorder (MONDO_0002050), Hyperhidrosis (HP_0000975), Gastrointestinal Disease (EFO_0010282)', 'newLinkedTargets_string': 'CHRM3 (ENSG00000133019), CHRM1 (ENSG00000168539)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1961, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.116 | Q22 | What is Rayaldee? | Rayaldee, also known generically as Calcifediol, was approved by the FDA in 1980 to treat chronic kidney disease, parathyroid disease, and secondary hyperparathyroidism. It is a small molecule therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%rayaldee%" OR LOWER(tradeNames_string) LIKE "%rayaldee%" OR LOWER(drugSynonyms_string) LIKE "%rayaldee%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_6195', 'tradeNames_string': 'Calderol, Rayaldee', 'drugName': 'Calcifediol', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Vitamin D receptor agonist', 'linkedDiseasesDrug_string': 'Chronic Kidney Disease (EFO_0003884), Secondary Hyperparathyroidism (EFO_1001173), Vitamin D Deficiency (EFO_0003762), Parathyroid Disease (EFO_0005754), Covid-19 (MONDO_0100096), Myocardial Infarction (EFO_0000612), Acute Kidney Injury (HP_0001919), Obstructive Sleep Apnea (EFO_0003918)', 'newLinkedTargets_string': 'VDR (ENSG00000111424)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1980, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.373 | Q22 | What is Zingo? | Zingo, also known generically as Lidocaine Hydrochloride, was approved by the FDA in 1948 to treat Back pain, prostate carcinoma, and pain. It is a small molecule therapy that acts as a(n) blocker. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%zingo%" OR LOWER(tradeNames_string) LIKE "%zingo%" OR LOWER(drugSynonyms_string) LIKE "%zingo%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4126', 'tradeNames_string': 'Akten, Alphacaine hydrochloride, Anestacon, Anodesyn, Bismodyne, Bradosol plus, Calgel, Co-phenylcaine fte, Denela, Dequaspray, Emla, Germoloids, Germoloids complete, Glydo, Hemocane, Iglu, Instillagel, Laryng-o-jet kit, Laryngojet, Laryngotracheal anesthesia kit, Lido hcl, Lidocaine hydrochloride, Lidocaine hydrochloride preservative free, Lidocaine hydrochloride viscous, Lidocaine viscous, Lidocaton, Lidopen, Lignokent, Lignospan special, Lignostab, Lignostab a 100, Lignostab n, Lignostab-a, Lta ii kit, Medijel, Oragard, Pediatric lta kit, Preparation h, Rexocaine, Versatis, Xylocaine, Xylocaine dental, Xylocaine preservative free, Xylocaine viscous, Xylotox e80, Zingo', 'drugName': 'Lidocaine Hydrochloride', 'drugMolecularType': 'Small molecule', 'drugActionType': 'blocker', 'drugMechanismOfAction': 'Sodium channel alpha subunit blocker', 'linkedDiseasesDrug_string': 'Diabetes Mellitus (EFO_0000400), Cancer (MONDO_0004992), Migraine Disorder (MONDO_0005277), Pain (EFO_0003843), Injury (EFO_0000546), Pregnancy (EFO_0002950), Prostate Carcinoma (EFO_0001663), Headache (HP_0002315), Rotator Cuff Tear (EFO_1001250), Thalassemia (EFO_1001996), Hypertension (EFO_0000537), Pruritus (HP_0000989), Pancreatic Carcinoma (EFO_0002618), Hemorrhoid (EFO_0009552), Spinal Stenosis (EFO_0007490), Back Pain (HP_0003418), Liver Cancer (MONDO_0002691), Chronic Pain (HP_0012532), Mucositis (EFO_1001898)', 'newLinkedTargets_string': 'SCN1A (ENSG00000144285), SCN5A (ENSG00000183873), SCN4A (ENSG00000007314), SCN7A (ENSG00000136546), SCN2A (ENSG00000136531), SCN9A (ENSG00000169432), SCN3A (ENSG00000153253), SCN11A (ENSG00000168356), SCN8A (ENSG00000196876), SCN10A (ENSG00000185313)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1948, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.176 | Q22 | What is Zegalogue (Autoinjector)? | Zegalogue (Autoinjector), also known generically as Dasiglucagon Hydrochloride, was approved by the FDA in 2021 to treat Hypoglycemia and type 1 diabetes mellitus. It is a unknown therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%zegalogue (autoinjector)%" OR LOWER(tradeNames_string) LIKE "%zegalogue (autoinjector)%" OR LOWER(drugSynonyms_string) LIKE "%zegalogue (autoinjector)%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4736', 'tradeNames_string': 'Zegalogue, Zegalogue (autoinjector)', 'drugName': 'Dasiglucagon Hydrochloride', 'drugMolecularType': 'Unknown', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Glucagon receptor agonist', 'linkedDiseasesDrug_string': 'Hypoglycemia (HP_0001943), Type 1 Diabetes Mellitus (MONDO_0005147)', 'newLinkedTargets_string': 'GCGR (ENSG00000215644)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2021, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.361 | Q22 | What is Kyleena? | Kyleena, also known generically as Levonorgestrel, was approved by the FDA in 1982 to treat Menorrhagia. It is a small molecule therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%kyleena%" OR LOWER(tradeNames_string) LIKE "%kyleena%" OR LOWER(drugSynonyms_string) LIKE "%kyleena%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2857', 'tradeNames_string': 'Athentia next, Emerres, Emerres una, Ezinelle, Fallback solo, Her style, Isteranda, Jadelle, Jaydess, Kyleena, Levonelle, Levonelle one step, Levonelle-2, Levonorgestrel, Levosert, Liletta, Microval, Mirena, Norgeston, Norplant, Norplant Ii, Norplant System, Opcicon one-step, Ovrette, Plan B, Plan b one-step, Postinor-2, Skyla, Upostelle', 'drugName': 'Levonorgestrel', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Progesterone receptor agonist', 'linkedDiseasesDrug_string': 'Ovarian Carcinoma (EFO_0001075), Cancer (MONDO_0004992), Adenomyosis (EFO_1001757), Menorrhagia (HP_0000132), Osteopenia (HP_0000938), Hiv Infection (EFO_0000764), Chronic Lymphocytic Leukemia (EFO_0000095), Chronic Hepatitis B Virus Infection (EFO_0004239), Hemorrhage (MP_0001914), Migraine Disorder (MONDO_0005277), Pain (EFO_0003843), Non-Alcoholic Steatohepatitis (EFO_1001249), Dysmenorrhea (HP_0100607), Hiv-1 Infection (EFO_0000180), Endometriosis (EFO_0001065), Chronic Hepatitis C Virus Infection (EFO_0004220), Type 2 Diabetes Mellitus (MONDO_0005148), Anorexia Nervosa (MONDO_0005351)', 'newLinkedTargets_string': 'PGR (ENSG00000082175)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1982, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.58 | Q22 | What is Ayvakit? | Ayvakit, also known generically as Avapritinib, was approved by the FDA in 2020 to treat cancer, neoplasm, and gastrointestinal stromal tumor. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%ayvakit%" OR LOWER(tradeNames_string) LIKE "%ayvakit%" OR LOWER(drugSynonyms_string) LIKE "%ayvakit%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3139', 'tradeNames_string': 'Ayvakit', 'drugName': 'Avapritinib', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Stem cell growth factor receptor inhibitor', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Neoplasm (EFO_0000616), Gastrointestinal Stromal Tumor (MONDO_0011719), Central Nervous System Cancer (EFO_0000326), Systemic Mastocytosis (MONDO_0016586), Mast-Cell Leukemia (EFO_0007359)', 'newLinkedTargets_string': 'PDGFRA (ENSG00000134853), KIT (ENSG00000157404)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2020, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_3140', 'tradeNames_string': 'Ayvakit', 'drugName': 'Avapritinib', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Platelet-derived growth factor receptor alpha inhibitor', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Neoplasm (EFO_0000616), Gastrointestinal Stromal Tumor (MONDO_0011719), Central Nervous System Cancer (EFO_0000326), Systemic Mastocytosis (MONDO_0016586), Mast-Cell Leukemia (EFO_0007359)', 'newLinkedTargets_string': 'PDGFRA (ENSG00000134853), KIT (ENSG00000157404)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2020, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.449 | Q22 | What is Vivitrol? | Vivitrol, also known generically as Naltrexone, was approved by the FDA in 1984 to treat alcohol abuse and alcohol dependence. It is a small molecule therapy that acts as a(n) antagonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%vivitrol%" OR LOWER(tradeNames_string) LIKE "%vivitrol%" OR LOWER(drugSynonyms_string) LIKE "%vivitrol%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3607', 'tradeNames_string': 'Celupan, Trexal, Trexan, Vivitrol', 'drugName': 'Naltrexone', 'drugMolecularType': 'Small molecule', 'drugActionType': 'antagonist', 'drugMechanismOfAction': 'Opioid receptors; mu/kappa/delta antagonist', 'linkedDiseasesDrug_string': "Psoriasis (EFO_0000676), Multiple Sclerosis (MONDO_0005301), Migraine Disorder (MONDO_0005277), Covid-19 (MONDO_0100096), Pain (EFO_0003843), Obesity (EFO_0001073), Cannabis Dependence (EFO_0007191), Dry Eye Syndrome (EFO_1000906), Eating Disorder (EFO_0005203), Ulcerative Colitis (EFO_0000729), Coronavirus Infectious Disease (EFO_0007224), Post-Traumatic Stress Disorder (EFO_0001358), Charcot-Marie-Tooth Disease (MONDO_0015626), Alcohol Abuse (MONDO_0002046), Breast Cancer (MONDO_0007254), Crohn'S Disease (EFO_0000384), Nicotine Dependence (EFO_0003768), Atopic Eczema (EFO_0000274), Fibromyalgia (EFO_0005687), Acute Respiratory Distress Syndrome (EFO_1000637), Endometriosis (EFO_0001065), Cocaine Dependence (EFO_0002610), Heroin Dependence (EFO_0004240), Alcohol Drinking (EFO_0004329), Methamphetamine Dependence (EFO_0004701), Drug Dependence (EFO_0003890), Obsessive-Compulsive Disorder (EFO_0004242), Binge Eating (EFO_0005924), Borderline Personality Disorder (HP_0012076), Pervasive Developmental Disorder (MONDO_0000594), Hair-Pulling (HP_0012167), Depressive Disorder (MONDO_0002050), Alcohol-Related Disorders (MONDO_0021698), Alcohol Dependence (MONDO_0007079), Opioid Dependence (EFO_0005611), Gambling Behaviour (EFO_0004699), Unipolar Depression (EFO_0003761), Opioid Use Disorder (EFO_0010702), Hiv Infection (EFO_0000764), Diabetic Neuropathy (EFO_1000783), Interstitial Cystitis (EFO_0008507), Chronic Pain (HP_0012532), Major Depressive Disorder (MONDO_0002009), Fatigue (HP_0012378), Low Back Pain (HP_0003419), Schizophrenia (MONDO_0005090), Severe Acute Respiratory Syndrome (EFO_0000694)", 'newLinkedTargets_string': 'OPRK1 (ENSG00000082556), OPRD1 (ENSG00000116329), OPRM1 (ENSG00000112038)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1984, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.226 | Q22 | What is Veletri? | Veletri, also known generically as Epoprostenol Sodium, was approved by the FDA in 1995 to treat pulmonary arterial hypertension. It is a small molecule therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%veletri%" OR LOWER(tradeNames_string) LIKE "%veletri%" OR LOWER(drugSynonyms_string) LIKE "%veletri%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1500', 'tradeNames_string': 'Epoprostenol sodium, Flolan, Veletri', 'drugName': 'Epoprostenol Sodium', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Prostanoid IP receptor agonist', 'linkedDiseasesDrug_string': 'Pulmonary Arterial Hypertension (EFO_0001361)', 'newLinkedTargets_string': 'PTGIR (ENSG00000160013)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1995, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_2186', 'tradeNames_string': 'Veletri', 'drugName': 'Tezosentan', 'drugMolecularType': 'Small molecule', 'drugActionType': 'antagonist', 'drugMechanismOfAction': 'Endothelin receptor ET-A antagonist', 'linkedDiseasesDrug_string': 'Heart Failure (EFO_0003144), Pulmonary Arterial Hypertension (EFO_0001361)', 'newLinkedTargets_string': 'EDNRB (ENSG00000136160), EDNRA (ENSG00000151617)', 'maxClinicalTrialPhase': 3, 'yearOfFirstApproval': 0, 'drugIsApproved': False}, {'UUID': 'DrugGeneTargets_v2_2187', 'tradeNames_string': 'Veletri', 'drugName': 'Tezosentan', 'drugMolecularType': 'Small molecule', 'drugActionType': 'antagonist', 'drugMechanismOfAction': 'Endothelin receptor ET-B antagonist', 'linkedDiseasesDrug_string': 'Heart Failure (EFO_0003144), Pulmonary Arterial Hypertension (EFO_0001361)', 'newLinkedTargets_string': 'EDNRB (ENSG00000136160), EDNRA (ENSG00000151617)', 'maxClinicalTrialPhase': 3, 'yearOfFirstApproval': 0, 'drugIsApproved': False}] | general | Similarity Search, Select | Metadata |
Q22.284 | Q22 | What is Xospata? | Xospata, also known generically as Gilteritinib Fumarate, was approved by the FDA in 2018 to treat acute myeloid leukemia and myeloid leukemia. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%xospata%" OR LOWER(tradeNames_string) LIKE "%xospata%" OR LOWER(drugSynonyms_string) LIKE "%xospata%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3307', 'tradeNames_string': 'Xospata', 'drugName': 'Gilteritinib Fumarate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Tyrosine-protein kinase receptor FLT3 inhibitor', 'linkedDiseasesDrug_string': 'Acute Myeloid Leukemia (EFO_0000222), Myeloid Leukemia (MONDO_0004643)', 'newLinkedTargets_string': 'FLT3 (ENSG00000122025), AXL (ENSG00000167601)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2018, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_3308', 'tradeNames_string': 'Xospata', 'drugName': 'Gilteritinib Fumarate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Tyrosine-protein kinase receptor UFO inhibitor', 'linkedDiseasesDrug_string': 'Acute Myeloid Leukemia (EFO_0000222), Myeloid Leukemia (MONDO_0004643)', 'newLinkedTargets_string': 'FLT3 (ENSG00000122025), AXL (ENSG00000167601)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2018, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.18 | Q22 | What is Lastacaft? | Lastacaft, also known generically as Alcaftadine, was approved by the FDA in 2010 to treat eye allergy and allergic conjunctivitis. It is a small molecule therapy that acts as a(n) antagonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%lastacaft%" OR LOWER(tradeNames_string) LIKE "%lastacaft%" OR LOWER(drugSynonyms_string) LIKE "%lastacaft%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5937', 'tradeNames_string': 'Lastacaft', 'drugName': 'Alcaftadine', 'drugMolecularType': 'Small molecule', 'drugActionType': 'antagonist', 'drugMechanismOfAction': 'Histamine H1 receptor antagonist', 'linkedDiseasesDrug_string': 'Allergic Conjunctivitis (EFO_0007141), Eye Allergy (EFO_0005751)', 'newLinkedTargets_string': 'HRH1 (ENSG00000196639)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2010, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.411 | Q22 | What is Relistor? | Relistor, also known generically as Methylnaltrexone Bromide, was approved by the FDA in 2008 to treat Constipation. It is a small molecule therapy that acts as a(n) antagonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%relistor%" OR LOWER(tradeNames_string) LIKE "%relistor%" OR LOWER(drugSynonyms_string) LIKE "%relistor%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2413', 'tradeNames_string': 'Relistor', 'drugName': 'Methylnaltrexone Bromide', 'drugMolecularType': 'Small molecule', 'drugActionType': 'antagonist', 'drugMechanismOfAction': 'Mu opioid receptor antagonist', 'linkedDiseasesDrug_string': 'Pancreatic Carcinoma (EFO_0002618), Constipation (HP_0002019), Ileus (MONDO_0004567)', 'newLinkedTargets_string': 'OPRM1 (ENSG00000112038)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2008, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.328 | Q22 | What is Corlanor? | Corlanor, also known generically as Ivabradine Hydrochloride, was approved by the FDA in 2015 to treat congestive heart failure and heart failure. It is a small molecule therapy that acts as a(n) blocker. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%corlanor%" OR LOWER(tradeNames_string) LIKE "%corlanor%" OR LOWER(drugSynonyms_string) LIKE "%corlanor%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_32', 'tradeNames_string': 'Corlanor, Procoralan', 'drugName': 'Ivabradine', 'drugMolecularType': 'Small molecule', 'drugActionType': 'blocker', 'drugMechanismOfAction': 'Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4 blocker', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Orthostatic Hypotension (EFO_0005252), Coronary Artery Disease (EFO_0001645), Non-St Elevation Myocardial Infarction (EFO_0008586), Hypotension (EFO_0005251), Aging (GO_0007568), Atrial Fibrillation (EFO_0000275), Congestive Heart Failure (EFO_0000373), Angina Pectoris (EFO_0003913), Septic Shock (EFO_0006834), Cardiovascular Disease (EFO_0000319), Lymphoma (EFO_0000574), Multiple Organ Failure (EFO_1001373), Tachycardia (HP_0001649), Diastolic Heart Failure (EFO_1000899), Systolic Heart Failure (EFO_1001207), Diabetic Nephropathy (EFO_0000401), Heart Failure (EFO_0003144), Mitral Valve Stenosis (EFO_0007372)', 'newLinkedTargets_string': 'HCN4 (ENSG00000138622)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2015, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_1183', 'tradeNames_string': 'Corlanor, Procoralan', 'drugName': 'Ivabradine Hydrochloride', 'drugMolecularType': 'Small molecule', 'drugActionType': 'blocker', 'drugMechanismOfAction': 'Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4 blocker', 'linkedDiseasesDrug_string': 'Heart Failure (EFO_0003144), Congestive Heart Failure (EFO_0000373)', 'newLinkedTargets_string': 'HCN4 (ENSG00000138622)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2015, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.259 | Q22 | What is Fentora? | Fentora, also known generically as Fentanyl Citrate, was approved by the FDA in 1968 to treat cancer and pain. It is a small molecule therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%fentora%" OR LOWER(tradeNames_string) LIKE "%fentora%" OR LOWER(drugSynonyms_string) LIKE "%fentora%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_6302', 'tradeNames_string': 'Abstral, Actiq, Breakyl, Duragesic, Duragesic-100, Duragesic-12, Duragesic-25, Duragesic-37, Duragesic-50, Duragesic-75, Durogesic, Durogesic dtrans, Effentora, Fencino, Fentalis reservoir, Fentanyl-100, Fentanyl-12, Fentanyl-25, Fentanyl-37, Fentanyl-50, Fentanyl-62, Fentanyl-75, Fentanyl-87, Fentora, Ionsys, Leptanal, Matrifen, Mezolar matrix, Mylafent, Opiodur, Oralet, Osmach, Osmanil, Pecfent, Recivit, Sublimaze, Subsys, Tilofyl, Victanyl, Yemex', 'drugName': 'Fentanyl', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Mu opioid receptor agonist', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Liver Disease (EFO_0001421), Pain (EFO_0003843), Covid-19 (MONDO_0100096), Obesity (EFO_0001073), Migraine Disorder (MONDO_0005277), Irritable Bowel Syndrome (EFO_0000555), Injury (EFO_0000546), Hypotension (EFO_0005251), Pregnancy (EFO_0002950), Gastric Cancer (MONDO_0001056), Respiratory Insufficiency (HP_0002093), Hypospadias (EFO_0004209), Bronchospasm (HP_0025428), Breast Cancer (MONDO_0007254), Neuropathic Pain (EFO_0005762), Acute Respiratory Distress Syndrome (EFO_1000637), Scoliosis (EFO_0004273), Respiratory Depression (EFO_0009842), Interstitial Lung Disease (EFO_0004244), Morbid Obesity (EFO_0001074), Bone Fracture (EFO_0003931), Bone Metastasis (EFO_0009870), Pancreatic Carcinoma (EFO_0002618), Delirium (EFO_0009267), Subarachnoid Hemorrhage (EFO_0000713), Adenoma (EFO_0000232), Brain Injury (MONDO_0043510), Obstructive Sleep Apnea (EFO_0003918), Opioid Dependence (EFO_0005611), Shortness Of Breath (EFO_0009727), Dyspnea (HP_0002094), Chronic Kidney Disease (EFO_0003884), Osteoarthritis (MONDO_0005178), Pulpitis (EFO_1001139), Neoplasm (EFO_0000616), Diabetic Neuropathy (EFO_1000783), Chronic Pain (HP_0012532), Low Back Pain (HP_0003419), Abscess (EFO_0003030), Aortic Coarctation (EFO_1001267)', 'newLinkedTargets_string': 'OPRM1 (ENSG00000112038)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1968, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_733', 'tradeNames_string': 'Abstral, Actiq, Fentanyl, Fentanyl citrate, Fentanyl citrate preservative free, Fentora, Lazanda, Onsolis, Sublimaze, Sublimaze preservative free, Thalamonal', 'drugName': 'Fentanyl Citrate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Mu opioid receptor agonist', 'linkedDiseasesDrug_string': 'Shortness Of Breath (EFO_0009727), Cancer (MONDO_0004992), Dyspnea (HP_0002094), Pulpitis (EFO_1001139), Pain (EFO_0003843), Chronic Pain (HP_0012532), Neuropathic Pain (EFO_0005762), Interstitial Lung Disease (EFO_0004244), Low Back Pain (HP_0003419), Injury (EFO_0000546)', 'newLinkedTargets_string': 'OPRM1 (ENSG00000112038)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1968, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.423 | Q22 | What is Rydapt? | Rydapt, also known generically as Midostaurin, was approved by the FDA in 2017 to treat acute myeloid leukemia, neoplasm, mast-cell leukemia, Mastocytosis, and systemic mastocytosis. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%rydapt%" OR LOWER(tradeNames_string) LIKE "%rydapt%" OR LOWER(drugSynonyms_string) LIKE "%rydapt%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5664', 'tradeNames_string': 'Rydapt', 'drugName': 'Midostaurin', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Protein kinase C (PKC) inhibitor', 'linkedDiseasesDrug_string': 'Rectum Cancer (EFO_1000657), Neoplasm (EFO_0000616), Leukemia (EFO_0000565), Liver Disease (EFO_0001421), Acute Lymphoblastic Leukemia (EFO_0000220), Mastocytosis (EFO_0009001), Systemic Mastocytosis (MONDO_0016586), Acute Myeloid Leukemia (EFO_0000222), Mast-Cell Leukemia (EFO_0007359), Myelodysplastic Syndrome (EFO_0000198), Blast Phase Chronic Myelogenous Leukemia, Bcr-Abl1 Positive (EFO_1000131)', 'newLinkedTargets_string': 'KIT (ENSG00000157404), KDR (ENSG00000128052), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), FLT3 (ENSG00000122025), PRKD3 (ENSG00000115825), PRKCI (ENSG00000163558), PRKCA (ENSG00000154229), PRKCG (ENSG00000126583), PRKCD (ENSG00000163932), PRKCB (ENSG00000166501), PRKCZ (ENSG00000067606), PRKCE (ENSG00000171132), PRKCH (ENSG00000027075), PRKD1 (ENSG00000184304), PRKCQ (ENSG00000065675)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2017, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_5665', 'tradeNames_string': 'Rydapt', 'drugName': 'Midostaurin', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Platelet-derived growth factor receptor inhibitor', 'linkedDiseasesDrug_string': 'Rectum Cancer (EFO_1000657), Neoplasm (EFO_0000616), Leukemia (EFO_0000565), Liver Disease (EFO_0001421), Acute Lymphoblastic Leukemia (EFO_0000220), Mastocytosis (EFO_0009001), Systemic Mastocytosis (MONDO_0016586), Acute Myeloid Leukemia (EFO_0000222), Mast-Cell Leukemia (EFO_0007359), Myelodysplastic Syndrome (EFO_0000198), Blast Phase Chronic Myelogenous Leukemia, Bcr-Abl1 Positive (EFO_1000131)', 'newLinkedTargets_string': 'KIT (ENSG00000157404), KDR (ENSG00000128052), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), FLT3 (ENSG00000122025), PRKD3 (ENSG00000115825), PRKCI (ENSG00000163558), PRKCA (ENSG00000154229), PRKCG (ENSG00000126583), PRKCD (ENSG00000163932), PRKCB (ENSG00000166501), PRKCZ (ENSG00000067606), PRKCE (ENSG00000171132), PRKCH (ENSG00000027075), PRKD1 (ENSG00000184304), PRKCQ (ENSG00000065675)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2017, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_5666', 'tradeNames_string': 'Rydapt', 'drugName': 'Midostaurin', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Stem cell growth factor receptor inhibitor', 'linkedDiseasesDrug_string': 'Rectum Cancer (EFO_1000657), Neoplasm (EFO_0000616), Leukemia (EFO_0000565), Liver Disease (EFO_0001421), Acute Lymphoblastic Leukemia (EFO_0000220), Mastocytosis (EFO_0009001), Systemic Mastocytosis (MONDO_0016586), Acute Myeloid Leukemia (EFO_0000222), Mast-Cell Leukemia (EFO_0007359), Myelodysplastic Syndrome (EFO_0000198), Blast Phase Chronic Myelogenous Leukemia, Bcr-Abl1 Positive (EFO_1000131)', 'newLinkedTargets_string': 'KIT (ENSG00000157404), KDR (ENSG00000128052), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), FLT3 (ENSG00000122025), PRKD3 (ENSG00000115825), PRKCI (ENSG00000163558), PRKCA (ENSG00000154229), PRKCG (ENSG00000126583), PRKCD (ENSG00000163932), PRKCB (ENSG00000166501), PRKCZ (ENSG00000067606), PRKCE (ENSG00000171132), PRKCH (ENSG00000027075), PRKD1 (ENSG00000184304), PRKCQ (ENSG00000065675)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2017, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_5667', 'tradeNames_string': 'Rydapt', 'drugName': 'Midostaurin', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Tyrosine-protein kinase receptor FLT3 inhibitor', 'linkedDiseasesDrug_string': 'Rectum Cancer (EFO_1000657), Neoplasm (EFO_0000616), Leukemia (EFO_0000565), Liver Disease (EFO_0001421), Acute Lymphoblastic Leukemia (EFO_0000220), Mastocytosis (EFO_0009001), Systemic Mastocytosis (MONDO_0016586), Acute Myeloid Leukemia (EFO_0000222), Mast-Cell Leukemia (EFO_0007359), Myelodysplastic Syndrome (EFO_0000198), Blast Phase Chronic Myelogenous Leukemia, Bcr-Abl1 Positive (EFO_1000131)', 'newLinkedTargets_string': 'KIT (ENSG00000157404), KDR (ENSG00000128052), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), FLT3 (ENSG00000122025), PRKD3 (ENSG00000115825), PRKCI (ENSG00000163558), PRKCA (ENSG00000154229), PRKCG (ENSG00000126583), PRKCD (ENSG00000163932), PRKCB (ENSG00000166501), PRKCZ (ENSG00000067606), PRKCE (ENSG00000171132), PRKCH (ENSG00000027075), PRKD1 (ENSG00000184304), PRKCQ (ENSG00000065675)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2017, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_5668', 'tradeNames_string': 'Rydapt', 'drugName': 'Midostaurin', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Vascular endothelial growth factor receptor 2 inhibitor', 'linkedDiseasesDrug_string': 'Rectum Cancer (EFO_1000657), Neoplasm (EFO_0000616), Leukemia (EFO_0000565), Liver Disease (EFO_0001421), Acute Lymphoblastic Leukemia (EFO_0000220), Mastocytosis (EFO_0009001), Systemic Mastocytosis (MONDO_0016586), Acute Myeloid Leukemia (EFO_0000222), Mast-Cell Leukemia (EFO_0007359), Myelodysplastic Syndrome (EFO_0000198), Blast Phase Chronic Myelogenous Leukemia, Bcr-Abl1 Positive (EFO_1000131)', 'newLinkedTargets_string': 'KIT (ENSG00000157404), KDR (ENSG00000128052), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), FLT3 (ENSG00000122025), PRKD3 (ENSG00000115825), PRKCI (ENSG00000163558), PRKCA (ENSG00000154229), PRKCG (ENSG00000126583), PRKCD (ENSG00000163932), PRKCB (ENSG00000166501), PRKCZ (ENSG00000067606), PRKCE (ENSG00000171132), PRKCH (ENSG00000027075), PRKD1 (ENSG00000184304), PRKCQ (ENSG00000065675)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2017, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.676 | Q22 | What is Incruse Ellipta? | Incruse Ellipta, also known generically as Umeclidinium Bromide, was approved by the FDA in 2013 to treat Airway obstruction, chronic obstructive pulmonary disease, emphysema, and chronic bronchitis. It is a small molecule therapy that acts as a(n) antagonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%incruse ellipta%" OR LOWER(tradeNames_string) LIKE "%incruse ellipta%" OR LOWER(drugSynonyms_string) LIKE "%incruse ellipta%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5459', 'tradeNames_string': 'Incruse ellipta', 'drugName': 'Umeclidinium Bromide', 'drugMolecularType': 'Small molecule', 'drugActionType': 'antagonist', 'drugMechanismOfAction': 'Muscarinic acetylcholine receptor M3 antagonist', 'linkedDiseasesDrug_string': 'Chronic Bronchitis (EFO_0006505), Asthma (MONDO_0004979), Chronic Obstructive Pulmonary Disease (EFO_0000341), Airway Obstruction (HP_0006536), Emphysema (EFO_0000464)', 'newLinkedTargets_string': 'CHRM3 (ENSG00000133019)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2013, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.193 | Q22 | What is Dyloject? | Dyloject, also known generically as Diclofenac Sodium, was approved by the FDA in 1988 to treat hemorrhage, rheumatoid arthritis, pain, and osteoarthritis. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%dyloject%" OR LOWER(tradeNames_string) LIKE "%dyloject%" OR LOWER(drugSynonyms_string) LIKE "%dyloject%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2818', 'tradeNames_string': 'Acoflam, Acoflam ret, Acoflam sr, Arthronac, Arthrotec 50, Arthrotec 75, Closteril 100, Defanac, Defanac retard, Defanac sr, Dexomon ret, Dexomon sr, Diclofenac sodium, Dicloflex, Dicloflex ret, Dicloflex sr, Diclomax ret, Diclomax sr, Diclotard 100 mr, Diclotard 75 mr, Diclovol, Diclovol ret, Diclovol sr, Diclozip 25, Diclozip 50, Difenor xl, Digenac xl 100, Dyloject, Econac, Econac sr, Econac xl, Enstar sr, Enstar xl, Enzed, Fenactol, Fenactol ret, Fenactol sr, Flamatak mr, Flamrase, Flamrase sr, Flexotard mr, Isclofen, Lofensaid 25, Lofensaid 50, Lofensaid ret 100, Lofensaid ret 75, Masidemen, Misofen, Mobigel, Mobigel paineze, Motifene, Pennsaid, Rheumatac ret 75, Rhumalgan, Rhumalgan cr 100, Rhumalgan cr 75, Rhumalgan sr, Rhumalgan xl, Slofenac, Solaraze, Valdic 100 ret, Valdic 75 ret, Valenac, Volraman, Volsaid ret 100, Volsaid ret 75, Voltaren, Voltaren arthritis pain, Voltaren emulgel, Voltaren ret, Voltaren-xr, Voltarene, Voltarene emulgel, Voltarene l.p., Voltarene ret, Voltarol, Voltarol 12 hour emulgel p, Voltarol active, Voltarol emulgel, Voltarol emulgel p, Voltarol gel patch, Voltarol ophtha, Voltarol pain-eze emulgel, Voltarol ret, Voltarol sr', 'drugName': 'Diclofenac Sodium', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Cyclooxygenase inhibitor', 'linkedDiseasesDrug_string': 'Gout (EFO_0004274), Toothache (EFO_0010072), Osteoarthritis (MONDO_0005178), Muscular Disease (EFO_0002970), Anemia (Phenotype) (EFO_0004272), Urinary Bladder Cancer (MONDO_0001187), Hemorrhage (MP_0001914), Pain (EFO_0003843), Chronic Pain (HP_0012532), Radiculopathy (MONDO_0002959), Osteoarthritis, Knee (EFO_0004616), Otitis Externa (EFO_0009560), Actinic Keratosis (EFO_0002496), Sprain (EFO_0009582), Inflammation (MP_0001845), Low Back Pain (HP_0003419), Rheumatoid Arthritis (EFO_0000685), Sunburn (EFO_0003958)', 'newLinkedTargets_string': 'PTGS2 (ENSG00000073756), PTGS1 (ENSG00000095303)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1988, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.445 | Q22 | What is Kloxxado? | Kloxxado, also known generically as Naloxone Hydrochloride, was approved by the FDA in 1971 to treat unipolar depression, pain, and septic shock. It is a small molecule therapy that acts as a(n) antagonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%kloxxado%" OR LOWER(tradeNames_string) LIKE "%kloxxado%" OR LOWER(drugSynonyms_string) LIKE "%kloxxado%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3927', 'tradeNames_string': 'Evzio, Evzio (autoinjector), Kloxxado, Nalone, Naloxone, Naloxone hydrochloride, Naloxone hydrochloride (autoinjector), Narcan, Narcan neonatal, Narconil, Prenoxad, Zimhi', 'drugName': 'Naloxone Hydrochloride', 'drugMolecularType': 'Small molecule', 'drugActionType': 'antagonist', 'drugMechanismOfAction': 'Opioid receptors; mu/kappa/delta antagonist', 'linkedDiseasesDrug_string': 'Unipolar Depression (EFO_0003761), Intestinal Obstruction (MONDO_0004565), Septic Shock (EFO_0006834), Pain (EFO_0003843), Constipation (HP_0002019), Opioid Dependence (EFO_0005611), Gambling Behaviour (EFO_0004699)', 'newLinkedTargets_string': 'OPRK1 (ENSG00000082556), OPRD1 (ENSG00000116329), OPRM1 (ENSG00000112038)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1971, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.623 | Q22 | What is Ibsrela? | Ibsrela, also known generically as Tenapanor Hydrochloride, was approved by the FDA in 2019 to treat irritable bowel syndrome and constipation disorder. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%ibsrela%" OR LOWER(tradeNames_string) LIKE "%ibsrela%" OR LOWER(drugSynonyms_string) LIKE "%ibsrela%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3816', 'tradeNames_string': 'Ibsrela', 'drugName': 'Tenapanor Hydrochloride', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Sodium/hydrogen exchanger 3 inhibitor', 'linkedDiseasesDrug_string': 'Irritable Bowel Syndrome (EFO_0000555), Constipation Disorder (MONDO_0002203), Chronic Kidney Disease (EFO_0003884), Hyperphosphatemia (HP_0002905)', 'newLinkedTargets_string': 'SLC9A3 (ENSG00000066230)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2019, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.497 | Q22 | What is Ibrance? | Ibrance, also known generically as Palbociclib, was approved by the FDA in 2015 to treat breast carcinoma, cancer, neoplasm, breast neoplasm, and breast cancer. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%ibrance%" OR LOWER(tradeNames_string) LIKE "%ibrance%" OR LOWER(drugSynonyms_string) LIKE "%ibrance%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2460', 'tradeNames_string': 'Ibrance', 'drugName': 'Palbociclib', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'CDK6/cyclin D1 inhibitor', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Multiple Myeloma (EFO_0001378), Pancreatic Neuroendocrine Tumor (EFO_1000045), Non-Hodgkins Lymphoma (EFO_0005952), Covid-19 (MONDO_0100096), Oligodendroglioma (EFO_0000632), Urothelial Carcinoma (EFO_0008528), Breast Ductal Adenocarcinoma (EFO_0006318), Colon Carcinoma (EFO_1001950), Squamous Cell Lung Carcinoma (EFO_0000708), Endometrial Cancer (MONDO_0011962), Ovarian Cancer (MONDO_0008170), Breast Carcinoma (EFO_0000305), Breast Neoplasm (EFO_0003869), Hepatocellular Carcinoma (EFO_0000182), Prostate Cancer (MONDO_0008315), Breast Cancer (MONDO_0007254), Mantle Cell Lymphoma (EFO_1001469), Oligoastrocytoma (EFO_0000630), Acute Lymphoblastic Leukemia (EFO_0000220), Lymphoma (EFO_0000574), Pancreatic Ductal Adenocarcinoma (EFO_0002517), Liposarcoma (EFO_0000569), Acute Myeloid Leukemia (EFO_0000222), Head And Neck Squamous Cell Carcinoma (EFO_0000181), Pancreatic Carcinoma (EFO_0002618), Clear Cell Renal Carcinoma (EFO_0000349), Soft Tissue Sarcoma (EFO_1001968), Renal Cell Carcinoma (EFO_0000681), Thymus Neoplasm (EFO_0002626), Head And Neck Malignant Neoplasia (EFO_0006859), Osteosarcoma (EFO_0000637), Ewing Sarcoma (EFO_0000174), Squamous Cell Carcinoma (EFO_0000707), Neoplasm (EFO_0000616), Lung Cancer (MONDO_0008903), Adenocarcinoma (EFO_0000228), Chordoma (MONDO_0008978), Non-Small Cell Lung Carcinoma (EFO_0003060), Nasopharyngeal Neoplasm (EFO_0004252), Kidney Disease (EFO_0003086), Melanoma (EFO_0000756), Glioblastoma Multiforme (EFO_0000519), Hereditary Breast And Ovarian Cancer Syndrome (Orphanet_145)', 'newLinkedTargets_string': 'CCND1 (ENSG00000110092), CDK6 (ENSG00000105810), CDK4 (ENSG00000135446)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2015, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_2461', 'tradeNames_string': 'Ibrance', 'drugName': 'Palbociclib', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Cyclin-dependent kinase 4/cyclin D1 inhibitor', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Multiple Myeloma (EFO_0001378), Pancreatic Neuroendocrine Tumor (EFO_1000045), Non-Hodgkins Lymphoma (EFO_0005952), Covid-19 (MONDO_0100096), Oligodendroglioma (EFO_0000632), Urothelial Carcinoma (EFO_0008528), Breast Ductal Adenocarcinoma (EFO_0006318), Colon Carcinoma (EFO_1001950), Squamous Cell Lung Carcinoma (EFO_0000708), Endometrial Cancer (MONDO_0011962), Ovarian Cancer (MONDO_0008170), Breast Carcinoma (EFO_0000305), Breast Neoplasm (EFO_0003869), Hepatocellular Carcinoma (EFO_0000182), Prostate Cancer (MONDO_0008315), Breast Cancer (MONDO_0007254), Mantle Cell Lymphoma (EFO_1001469), Oligoastrocytoma (EFO_0000630), Acute Lymphoblastic Leukemia (EFO_0000220), Lymphoma (EFO_0000574), Pancreatic Ductal Adenocarcinoma (EFO_0002517), Liposarcoma (EFO_0000569), Acute Myeloid Leukemia (EFO_0000222), Head And Neck Squamous Cell Carcinoma (EFO_0000181), Pancreatic Carcinoma (EFO_0002618), Clear Cell Renal Carcinoma (EFO_0000349), Soft Tissue Sarcoma (EFO_1001968), Renal Cell Carcinoma (EFO_0000681), Thymus Neoplasm (EFO_0002626), Head And Neck Malignant Neoplasia (EFO_0006859), Osteosarcoma (EFO_0000637), Ewing Sarcoma (EFO_0000174), Squamous Cell Carcinoma (EFO_0000707), Neoplasm (EFO_0000616), Lung Cancer (MONDO_0008903), Adenocarcinoma (EFO_0000228), Chordoma (MONDO_0008978), Non-Small Cell Lung Carcinoma (EFO_0003060), Nasopharyngeal Neoplasm (EFO_0004252), Kidney Disease (EFO_0003086), Melanoma (EFO_0000756), Glioblastoma Multiforme (EFO_0000519), Hereditary Breast And Ovarian Cancer Syndrome (Orphanet_145)', 'newLinkedTargets_string': 'CCND1 (ENSG00000110092), CDK6 (ENSG00000105810), CDK4 (ENSG00000135446)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2015, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.97 | Q22 | What is Alphagan P? | Alphagan P, also known generically as Brimonidine Tartrate, was approved by the FDA in 1996 to treat Erythema, glaucoma, hypertension, open-angle glaucoma, rosacea, and ocular hypertension. It is a small molecule therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%alphagan p%" OR LOWER(tradeNames_string) LIKE "%alphagan p%" OR LOWER(drugSynonyms_string) LIKE "%alphagan p%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4923', 'tradeNames_string': 'Alphagan, Alphagan p, Brimonidine tartrate, Brymont, Lumify, Mirvaso, Qoliana', 'drugName': 'Brimonidine Tartrate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Adrenergic receptor alpha-2 agonist', 'linkedDiseasesDrug_string': 'Allergic Conjunctivitis (EFO_0007141), Flushing (HP_0031284), Rosacea (EFO_1000760), Presbyopia (MONDO_0001330), Hand-Foot Syndrome (EFO_1001893), Open-Angle Glaucoma (EFO_0004190), Hypertension (EFO_0000537), Erythema (HP_0010783), Dry Eye Syndrome (EFO_1000906), Hyperemia (EFO_0003822), Ocular Hypertension (EFO_1001069), Glaucoma (MONDO_0005041), Alcohol-Related Disorders (MONDO_0021698), Corneal Edema (EFO_1000879)', 'newLinkedTargets_string': 'ADRA2A (ENSG00000150594), ADRA2C (ENSG00000184160), ADRA2B (ENSG00000274286)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1996, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.183 | Q22 | What is Topicort? | Topicort, also known generically as Desoximetasone, was approved by the FDA in 1977 to treat psoriasis, skin disease, and psoriasis vulgaris. It is a small molecule therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%topicort%" OR LOWER(tradeNames_string) LIKE "%topicort%" OR LOWER(drugSynonyms_string) LIKE "%topicort%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5225', 'tradeNames_string': 'Desoximetasone, Stiedex, Stiedex lp, Stiedex lpn, Topicort, Topicort lp', 'drugName': 'Desoximetasone', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Glucocorticoid receptor agonist', 'linkedDiseasesDrug_string': 'Psoriasis (EFO_0000676), Skin Disease (EFO_0000701), Psoriasis Vulgaris (EFO_1001494)', 'newLinkedTargets_string': 'NR3C1 (ENSG00000113580)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1977, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.305 | Q22 | What is Vantrela Er? | Vantrela Er, also known generically as Hydrocodone Bitartrate, was approved by the FDA in 1943 to treat pain. It is a small molecule therapy that acts as a(n) agonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%vantrela er%" OR LOWER(tradeNames_string) LIKE "%vantrela er%" OR LOWER(drugSynonyms_string) LIKE "%vantrela er%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2476', 'tradeNames_string': 'Dicodid, Hysingla, Hysingla er, Mercodinone, Vantrela er, Zohydro er', 'drugName': 'Hydrocodone Bitartrate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'agonist', 'drugMechanismOfAction': 'Opioid receptors; mu/kappa/delta agonist', 'linkedDiseasesDrug_string': 'Drug Dependence (EFO_0003890), Osteoarthritis (MONDO_0005178), Rotator Cuff Tear (EFO_1001250), Liver Disease (EFO_0001421), Pain (EFO_0003843), Chronic Pain (HP_0012532), Neuropathic Pain (EFO_0005762), Kidney Disease (EFO_0003086), Injury (EFO_0000546), Low Back Pain (HP_0003419)', 'newLinkedTargets_string': 'OPRK1 (ENSG00000082556), OPRD1 (ENSG00000116329), OPRM1 (ENSG00000112038)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 1943, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.648 | Q22 | What is Xeljanz Xr? | Xeljanz Xr, also known generically as Tofacitinib Citrate, was approved by the FDA in 2012 to treat rheumatoid arthritis and psoriatic arthritis. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%xeljanz xr%" OR LOWER(tradeNames_string) LIKE "%xeljanz xr%" OR LOWER(drugSynonyms_string) LIKE "%xeljanz xr%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3515', 'tradeNames_string': 'Xeljanz, Xeljanz xr', 'drugName': 'Tofacitinib Citrate', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Janus Kinase (JAK) inhibitor', 'linkedDiseasesDrug_string': 'Discoid Lupus Erythematosus (MONDO_0019558), Atopic Eczema (EFO_0000274), Psoriatic Arthritis (EFO_0003778), Systemic Lupus Erythematosus (MONDO_0007915), Rheumatoid Arthritis (EFO_0000685)', 'newLinkedTargets_string': 'JAK3 (ENSG00000105639), JAK1 (ENSG00000162434), JAK2 (ENSG00000096968), TYK2 (ENSG00000105397)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2012, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.518 | Q22 | What is Turalio? | Turalio, also known generically as Pexidartinib Hydrochloride, was approved by the FDA in 2019 to treat Tenosynovial Giant Cell Tumor. It is a small molecule therapy that acts as a(n) inhibitor. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%turalio%" OR LOWER(tradeNames_string) LIKE "%turalio%" OR LOWER(drugSynonyms_string) LIKE "%turalio%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4377', 'tradeNames_string': 'Turalio', 'drugName': 'Pexidartinib Hydrochloride', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Tyrosine-protein kinase receptor FLT3 inhibitor', 'linkedDiseasesDrug_string': 'Tenosynovial Giant Cell Tumor (EFO_1000562)', 'newLinkedTargets_string': 'KIT (ENSG00000157404), FLT3 (ENSG00000122025), CSF1R (ENSG00000182578)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2019, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_4378', 'tradeNames_string': 'Turalio', 'drugName': 'Pexidartinib Hydrochloride', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Macrophage colony stimulating factor receptor inhibitor', 'linkedDiseasesDrug_string': 'Tenosynovial Giant Cell Tumor (EFO_1000562)', 'newLinkedTargets_string': 'KIT (ENSG00000157404), FLT3 (ENSG00000122025), CSF1R (ENSG00000182578)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2019, 'drugIsApproved': True}, {'UUID': 'DrugGeneTargets_v2_4379', 'tradeNames_string': 'Turalio', 'drugName': 'Pexidartinib Hydrochloride', 'drugMolecularType': 'Small molecule', 'drugActionType': 'inhibitor', 'drugMechanismOfAction': 'Stem cell growth factor receptor inhibitor', 'linkedDiseasesDrug_string': 'Tenosynovial Giant Cell Tumor (EFO_1000562)', 'newLinkedTargets_string': 'KIT (ENSG00000157404), FLT3 (ENSG00000122025), CSF1R (ENSG00000182578)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2019, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Q22.649 | Q22 | What is Jynarque? | Jynarque, also known generically as Tolvaptan, was approved by the FDA in 2009 to treat Hyponatremia, cardiovascular disease, congestive heart failure, heart failure, Polycystic Kidney Disease, and polycystic kidney disease. It is a small molecule therapy that acts as a(n) antagonist. | SELECT UUID, tradeNames_string, drugName, drugMolecularType, drugActionType, drugMechanismOfAction, linkedDiseasesDrug_string, newLinkedTargets_string, maxClinicalTrialPhase, yearOfFirstApproval, drugIsApproved
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%jynarque%" OR LOWER(tradeNames_string) LIKE "%jynarque%" OR LOWER(drugSynonyms_string) LIKE "%jynarque%")
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5028', 'tradeNames_string': 'Jinarc, Jynarque, Samsca', 'drugName': 'Tolvaptan', 'drugMolecularType': 'Small molecule', 'drugActionType': 'antagonist', 'drugMechanismOfAction': 'Vasopressin V2 receptor antagonist', 'linkedDiseasesDrug_string': 'Dyspnea (HP_0002094), Chronic Kidney Disease (EFO_0003884), Cardiac Edema (EFO_1001771), Congestive Heart Failure (EFO_0000373), Inappropriate Adh Syndrome (EFO_1000982), Heart Failure (EFO_0003144), Cardiovascular Disease (EFO_0000319), Hyponatremia (HP_0002902), Kidney Disease (EFO_0003086), Polycystic Kidney Disease (EFO_0008620), Autosomal Dominant Polycystic Kidney Disease (EFO_1001496), Carcinoma (EFO_0000313), Nephrolithiasis (EFO_0004253), Cirrhosis Of Liver (EFO_0001422)', 'newLinkedTargets_string': 'AVPR2 (ENSG00000126895)', 'maxClinicalTrialPhase': 4, 'yearOfFirstApproval': 2009, 'drugIsApproved': True}] | general | Similarity Search, Select | Metadata |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.